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In this chapter, we will introduce the biological target of this thesis, 1-deoxy-D-xylulose-5-
phosphate synthase (DXS), contextualizing it within the 2C-methyl-D-erythritol-4-
phosphate (MEP) pathway, the metabolic pathway DXS belongs to. We will also describe 
in detail the MEP pathway and we will discuss how the enzymes of this pathway have 
been exploited toward the development of anti-infective agents, giving an overview of the 
most potent inhibitors reported for each enzyme. Finally, we will discuss in detail structural 
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 Chapter 1 
1.1 Drug discovery for poverty-related diseases 
Poverty-related diseases are infectious diseases that primarily, though not exclusively, 
affect vulnerable populations in developing countries, where the transmission and 
proliferation of the diseases are facilitated by poor sanitation and little or no access to 
health care. They represent a significant health burden in large parts of the world, being 
responsible for high mortality rates (they cause 35,000 deaths per day in the developing 
world), chronic disability and poverty.1 In place of “poverty-related diseases”, the term 
“neglected diseases” (ND) is often used. Given that ND are particularly endemic in tropical 
areas in Africa, Asia and America, they are often defined as “neglected tropical diseases” 
(NTDs). The term NTDs is not clearly defined and several definitions of NTDs are in 
common use together with different classification systems.2 In general, the term 
“neglected” refers to the fact that these diseases are overlooked by drug developers, 
funders, policy-makers, public health programs and the news media. In particular, the 
private sector has little incentive to dedicate scientific research and development 
resources to developing medicines for these markets, because of the low likelihood of a 
satisfactory return on investment.3 This definition has as a consequence that, in most 
classifications, NTDs do not include malaria, tuberculosis and human immunodeficiency 
virus infection/acquired immunodeficiency syndrome (HIV/AIDS), which are nowadays 
considered less neglected than other diseases, although their incidence in developing 
countries is clearly poverty-related.4 
What is known as the “10/90 gap” states that only 10% of the international research funding 
on medicine is used toward the development of drugs for diseases which affect 90% of the 
world population. The fact that between 1975 and 1999, only 1.1% of new therapeutic 
products brought to the market were for poverty-related diseases, supports this 
assumption.5 A more recent study analyzing the research and development pipeline of 
drugs and vaccines for ND from 2000 to 2011 shows that the situation has overall not 
improved with respect to the previous 20 years: in fact, in this period of time, only four new 
chemical entities were approved for poverty-related diseases, accounting for 1% of all the 
new chemical entities approved. Although no evidence of a substantial improvement was 
detected over the past decade, the research and development landscape for poverty-
related diseases is slowly improving, with an anticipated number of new registered 
products (4 ̶ 7 per year through 2018), which is nearly doubled with respect to the previous 
decade (2  ̶4 from 2000 to 2011).2 This is the result of the emergence of new consortia and 




initiative and Medicines for Malaria Venture), the fundamental contribution of funding 
agencies such as the Bill and Melinda Gates Foundation and the Wellcome Trust and of a 
newly born interest of the pharmaceutical sector for this not-for-profit area. The fact that 
the Millennium Development Goals, declared in 2000, included specific points regarding 
the fight against HIV/AIDS, malaria and tuberculosis, focused the public attention even 
more on these topics. 
 
1.2 Target-based approaches vs phenotypic screening for the development of new       
drugs for poverty-related diseases 
Two main strategies are used when searching for a new chemical entity such as a potential 
new drug. In target-based approaches, lead compounds are commonly identified by 
screening (in vitro or in silico) libraries of compounds against a certain validated target. 
Alternatively, rational approaches can be used where the potential inhibitor is (de novo) 
designed using modelling tools, so as to efficiently bind to the target. The latter approach 
requires availability of structural information, coming from crystallographic data or from 
NMR studies in solution. Target-based approaches have been heavily exploited over the 
past decade, after the genomes of organisms such as M. tuberculosis6 and Plasmodium 
falciparum7 have become available. Once a suitable lead compound has been identified, 
it has to be optimized for potency, selectivity and pharmacokinetic properties. Target-
based approaches require a careful selection of the molecular target in terms of its 
druggability, essentiality, assayability, resistance potential and structural information.8,9 
The molecular target has to be validated, for example by performing genetic knock-out 
studies, and its role in the disease must be clearly defined. Unfortunately, the number of 
validated targets in the field of poverty-related diseases is still relatively low, mainly due to 
the lack of adequate genetic tools for the parasites involved.10 By looking at the currently 
registered drugs used for the treatment of kinetoplastid infections, one can easily illustrate 
this assumption: for most of them, the mode of action is not (or poorly) understood and for 
many, interactions with multiple targets are likely involved.11  
Although there is a number of successful target-based approaches reported for poverty-
related diseases,12, 13 there is often no correlation between the in vitro biochemical activity 
against the isolated enzyme and the inhibition of the growth of the pathogenic organism.14 
This fact is the main limit of target-based approaches and could be due to several reasons 
such as lack of cellular penetration, high non-specific protein binding or sequestration of 
the compound into lipid compartments.15 For P. falciparum, for example, nearly 60 
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biological targets exist for which there are inhibitors reported in the literature. 
Nevertheless, none of these inhibitors – developed by target-based approaches – has yet 
delivered a drug candidate.16 The same holds true for the discovery of antituberculotic 
drugs.17 
To overcome this problem, there has been a renewed interest for phenotypic screening, 
especially after the development of its high-throughput version.18 A number of successful 
studies has been reported in the field of poverty-related diseases where phenotypic 
screening has been used to identify hit compounds.11 On the one hand, screening of 
libraries of compounds against whole cells, allows for the identification of hit compounds 
that do not have issues in terms of cell uptake or cell efflux. On the other hand, an efficient 
hit-to-lead optimization would require the identification of the target(s), which can be far 
from trivial. This is complicated even further by the fact that the activity at the cellular level 
can arise from interactions with multiple targets within the cell.19 It is intriguing that one 
part of the scientific community states that identification of the target should not strictly 
speaking be required for hit-to-lead optimization.20 
Overall, the two strategies look complementary to each other. If we look at the new 
molecular entities registered between 1999 and 2008 by pharmaceutical companies 
(Figure 1), one can observe that phenotypic screening has been more successful than 
target-based approaches for first-in-class drugs (drugs using a new mechanism of action), 
whereas target-based screening has been more successful for follower drugs.21 
 
Figure 1. Comparison between phenotypic and target-based screening as drug-discovery 








































Mycobacteria belong as a family to the genus Actinobacteria that have similarities with 
both Gram-negative and Gram-positive bacteria. This large family includes pathogens, 
which are responsible for millions of annual deaths: Mycobacterium tuberculosis, 
causative agent of tuberculosis, M. ulcerans, causing the Buruli ulcer diseases and 
M. leprae, responsible for leprosy.22 
First discovered by Robert Koch in 1882, M. tuberculosis is responsible nowadays for more 
than 1 million deaths per year,23 most of them in resource-poor countries, where co-
infection with human immunodeficiency virus (HIV) increases its lethality. It typically affects 
lungs (pulmonary TB) but can also affect other parts of the body (extrapulmonary TB) and 
is easily transmitted through the air by respiratory fluids, usually by coughing or sneezing. 
M. tuberculosis has several peculiar features: it is able to evade immune surveillance and 
survive for long periods of time in host cells, by subverting host-cell signalling pathways.24 
Its particularly thick cell wall has a remarkable hydrophobic character and it is only 
moderately permeable to nutrients, causing a rather slow replication of the bacteria. 
Penetration of drugs through the hydrophobic mycobacterial cell wall is one of the main 
issues in treating TB. As we will discuss in paragraph 1.3, this is the main reason why over 
time, phenotypic screening has emerged as a more successful strategy with respect to 
target-based approaches.25 The biosynthetic pathways leading to the components of the 
mycobacterial cell wall, should also be mentioned as promising drug targets. Current 
antituberculotic drugs already take advantage of this strategy: for example, isoniazid (1) 
inhibits the biosynthesis of mycolic acid and ethambutol (2) inhibits the synthesis of 
arabinogalactan, both constituents of the mycobacterial cell wall.26 
In the last Global tuberculosis report, in 2014, the WHO remarks that the number of TB 
deaths is unacceptably large, given that most of them would be preventable if infected 
people could easily access diagnosis and a short-course regimen of first-line drugs, which 
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Figure 2. Estimated tuberculosis-incidence rates, 2013. (Reproduced, with the permission 
of the publisher, from Global Tuberculosis Report 2014, World Health Organization) 
 
This regimen, used for the so-called drug-susceptible TB, consists of a six-month 
treatment with isoniazid (1), rifampicin (2), ethambutol (3) and pyrazinamide (4) (Figure 3). 
In recent years, the TB epidemic has been further fuelled by the emergence of multi- and 
extensively-drug resistant (MDR- and XDR-) strains of M. tuberculosis, caused mainly by 
improper use of antibiotics in chemotherapy.  
 
Figure 3. First-line drugs used for the treatment of drug-susceptible tuberculosis: isoniazid 
(1), rifampicin (3), ethambutol (2) and pyrazinamide (4). 
 
MDR-TB is resistant to at least 1 and 2 and the cure rates typically range from 50% to 
70%. XDR-TB is resistant to 1, 2 and to any member of the quinolone family, as well as at 




bedaquiline (®Sirturo, 5, Figure 4) has been approved by the US Food and Drug 
Administration (FDA) for the treatment of MDR- and XDR-TB in addition to conventional 
treatments, and has been the first new anti-TB drug in more than forty years.27 The last 
drug introduced specifically for the treatment of TB was 3, in the late 1960s. 5 is a 
diarylquinoline but has a different mode of action than existing quinolone antibiotics, which 
target DNA gyrase: in fact, it interferes with bacterial energy metabolism, inhibiting 
mycobacterial adenosine 5’-triphosphate (ATP) synthase therefore blocking bacteria from 
spreading across the whole body.28 5 has only been evaluated in two Phase IIb trials for 
safety and efficacy and its fast-track approval has been controversial due to the serious 
side effects observed during the trials. In 2013, the WHO has issued interim guidance for 
its use.  A Phase III trial, to be completed by 2020, has been scheduled, which will hopefully 
assess all the safety issues. 29   
 
Figure 4. Bedaquiline (®Sirturo, 5), last drug approved for the treatment of multi- and 
extensively-drug resistant tuberculosis. 
 
In general, the development pipeline for new TB drugs as of August 2014 has never been 
so rich over the past four decades, containing ten new or repurposed drugs in Phase II or 
Phase III trials and several other chemical entities in the earlier stages of the drug-
discovery process.23 
Besides the active form of TB, one third of the world’s population is estimated to be infected 
with an asymptomatic, latent form of TB with a lifelong risk of disease reactivation even 
after decades of subclinical persistence. The risk of reactivation is increased by HIV co-
infection, malnutrition, diabetes and alcohol abuse. Proper diagnosis and treatment of 
latent TB would play a key role in TB eradication. Whereas diagnostic tools to identify 
latent TB and distinguish it from active TB – this distinction is fundamental to establish the 
type of treatment to be administered – still do not exist, some treatments gave good 
completion rates such as the isoniazid preventive therapy or the rifampicin- and 
rifapentine-containing regimens.30 Unfortunately, a complete understanding of the 
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pathogenesis of latent TB is still lacking and the scientific attention toward this issue is 
very limited.  
 
1.4 The 2C-methyl-D-erythritol 4-phosphate (MEP) pathway 
1.4.1 Isoprenoids 
Isoprenoids constitute a large class of natural products present in fungi, bacteria, plants 
and mammals.31 More than 35,000 isoprenoids have been identified to date, with striking 
structural diversity and fulfilling very different, fundamental biological functions such as 
protein degradation, apoptosis, regulation of transcription and post-translational 
processes.32 In the life cycle of M. tuberculosis and several other bacterial pathogens, for 
example, they play essential roles in the biosynthesis of the components of the bacterial 
cell wall.33 Some examples of isoprenoids are depicted in Figure 5. Lanosterol (6) is the 
biosynthetic precursors of all steroids, such as cholesterol, which are essential to protect 
eukaryotic cell membranes. The group of vitamins A, which include retinol (7) and its 
derivatives, the retinoids, acts as a photoreceptor in animals and is a constituent of a light-
driven proton pump in some bacteria. ( ̶ )-Menthol (8), the main form of menthol which 
occurs in nature, has local anaesthetic and counterirritant qualities and it is widely used to 
relieve minor throat irritation.34 
 
Figure 5. Examples of isoprenoids: lanosterol (6), retinol (7) and (  ̶)-menthol (8). 
 
1.4.2 Biosynthesis of isoprenoid precursors isopentenyl diphosphate and 
dimethylallyl diphosphate: two distinct metabolic pathways 
Despite their remarkable diversity, isoprenoids are biosynthesized in all organisms using 
two common building blocks, namely isopentenyl diphosphate (9) and dimethylallyl 
diphosphate (10). Until the beginning of the 1990s, it was believed that the mevalonate 
pathway – named after the central intermediate of the pathway and utilizing acetyl-CoA as 




biosynthesis of 9 and 10.35 The work of Rohmer36 and Arigoni,37 independently, set the 
stage for the discovery of a completely distinct pathway for the synthesis of 9 and 10, 
employing pyruvate (11) and D-glyceraldehyde-3-phosphate (12) as building blocks 
(Scheme 1).38, 39 This biosynthetic pathway was initially named non-mevalonate pathway, 
although the more recent literature uses the term 2C-methyl-D-erythritol-4-phosphate 
(MEP, 13) pathway, named after the first committed precursor 13.  
After the discovery of the MEP pathway, the taxonomic distribution of the two pathways 
has been extensively studied,40 which demonstrated that whereas the mevalonate 
pathway is used by humans, animals, archaea and fungi, the MEP pathway is the sole 
source of 9 and 10 for green algae and numerous pathogenic bacteria and apicomplexan 
protozoa, including important human pathogens such as M. tuberculosis and 
P. falciparum, causative agents of tuberculosis and malaria, respectively.41 ̶ 43 Interestingly, 
higher plants use both pathways with a clear compartmentalization: the biosynthesis of 
sterols and triterpenes occurs in the cytoplasm via the mevalonate pathway, whereas the 
MEP pathway is used in plastids to biosynthesize carotenoids and phytol.44 This distinct 
distribution among organisms, together with the fact that the MEP pathway is essential in 
several organisms, – including P. falciparum,45 M. tuberculosis,46 Toxoplasma gondii, 
Pseudomonas aeruginosa and other infectious-diseases-causing organisms –,43, 47 has 
encouraged scientists to target the enzymes of the MEP pathway on the way to the 
development of novel antibacterial agents as well as novel and more potent herbicides.48 
 A rapidly growing number of (co-)crystal structures of the seven enzymes of the MEP 
pathway has been deposited in the RCSB Protein Data Bank (PDB) over the last two 
decades for the constituent enzymes of the MEP pathway, including several structures 
from pathogenic bacterial and plasmodial enzymes.49  No such structures have been 
reported so far for DXS, IspG and IspH, which are, in fact, the least studied among the 
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Scheme 1. Synthesis of the isoprenoid precursors isopentenyl diphosphate (9) and 
dimethylallyl diphosphate (10) via the 2C-methyl-D-erythritol-4-phosphate (MEP) pathway. 
 
1.4.3 Challenges in targeting the enzymes of the MEP pathway 
The fact that most of the intermediates of the MEP pathway are phosphorylated, means 
that the corresponding active sites of the enzymes are particularly polar, rendering the 
rational design of drug-like inhibitors targeting the active sites of these enzymes 




assessment of the enzymes of the MEP pathway using the web-based programme 
DoGSiteScorer,50 showing that all the substrate- and cofactor-binding pockets are overall 
druggable.51 Druggability assessment of biological targets has become a powerful tool for 
reducing drug attrition and it refers to the ability of a biological target to bind a drug-like 
molecule with adequate absorption, permeability and a binding affinity in the nanomolar 
range.52 The term ‘ligandability’ (or ‘bindability’) is often used to underline the notion that a 
good ligand (binder) will not necessarily lead to a good drug given that the target should 
also be disease-modifying.53 Nevertheless, in the druggability score, most programmes for 
druggability evaluation incorporate the likelihood that drug-like compounds can be 
developed.54 Therefore, we will use the term druggability to describe the ability of selected 
pockets to host drug-like organic molecules. 
Global pocket descriptors for discrimination between druggable and undruggable pockets 
are typically the volume (900 Å3)i, depth (21 Å2)i and enclosure (0.08).i The lipophilic 
surface fraction (0.7)i and the apolar amino acid ratio (AAAr, 0.57)i are also taken into 
account. In general, druggable pockets tend to be bigger, deeper, less solvent-exposed 
and have a higher hydrophobic character than undruggable pockets. 
When performing the druggability assessment of the enzymes of the MEP pathway, we 
observed that whereas the volume, depth and enclosure of the pockets identified by 
DoGSiteScorer are, in most cases, typical of druggable sites, the AAAr is below average 
for druggable pockets in all cases. On the one hand, the active site of IspD is the least 
lipophilic of all enzymes analysed. The fact that only a few substrate-competitive inhibitors 
have been developed so far, with inhibitory potency in the millimolar range,55 confirms the 
challenge in targeting IspD. On the other hand, druggability assessment of the binary 
complex of E. coli IspF (PDB: 1H48)56 with the product of the IspF-catalyzed reaction 2C-
methyl-D-erythritol 2,4-cyclodiphosphate (14) gave one of the highest druggability scores 
and AAAr. Of particular interest are potentially allosteric pockets that could be explored in 
future drug-design projects for the development of allosteric inhibitors. Potent allosteric 
inhibitors for Arabidopsis thaliana IspD have been reported by Witschel et al.57 and we 
identified other potentially allosteric pockets for DXS, IspD, IspF and IspG during our 
druggability assessment of the enzymes of the MEP pathway, which could be worth 
exploring.51 Unfortunately, a structure-based design of allosteric inhibitors for the enzymes 
of the MEP pathway appears to be more challenging. For A. thaliana IspD, for instance, 
these pockets are often formed only upon binding of a suitable ligand. As a result, high-
                                               
i Median values for druggable pockets as reported by Volkamer et al.50 
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throughput screening (HTS) approaches are better suited for the identification of an initial 
allosteric hit, which can subsequently be rationally optimized. 
Other challenges exist, in particular selectivity over human, related enzymes, specifically 
when targeting DXS, IspE, IspG and IspH. DXS is a thiamine diphosphate (TDP, 15)-
dependent enzyme just like some human enzymes (e.g., transketolase (TK), pyruvate 
dehydrogenase (PDH)), therefore selectivity can be an issue when developing TDP-
competitive inhibitors, considering that these pockets are usually highly conserved. On the 
other hand, DXS has several features, which distinguish it from other TDP-dependent 
enzymes, such as its peculiar domain arrangement, with the TDP-binding site located 
within the same monomer,58 the particularly large active site59 and the requirement for a 
ternary complex between TDP, 11 and 12 for the catalytic process to occur.60 In contrast, 
mammalian TDP-dependent enzymes bear the TDP-binding pocket at the dimer 
interface61 and follow classical ping-pong kinetics.62 These differences suggest that 
selective inhibition of DXS over mammalian TDP-dependent enzymes should be possible, 
in particular when also targeting the substrate-binding pocket. 
IspE is a kinase, which catalyses the transfer of the γ-phosphoryl group from ATP to the 
2-hydroxyl group of 4-diphosphocytidyl-2C-methyl-D-erythritol (16), affording 4-
diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate (17, Scheme 1). IspE  belongs to the 
galactose/homoserine/mevalonate/phosphomevalonate (GHMP) kinase superfamily, 
named after several mammalian proteins (galactose kinase, homoserine kinase, 
mevalonate kinase and phosphomevalonate kinase) and exhibits a high degree of 
similarity – in terms of sequence alignment and structural features – with these ATP-
dependent proteins,63 which could cause selectivity problems when targeting bacterial 
IspE.64 Nevertheless, significant differences between the active site of IspE and that of the 
kinases of the GHMP superfamily exist, suggesting that IspE could be targeted 
selectively.65, 66 
IspG and IspH contain both unusual [4Fe-4S] clusters, coordinated to three cysteine 
residues, with a unique fourth iron atom that is not in contact with any amino acid residue. 
Metalloproteins containing [4Fe-4S] clusters carry out a broad series of reactions in all 
organisms,67 including mammals, and targeting these clusters for the development of anti-
infectives, could lead to selectivity issues. On the other hand, the possibility to target both 
IspG and IspH at the same time, looks very appealing for the development of more 
effective antibacterial agents, potentially able to slow down the emergence of drug-




inflammatory effects of the product of the IspG-catalysed reaction, (E)-4-hydroxy-3-methyl-
but-2-enyl diphosphate (18) in acute infections. In fact, inhibition of only IspH, would lead 
to accumulation of 18, which would activate JδT cells leading to inflammation-related 
damage.68 
 
1.4.4 Mechanism of regulation of the MEP pathway and branch points with other 
metabolic pathways 
Very little is known regarding the mechanism of regulation of the MEP pathway, although 
a sound understanding of this aspect is essential when targeting its constituent enzymes. 
A recent in silico study of the MEP pathway in P. falciparum using an elaborate kinetic 
model, highlighted how two strategies can be used to develop inhibitors blocking 
isoprenoid biosynthesis in organisms at the MEP-pathway level. The first strategy consists 
in reducing the flux through the pathway by inhibiting the two enzymes having the highest 
flux-control coefficients (DXS and IspC). The second strategy consists in inhibiting the 
enzymes having the lowest flux-control coefficients (IspG and IspH), thereby causing the 
accumulation of certain metabolites leading to toxicity in the cell.69  Both types of enzyme 
targets proved to be valuable drug targets in the in silico study. More recent studies show 
that Populus trichocarpa DXS is inhibited by 9 and 10 in a TDP-competitive manner; this 
feedback inhibition is also part of the regulatory role of DXS for the whole MEP pathway. 
Several studies have also focused on the potential regulatory role of the bifunctional 
enzyme IspDF. 70 
Possible branch points of the MEP pathway with other metabolic pathways are of 
fundamental interest, especially in light of the development of inhibitors, which might be 
less prone to the emergence of resistance in bacteria. The strategy of targeting multiple 
MEP pathway enzymes at the same time could have the same advantage. On the one 
hand, DXS is a particularly interesting target, given the involvement of DXS in the 
biosynthesis of both vitamin B1 (19)71 and vitamin B6 (20)72 (Scheme 1). On the other 
hand, effective antibacterial activity could arise from drug combinations of IspC and IspF 
inhibitors, given that 13, the product of the IspC-catalyzed reaction, supposedly has a 
regulatory effect on the levels of 14 in pathogenesis. This is particularly important also in 
light of the recent discovery of a new mechanism of regulation of the MEP pathway, 
involving a sugar phosphatase whose loss of function is able to increase the level of the 
metabolites in the MEP pathway, particularly at the IspC level.73 It has been shown that 
overproduction of 1-deoxy-D-xylulose 5-phosphate (21), the substrate of IspC, can 
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overcome competitive inhibition of P. falciparum IspC by fosmidomycin (22, Figure 6), 
rendering the emergence of resistance to 22 a real problem. Moreover, the feed-forward 
mechanism to maximize the production of 14, confirms that sustained levels of 14 are 
required for the biosynthesis of other essential metabolites, besides isoprenoids.  
Feedback inhibition of the IspF-13 complex by the downstream isoprenoid farnesyl 
diphosphate (FDP) was also observed, while FDP does not inhibit IspF itself, suggesting 
that the IspF-13 complex may be the physiologically relevant form of the enzyme. 
. 
1.5 Overview of inhibitors of the enzymes of the MEP pathwayii 
A detailed overview of DXS, including structural features and discussion of the inhibitors 
reported in the literature, will be given in Chapter 1.6. 
IspC is the most widely studied among the enzymes of the MEP pathway and it catalyzes 
both an intramolecular isomerization and an NADPH-dependent reduction to generate the 
product 13. For the reaction to occur, the presence of a divalent cation (Mg2+, Co2+ or Mn2+) 
is necessary. The mechanism of IspC, especially the isomerization step, is particularly 
intriguing and has been extensively studied over the past years.  
 
Scheme 2. Proposed mechanism of the IspC-catalyzed reaction via a retroaldol/aldol 
mechanism. The divalent cation of the M2+-IspC-NADPH complex, responsible for 
coordinating 21, 24 and 25 is not shown. 
 
                                               
ii All specific references for the inhibitors and crystal structures discussed in this Chapter can be 
found in: Masini, T.; Hirsch, A. K. H. Development of inhibitors of the 2C-methyl-D-erythritol-4-





This step is thought to proceed through the aldehyde intermediate 23, which is 
subsequently reduced by NADPH. Multiple mechanisms have been proposed for the 
conversion of 21 to 23, but most experimental observations support a retroaldol/aldol 
pathway, as shown in Scheme 2. The divalent cation facilitates the reaction by coordinating 
the substrate 21 and, subsequently, 24 and 25. In fact, being tightly coordinated to the 
metal cation, they can easily recombine via the aldol reaction to yield 23.74, 75 
The number of derivatives of 22 and FR900098 (26), potent inhibitors of IspC and 
antimalarial agents, reported in the literature so far is enormous, and substantial progress 
has recently been made especially aimed at improving their bioavailability and on 
enhancing their lipophilic character to obtain whole-cell antimycobaterial activity. 22 as 
antimalarial agent suffers from low bioavailability, rapid clearance from the parasite and a 
short serum half-life and is, in fact, currently under clinical investigation in conjunction with 
piperaquine so as to overcome the above-mentioned drawbacks. Moreover, 22 is a potent 
inhibitor of M. tuberculosis IspC in vitro but does not have any inhibitory activity in 
mycobacteria, presumably because of its inability to cross the mycobacterial cell wall. The 
major modifications of the chemical scaffolds of 22 and 26, which have been exploited, 
are summarized in Figure 6a.  
 
Figure 6. (a) Major modifications of the chemical scaffolds of fosmidomycin (22) and 
FR900098 (26) to improve their potency against IspC in vitro and in cell-based assays; (b) 
Two examples of inhibitors developed for IspC. 
 
While most of the attempts aimed at the identification of a suitable replacement for the 
hydroxamic moiety – which chelates the IspC cation – failed, the introduction of 
substituents on the central linker, specifically at the α-carbon atom of the phosphonate 
moiety, resulted in derivatives such as 27 displaying low nanomolar inhibition of 
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P. falciparum IspC and potent inhibitory activity against the MDR K1 strain of P. falciparum, 
about 10-fold higher than the one of 22, together with no cytotoxicity on human MRC-5 
cells (Figure 6b). Modifications at the phosphonate moiety focus mainly on the 
development of more apolar prodrugs, which would be able to cross the very apolar 
mycobacterial cell wall before being hydrolysed by an endogenous esterase. 28, for 
example, is able to inhibit the growth of M. smegmatis (MIC = 250500 μM), although less 
efficiently than the antituberculotic drug 1 (MIC = 1020 μM). 
IspD is rather underexplored as a target and this does not come as a surprise considering 
the particularly high polar character of its active site. Nevertheless, two classes of potent, 
allosteric inhibitors have been identified, with the azolopyrimidine 29 having double-digit 
nanomolar activity against A. thaliana IspD and the pseudilin-type compound 30 having 
double-digit micromolar activity against P. vivax IspD (Figure 7a). Although co-crystal 
structures of this class of compounds have been reported in complex with A. thaliana IspD, 
which might guide further rational optimization of these scaffolds, a dedicate approach for 
the development of these compounds as antimalarial agents is recommended, given the 
remarkable sequence dissimilarities between P. falciparum IspD and its orthologues. 
 
Figure 7. (a) Allosteric inhibitors of IspD; (b) Selection of reported inhibitors of IspE. 
 
In 2007, Diederich and co-workers reported the first inhibitor of E. coli IspE targeting the 
substrate-binding pocket whilst exploring an adjacent lipophilic pocket, having a Ki value 
of 290 nM (compound 31, Figure 7b). After that, a lot of effort has been devoted in trying 
to optimize this scaffold but without success. This fact suggests that a bottleneck has been 
reached for this scaffold and that chemical diversity needs to be explored. In fact, many 
recent studies have reported a broad variety of scaffolds (mainly fragments) obtained by 
(in silico) HTS-approaches, having micromolar inhibitory potency against E. coli IspE and 




Unfortunately, for none of the reported inhibitors of IspE, there are data regarding their 
activity against IspE of pathogenic organisms, although the high level of sequence identity 
among different IspE orthologues (3038% identity between M. tuberculosis IspE and 
Thermus thermophilus, E. coli and Aquifex aeolicus IspE) as well as high overall structural 
similarity, suggests that they might be active also against other IspE orthologues.  
Despite intensive studies of the structural and mechanistic features of IspF, few inhibitors 
for this enzyme have been reported in the literature so far, with the most successful ones 
being the non-cytidine-like thiazolopyrimidines derivatives reported by Diederich and co-
workers in 2010, having single-digit micromolar activity against both P. falciparum and M. 
tuberculosis IspF (e.g., 33, Figure 8a). No information about their binding mode is 
available, and their optimization has not been reported to date. A hydrophobic cavity found 
at the core of the IspF trimer was found to be druggable in our druggability assessment 
and given its presumed role in regulating the MEP pathway – several downstream 
isoprenoid products have been identified in this pocket by crystallographic studies and 
mass-spectrometry experiments –, it could be particularly interesting to explore for the 
development of inhibitors for IspF. 
 
Figure 8. (a) Most successful inhibitor of IspF; (b) Most successful inhibitors of IspG and 
IspH. 
 
Most of the inhibitors developed so far for IspG and IspH target the [4Fe-4S] cluster, in 
particular its unique fourth iron site. The ability of a certain ligand to interact with the fourth 
iron atom of the cluster constitutes a key feature for enhancing its inhibitory potency with 
respect to these enzymes. 34 and 35, bearing an amino and a thiol group, respectively, 
both able to interact with the fourth iron site of the [4Fe-4S] cluster, were found to inhibit 
IspG and IspH with single-digit micromolar (IspG) and nanomolar (IspH) IC50 values 
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(Figure 8b). A recent EPR investigation of their binding mode within IspG and IspH 
highlighted a remarkable difference in their binding behaviour with the two enzymes, which 
should be considered especially when targeting both IspG and IspH at the same time. 
Replacement of the terminal hydroxyl group of 18 with a pyridyl moiety, which can interact 
with the [4Fe-4S] cluster via a Lewis acid-base mechanism, was less successful, with the 
best compound, 36, showing just single-digit micromolar inhibition of A. aeolicus IspH 
(Figure 8b). 
 
1.6 1-Deoxy-D-xylulose-5-phosphate synthase (DXS) 
DXS catalyzes the first and rate-limiting step of the MEP pathway, consisting in the 
biosynthesis of 21 in a head-to-tail condensation of 11 and 12 and concomitant TDP (15)- 
and Mg2+-dependent decarboxylation.76 As shown in Scheme 3a, 15 is first converted to 
yilde 37. This step is induced by a Glu residue that is strictly conserved amongst TDP-
dependent enzymes and that lies within hydrogen-bonding distance of the N1’ atom of the 
aminopyrimidine ring of TDP. Proton transfer from Glu to N1’ aids the amino-imino 
tautomerization of the aminopyrimidine moiety. After that, internal transfer of a proton from 
C2-H to the imino nitrogen produces ylide 37. Interestingly, replacement of the conserved 
Glu residue with other amino acids, does not allow for ylide formation resulting in lack of 
enzymatic activity.62 After 37 is formed, the deprotonated C2 carbon atom of the thiazolium 
moiety, acts as a nucleophile onto the carbonyl group of 11, thus forming 38 (Scheme 3b). 
By a careful study of the individual rate constants in the DXS-catalyzed reaction, it has 
been shown that the formation of 38 is the rate-limiting step.77 The group of Jordan and 
co-workers also found that the predecarboxylation intermediate 38 is relatively stable in 
the absence of 12, while addition of 12 causes a 600-fold enhancement of the rate of the 
decarboxylation step. These studies support the necessity for the formation of a ternary 
complex in the DXS-catalyzed reaction, with DXS bound to 38 and 12, as previously 
proposed by Eubanks and Poulter,78 highlighting a unique feature of DXS that could be 
exploited for inhibitor design. In fact, as mentioned in Chapter 1.4.3, all other TDP-
dependent enzymes are known to follow classic ping-pong kinetics. Jordan and co-
workers propose a few explanations for the essential role played by 12 in promoting the 
decarboxylation step: a likely explanation suggests that the decarboxylation is reversible 
and that CO2 release is potentiated by 12 bound to DXS. Another plausible explanation 
would involve the requirement for a zwitterionic form of 38 to have an acceptable 




of the carboxylate of 38 from amino acid residues of DXS lying in close proximity might 
occur, reducing the rate of decarboxylation to a great extent.77  
 
Scheme 3. Mechanism of the DXS-catalyzed reaction. (a) Details about the formation of 
the catalytically active species 37; (b) Catalytic cycle. The Scheme is only meant to convey 
the chemical steps of the DXS-catalyzed reaction. Details about the enzymatic mechanism 
are emerging.60, 7779 
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Recently, Freel Meyers and co-workers identified residues of E. coli DXS that are involved 
in binding of 12. Despite not being essential for catalysis, Arg420, Arg478 and Tyr392 (E. 
coli DXS) have been shown to have an essential role in binding 12.79 
After decarboxylation of 38, the enamine intermediate 39 is formed, which then undergoes 
a nucleophilic attack on 12 affording 40 and finally releasing the product 21 as well as the 
catalytically active thiamine ylide moiety 37.80 
As shown in Scheme 1, 21 is an intermediate not only in isoprenoid biosynthesis but also 
in vitamin B1 (19)71 and vitamin B6 (20)72 biosynthesis, rendering the DXS-catalyzed 
reaction a crucial branch point in pathogen metabolism and therefore DXS a very attractive 
drug target. Given its presumably important regulatory role for the whole MEP pathway 
(previously discussed in Chapter 1.4.4), it is therefore surprising that DXS is the least 
studied among all the enzymes of the MEP pathway, with just two crystal structures 
deposited in the PDB of Deinococcus radiodurans and E. coli DXS in complex with its 
cofactor TDP and Mg2+ (PDB codes: 2O1X and 2O1S, respectively)58 and very few 
inhibitors reported in the literature. DXS is a tightly associated dimer, where each monomer 
consists of three domains and the TDP-binding site of DXS is located at the interface of 
two domains within the same monomer.58 This feature distinguishes DXS from other 
homologous enzyme, including mammalian TDP-dependent enzymes, where the active 
site is located at the interface of two monomers. Other peculiar features of DXS over 
mammalian TDP-dependent enzymes have been discussed in detail in Chapter 1.4.3. In 
particular, DXS appears to be unique for its mechanism of action: 11 and 12 have been 
shown to bind independently and reversibly to DXS, en route to the formation of a 
catalytically active ternary complex, whereas all other TDP-dependent enzymes are known 
to follow classical ping-pong kinetics.60  
15 binds tightly to DXS (D. radiodurans DXS, Kd = 0.114 ± 0.01 μM; M. tuberculosis DXS, 
Kd = 3.1 ± 0.3 μM), in a relatively buried pocket of the protein (Figure 9) and we have 
recently shown how the diphosphate moiety of 15 accounts for a good part of its binding 
energy to the enzyme. 81   
Although no structural information is available about the substrate-binding pocket, 
mutagenesis studies have identified which amino acid residues of DXS are involved in the 
substrate-recognition process. His51 (D. radiodurans DXS) was shown to be essential for 
the catalytic process82 while a recent study by Freel Meyers and co-workers confirmed the 




process, although they were shown not to be essential for catalysis.79 His434 and Asp430 
(D. radiodurans DXS) might also be involved in substrate recognition (Figure 10).58 
 
Figure 9. Thiamine diphosphate (TDP, 15)-binding pocket within Deinococcus 
radiodurans DXS (PDB: 2O1X).58 Color code: protein (shown as surface): C: grey; O: 
red; N: blue; S: yellow. Mg2+ ion is shown as a cyan sphere. 15 skeleton: C: green. 




Figure 10. Putative substrate-binding pocket of D. radiodurans DXS. The amino acid 
residues involved in the catalytic process or in the substrate-recognition process are 
shown as sticks. 
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Nevertheless, a rational design of substrate-competitive inhibitors does not seem feasible, 
given that the substrate-binding pocket is not well defined in the crystal structure of 
D. radiodurans DXS in complex with 15. This pocket might, in fact, form just upon 
substrate-binding by proper positioning of a loop (defined approximately by residues 
Lys208 and Ala327 in D. radiodurans DXS), which is otherwise rather flexible. 
 
1.6.1 Known inhibitors of DXSiii 
Ketoclomazone (41, Figure 11), a metabolite of the known herbicide clomazone, is known 
to inhibit Chlamydomonas DXS with an IC50 value of 0.1 mM. A more recent study reports 
its ability to suppress the growth of Haemophilus influenzae with a minimum inhibitory 
concentration (MIC) of 12.5 μg/mL; 41 is able to inhibit H. influenzae DXS at low 
micromolar concentration (Ki = 23 μM) in a non-competitive and mixed-type manner with 
respect to 11 and 12, respectively. Recently 42 (Figure 11), a derivative of 41 produced 
by the hydrolysis of the latter, was reported to inhibit H. influenzae DXS with an IC50 value 
of 1.0 μM and shown to inhibit the growth of H. influenzae with a MIC value of 32 μg/mL. 
Addition of 1-deoxy-D-xylulose (DX), used as exogenous nutrient of the MEP pathway, 
capable to rescue the second step of the MEP pathway, led to a suppression of the 
inhibitory effect, showing that the antibacterial activity can be ascribed to inhibition of DXS. 
The absence of the hydroxyl group on the nitrogen atom, the dimethyl substitution or the 
removal of the carbonyl group of the carboxylic acid of 41, resulted in a significant loss of 
the in vitro activity. Nevertheless, compound 43 (IC50 = 3.1 μM, H. influenzae DXS) showed 
a moderate MIC value (MIC = 64 μg/mL), suggesting that cell permeation might be partially 
prevented by the negative charge present on 42. The fact that 41 exhibits stronger cell-
based activity than 42 despite their comparable in vitro activity against H. influenzae DXS, 
suggests that cell-permeability might be an issue and that 41 might be a prodrug for the 
generation of 42 in situ. Another known inhibitor of DXS is fluoropyruvate (44, Figure 11) 
which has an IC50 value of 400 μM against Pseudomonas aeruginosa DXS and 80 μM for 
E. coli DXS. It was postulated that 44 binds covalently to the active site of DXS. Compound 
45 (Figure 11), a transketolase-inspired inhibitor, has an IC50 of 10.6 μM against M. 
tuberculosis DXS but insufficient structure  ̶activity relationships (SARs) together with a 
lack of information about its binding mode, did not allow for further optimization of this 
                                               
iii All the specific references for the inhibitors discussed in this Chapter can be found in: Masini, T.; 
Hirsch, A. K. H. Development of inhibitors of the 2C-methyl-D-erythritol-4-phosphate (MEP) pathway 




scaffold. Moreover, despite displaying reasonably good inhibition of mycobacterial growth, 
it was also shown to be cytotoxic, indicating that it might have off-target activity against 
mammalian enzymes such as TK. This would not be surprising considering that the 
scaffold originates from a known TK inhibitor. 
Figure 11. Known inhibitors of 1-deoxy-D-xylulose-5-phosphate synthase (DXS). 
 
In 2013, BASF initiated an HTS-based program to identify additional inhibitors of the 
enzymes of the MEP pathway on the way to the development of new herbicides, using the 
plant enzymes from A. thaliana.  In the HTS screening with A. thaliana DXS, two main 
clusters of compounds have been identified, corresponding to hydrazine derivatives and 
diphenyl oxazole scaffolds, with the best inhibitors being 46 and 47 for the two clusters, 
respectively (46, IC50 = 33 μM; 47, IC50 = 32 μM, Figure 11). The results were rather 
disappointing considering that 41 gave an IC50 of 80 nM in the same assay. Moreover, the 
absence of convincing SARs among the best hits, did not allow for further rationalization 
of the results. 
Recently, the group of Freel Meyers reported the development of substrate-competitive 
inhibitors for DXS such as compounds 4850 (Figure 11). Taking advantage of the 
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previously discovered flexibility of DXS toward non-polar acceptor substrates and 
considering that α-keto acids modified at the acyl position had been found to be poor 
alternative donor substrates for DXS, they designed a series of acetylphosphonates as 
bisubstrate inhibitors, accommodating features from both 11 and unnatural acceptor 
substrates. These derivatives inhibit E. coli DXS in a competitive manner with respect to 
11, with single-digit micromolar Ki values and, as expected, increasing the length of the 
acyl groups results in a dramatic decrease of the inhibitory activity. Their mode of action 
presumably involves reaction with bound TDP to form a stable phosphonolactyl-TDP 
intermediate, which prevents the enzyme from catalyzing the decarboxylation step to yield 
21. Interestingly, remarkable selectivity over mammalian TDP-dependent enzymes was 
also reported, in particular against porcine PDH and Saccharomyces cerevisiae TK. 
Butylacetylphosphonate (49, Figure 11) has single-digit micromolar inhibitory activity 
against Yersinia pestis (Ki = 7.5 μM), Salmonella enterica (Ki = 8.4 μM) and M. tuberculosis 
DXS (Ki = 4.0 μM) but exhibits weak antimicrobial activity against both Gram-negative and 
Gram-positive strains including E. coli and S. enterica, probably due to poor cellular 
uptake. The fact that the activity of DXS is rescued in the presence of DX or 19, or under 
conditions of DXS overexpression, demonstrates that the antimicrobial activity of 49 is a 
consequence of the specific inhibitory effect of 49 against DXS. Despite its weak 
antimicrobial effects, 49 can act synergistically with established antimicrobial agents such 
as fosmidomycin (22). Biochemical experiments conducted by Freel Meyers and co-
workers suggest that reducing the flux of the MEP pathway at the DXS and IspC level 
might have a strong impact on IspF activity, by rapidly depleting levels of 13. As discussed 
in Chapter 1.4.4, in fact, 13 has supposedly a regulatory effect on the levels of 14 – the 
product of the IspF-catalyzed reaction – in pathogenesis. Drug synergism in the MEP 
pathway has already been reported and should be considered as a powerful strategy to 
prevent the emergence of drug resistance. Moreover, it has been shown that the 
combination of 49 and ampicillin is additive. 
Freel Meyers and co-workers have recently analyzed the peculiar features of the active 
site of DXS compared to other TDP-dependent enzymes. They have shown that the 
particularly big size of the active site of DXS, which can accommodate also sterically 
demanding scaffolds, could be successfully exploited to design aryl-substituted 
acetylphosphonates as selective DXS inhibitors. Benzylacetylphosphonate (50) was 
shown to inhibit E. coli DXS with a Ki value of 10.4 μM and exhibits an increased selectivity 




1.7 Project goals and outline 
Despite being such an interesting biological target, DXS is underexplored, owing to the 
lack of structural information. In this thesis, we will describe the application of multiple hit-
identification and optimization strategies that we have exploited for the development of 
inhibitors of DXS. 
In Chapter 2, we will describe the first application of an innovative NMR methodology to a 
fragment-based design project. We first designed de novo a series of fragments aimed at 
occupying the TDP-binding pocket of DXS, with the potential of being grown towards the 
substrate- and the diphosphate-binding pockets. To overcome the issue of not having 
access to any (co-)crystallographic information to establish their binding mode within DXS, 
we used a three-step NMR methodology, which allowed us to validate the binding mode 
of the fragment hits in solution and successfully guide the next cycle of fragment-
optimization.  
In Chapter 3, we will show the application of a simple but powerful hit-identification 
methodology, namely phage display, for the development of the first peptidic inhibitors of 
DXS, with low micromolar activity against D. radiodurans DXS. We will also describe the 
identification of key motifs as well as parts of the amino acid sequence, which can be 
further modified to enhance the inhibitory potency of the inhibitor.  
Chapter 4 is about the rationalization of the differences in inhibitory activity between 
D. radiodurans and M. tuberculosis DXS of thiamine analogues. By advanced docking 
studies, we were able to develop and validate a homology model of M. tuberculosis DXS 
which can be used for rational design of inhibitors for M. tuberculosis DXS in the absence 
of crystallographic information. Moreover, we exploited bioisosteres of the diphosphate 
moiety of TDP, such as sugars.  
In Chapter 5, we describe the development and use of a web-based software called 
TPPQuery, which allows for pharmacophore search of anchor-oriented virtual libraries and 
helps in identifying potential TDP-competitive inhibitors that can be synthesized via multi-
component reactions. We will discuss the putative binding modes of a selection of 
scaffolds and their synthesis via the Zhu, Van Leusen and Groebke reactions. 
In Chapter 6, we will demonstrate the power of ligand-based virtual screening (LBVS) as 
hit-identification methodology. Starting from the scaffolds of some fragments that we 
designed and tested as reported in Chapter 2, we performed several cycles of LBVS to 
screen the ZINC database. This allowed us to identify low-micromolar inhibitors of both 
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D. radiodurans and M. tuberculosis DXS, with potent activity in cell-based assays against 
MDR and XDR strains of M. tuberculosis. Moreover, we could establish a high degree of 
selectivity of the hit compounds over mammalian TDP-dependent enzymes. 
Each chapter contains a final section in which we discuss an overview of the results 
obtained and we evaluate the future perspectives. 
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De novo fragment-based design of inhibitors 
of DXS guided by NMR spectroscopy 
 
In this chapter, we will describe the first application of an innovative NMR methodology in 
a de novo fragment-based design project. After the design of the first fragments, which 
showed weak inhibitory potency against Deinococcus radiodurans DXS, we exploited a 
combination of STD-NMR, trNOE and INPHARMA (STI) to validate their binding mode 
within D. radiodurans DXS in solution, circumventing the requirement for an X-ray co-
crystal structure. Based on this finding, we carried out fragment growing and optimization, 
which led to a three-fold more potent fragment, about as potent as the well-established 
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 Chapter 2 
2.1 Fragment-based drug design 
Fragment-based design (FBD) has emerged as a powerful tool for the discovery and 
optimization of drug-like compounds.1 Whereas the most common approach for the 
identification of fragments as hits still remains the screening of fragment libraries,2 de novo 
design of fragments is attracting more and more attention,3 in particular for targets for 
which an initial screen of a fragment library is impossible owing to the type of assay used 
or insufficient quantities of protein available. The use of FBD is particularly attractive due 
to its potential to cover a greater fraction of chemical space and to afford fragments with 
high ligand efficiencies (LEs, defined as LE = −ΔG/N where ΔG corresponds to the Gibbs 
free energy of binding (kcal/mol) and N is the number of non-hydrogen atoms) that should 
be maintained during the optimization stages.4 Despite these advantages, several hurdles 
persist: the fragment hit identified may not be amenable to follow-up synthesis, which is 
often a time-consuming and resource-intensive undertaking. Furthermore, the fragment-
to-lead process consists of optimizing (e.g., fragment growing, fragment linking) the initial 
fragment hit towards a more potent lead-like compound.5 During this process, the binding 
mode of the initial fragment must be maintained, requiring ideally a co-crystal structure of 
the (modified) fragment to be solved at every optimization step.6 Unfortunately, for 
approximately 40% of the pharmaceutically relevant protein targets, crystal structures of 
sufficient quality cannot be obtained, and for those proteins that are crystallizable, this is 
often a time- and resource-consuming process, as reliable soakable crystallographic 
systems are not always available.7 Moreover, it can be very difficult to co-crystallize 
fragments obtained in the early stages of the fragment-to-lead process because of their 
weak affinities for the target, requiring prohibitively high concentrations of ligand. 
 
2.2 Study of the TDP-binding mode within D. radiodurans DXS 
As a starting point for our FBD project, we decided to target the thiamine diphosphate 
(TDP, 1)-binding pocket of DXS rather than the ill-defined substrate-binding pocket. 
Despite the low lipophilic character of the TDP-binding pocket with respect to the average 
for druggable pockets, it obtained a rather high Dscore when analyzed with the program 
DogSiteScorer.8 The fragments were designed so that they could be further grown either 
toward the diphosphate pocket or ideally toward the substrate-binding pocket, where 
selectivity could be gained. We used Deinococcus radiodurans DXS as a model enzyme 
for our studies given the high degree of sequence identity between D. radiodurans and 
Mycobacterium tuberculosis DXS (38% overall, 68% in the TDP-binding pocket). 
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As a first step, we analyzed the binding mode of 1, which is deeply buried inside 
D. radiodurans DXS (Protein Data Bank (PDB) code: 2O1X).9 As highlighted in Figure 1, 
the aminopyrimidine moiety of 1 is involved in three hydrogen bonds with the protein 
(d(N3···HN–Ala125) = 3.1 Å, d(H2N···O=C-Gly123) = 2.9 Å, d(N1···HO–C–Glu373) = 
2.7 Å) and a π-stacking interaction with the side chain of Phe398. The catalytically active 
part of 1, the thiazolium ring, is surface-exposed and involved in a few hydrophobic 
interactions (with Ile187, Ile371 and Val80), while the diphosphate moiety engages in 
numerous polar interactions both with polar amino acid side chains and with the protein 
backbone. The catalytic Mg2+ ion is complexed by both phosphate groups.  
 
Figure 1. Thiamine diphosphate (TDP, 1) in the TDP-binding pocket of D. radiodurans 
DXS (PDB code: 2O1X).9 The three subpockets are highlighted and labeled as pocket A 
(aminopyrimidine pocket), B (thiazolium pocket) and C (diphosphate pocket), respectively. 
Color code: protein skeleton: C: gray; O: red; N: blue; S: yellow. Mg2+ ion is shown as a 
purple sphere. The color code is maintained throughout, if not otherwise stated. All the 
figures of this chapter refer to compounds modeled within D. radiodurans DXS (PDB: 
2O1X), unless otherwise stated and were all generated using the software PyMOL.10  
 
We determined the dissociation constant (Kd) of 1 with D. radiodurans and M. tuberculosis 
DXS (D. radiodurans DXS, Kd = 0.114 ± 0.01 μM; M. tuberculosis DXS, Kd = 3.1 ± 0.30 
μM), which confirmed the binding of 1 with DXS to be rather tight. Moreover, we 
synthesized and tested two closely related analogues of 1, namely deazathiamine (2) and 
deazathiamine diphosphate (3)11 (Figure 2), so as to have an indication about the 
contribution of the diphosphate moiety to the inhibitory potency. While the in vitro 
biochemical evaluation of 2 against D. radiodurans DXS resulted in a modest inhibitory 
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potency (IC50 = 430 ± 68 μM), 3, bearing the diphosphate group, proved to be a much more 
potent inhibitor of D. radiodurans DXS, with a double-digit nanomolar IC50 value (IC50 = 
0.034 ± 0.006 μM). It is therefore evident that the diphosphate moiety accounts for a good 
part of the binding energy of TDP to the protein. Being aware of the challenges in targeting 
polar diphosphate-binding pockets with drug-like moieties, we decided to first model 
fragments, which could occupy the more druggable aminopyrimidine and thiazolium 
subpockets (pockets A and B in Figure 1, respectively) 
 
Figure 2. Thiamine diphosphate (TDP, 1) and the respective dissociation constants (Kd) 
with Deinococcus radiodurans and Mycobacterium tuberculosis DXS; 2 and 3 are two 
examples of closely related analogues of 1, with their respective IC50 values against 
D. radiodurans DXS. (a)Compound 3 was synthesized and tested as a 1:1 mixture with 
(NH4)OTs. 
 
2.3 First generation of fragment-like inhibitors for DXS 
 
2.3.1 Modeling studies and synthesis of fragments 4 and 5 
Using the modeling software MOLOC,12 we designed fragments 4 and 5 de novo so as to 
explore two subpockets of the TDP-binding pocket (Figure 3). The ethylene substituent of 
4, bearing a thiophene group, replaces the methyl group of 1. The thiophene ring is 
engaged in a CHπ-stacking interaction with His124 and in a cation-π interaction with 
Arg401. However, the ethylene linker is not in a perfect zig-zag conformation. To allow for 
these interactions to occur, the aminopyridine ring has moved toward the thiazolium-
binding pocket where, together with the ethylene linker, it forms numerous hydrophobic 
contacts with the side chains of Ile371, Ile187 and Val80, while the amino group is engaged 
in a hydrogen-bonding interaction with the side chain of His434 (d(NH2··N(His434) = 
3.1 Å). 
Fragment 5 and, specifically, its indole moiety, was designed so as to occupy a newly 
identified pocket lined by residues His304, His82, His51, Phe109 and His43. According to 
our modeled pose, the indole moiety is engaged in many hydrophobic contacts with these 
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residues. This pocket, from now on referred to as “histidine-rich pocket”, is presumably 
involved in the substrate-recognition process. The aminopyridine ring is, in this case, 
positioned as the original aminopyrimidine ring of 1, maintaining the same network of 
hydrogen-bonding interactions. Moreover, the hydroxyl substituent on the indole ring 
anchors the scaffold to the protein via a hydrogen-bonding interaction with His51 




Figure 3. Schematic representation of the modeled binding mode of fragments 4 
(Figure 3a) and 5 (Figure 3b). Side chains of amino acid residues involved in hydrogen-
bonding interactions are written out while side chains of amino acid residues involved in 
hydrophobic contacts and other kind of interactions, as discussed in the main text, are 
omitted for simplicity. 
The synthesis of 4 and 5 is shown in Scheme 1. 4 was synthesized starting from 
commercially available 6, which was subjected to a Sonogashira reaction with trimethylsilyl 
(TMS)-acetylene and subsequently deprotected with TBAF to yield 7 in 80% yield (over 
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two steps).13 The thiophene ring was introduced via another Sonogashira reaction, and 8 
was hydrogenated to yield the final product 4 in 72% yield. 
 
 
Scheme 1. Synthesis of fragments 4 and 5. 
 
We synthesized 5 starting from 9, which was reduced to the alcohol 10 and subsequently 
chlorinated to yield 11.HCl.14 The indole moiety was installed via a SN2 reaction yielding 
12 in 20% yield. This very low yield is caused by incomplete conversion which was not 
improved by addition of tetrabutyl ammonium iodide (TBAI) and also by the reaction of the 
indole as a nucleophile at its C3-position. The C3-alkylated side product and 12 turned out 
to be difficult to separate from the desired product 12 and only a small fraction of 12 could 
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be obtained in pure form. The target molecule 5 was obtained by reducing the ester 
functionality of 12 with LiAlH4.  
 
2.3.2 Modeling studies and synthesis of fragments 13 and 14. 
Fragment 13 was designed so as to occupy the TDP-binding pocket and potentially be 
grown either toward the diphosphate- or the putative substrate-binding pockets. In the 
modeled pose, as shown in Figure 4, the favorable π-stacking interaction with Phe398 is 
maintained in the same way as for 1, but the pyridine ring of 13 is slightly displaced with 
respect to the amino-pyrimidine ring of 1 leading to a more favorable parallel-displaced π-








Figure 4. Fragment 13 designed de novo and its modeled binding mode in the thiamine 
diphosphate-binding pocket of Deinococcus radiodurans DXS (PDB: 2O1X). Color code: 
13 skeleton: C: yellow. 
 
In the modeled pose, the imidazole ring of 13 is accommodated in the thiazolium pocket 
and is displaced with respect to the thiazolium ring of 1. As a result, the van-der-Waals 
interactions with Ile187 and Ile371 − which help to keep the thiazolium ring in place in the 
case of 1 – should be strengthened. According to the modeling studies, the imidazolic N3 
is involved in a favorable hydrogen bond with the side chain of Ser186 (d(N··HO-Ser186) 
= 3.0 Å). The 3-methoxy group of the pyridine ring forms a hydrogen bond with the 
backbone N-H of Ala125 (d(O··HN-Ala125 = 2.8 Å), mimicking the hydrogen bond of the 
N3 of the aminopyrimidine ring of 1. Not surprisingly, the N1 of the pyridine ring of 13 is 
not involved in a hydrogen bond with Glu373 anymore, due to the displacement of the ring 
with respect to the aminopyrimidine ring of 1. 
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Fragment 14 was designed de novo so as to explore the newly identified “histidine-rich” 
pocket (Figure 5). According to the modeling studies, we introduced a pyrazole moiety 
bearing a diol functionality to hydrogen bond to Lys101 (d(OH··2HN–Lys101 = 3.3 Å), 
Asp430 (d(OH··O=C–Asp430 = 2.8 Å) and His434(d(OH··N–His434 = 2.8 Å). Although the 
pyrazolyl ring is not directly interacting with His51, it is believed to interfere with the 
catalytic role of His51, supposedly in the substrate-recognition process.15 An ethylene 
linker (torsional angle τ(Npyrazole–C–C–Cimidazole): –168º) connects the pyrazolyl ring 
to an imidazolyl ring accommodated in the thiazolium pocket. In addition to the van-der-
Waals interactions with the side chains of Ile187 and Ile371, the imidazolyl ring is involved 
in a favorable Saromatic interaction with the side-chain sulfur atom of Met349. The linker 
itself is also involved in numerous lipophilic contacts with the side chain of Ile187 and 







Figure 5. Fragment 14 designed de novo and its modeled binding mode in the thiamine 
diphosphate-binding pocket of Deinococcus radiodurans DXS. Color code: 14 skeleton: 
C: purple. 
 
We synthesized fragment 13 starting from commercially available 5-hydroxynicotinic acid 
(15), which was esterified in MeOH using Amberlyst-15 as a solid acid catalyst (Scheme 
2). The corresponding methyl ester (16) was obtained in 86% yield. For the methylation of 
the hydroxyl group of 16, we used phenyltrimethylammonium chloride as a methyl source, 
performing the reaction in the microwave (200 W, 80 °C) for 1 hour and we obtained the 
product (17) in 40% yield. To increase the yield, we attempted the treatment of 16 with 
methyl iodide and K2CO3 by refluxing in acetone for 16 hours, but we observed degradation 
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of the starting material. After these first attempts, we established a more convenient 
synthetic protocol, which allows for the methylation of both the carboxylic acid and the 
hydroxyl group of 15 at once, by using trimethylsilyldiazomethane, affording 17 
conveniently in one step in quantitative yield. We subsequently treated 17 with DIBAL-H 
at 78 °C and we obtained the corresponding alcohol 18 in 97% yield. 
 
Scheme 2. Synthesis of fragments 13 and 22. 
 
Attempts to convert 18 into the corresponding tosylate were unsuccessful. Therefore, we 
decided to insert a chloride onto 18 and we attempted the synthesis of 19 via the Appel 
reaction. Given that we observed the formation of a complex mixture of products, we 
abandoned this protocol and we successfully synthesized 19 (as its HCl salt) by treating 
18 with SOCl2 in CHCl3 or CHCl2 for 45 minutes. Many attempts to purify 19.HCl, were 
unsuccessful. In particular, when trying to neutralize 19.HCl by performing a basic work 
up, we obtained 18 back. Therefore, we used 19 as a crude product for performing the 
subsequent SN2 reaction with imidazole (20). Among the several bases that we have 
screened (e.g., NaH, Cs2CO3, K2CO3), NaH gave the best result and we obtained 13 in 
66% isolated yield (over two steps). 
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To understand the importance of the pyridine nitrogen atom when testing these molecules 
against the target enzyme, we also conveniently synthesized a closely related derivative 
of 13 starting from commercially available starting materials (20 and 1-(chloromethyl)-3-
methoxybenzene 21) and we obtained 22 in 80% yield (Scheme 2). 
We synthesized fragment 14 as shown in Scheme 3. To prevent alkylation of the imidazolic 
nitrogen atom of 20 in the next steps, we first protected it with a sulfamoyl group affording 
23 (78% yield).16  
 
Scheme 3. Synthesis of fragment 14. 
 
We chose this protecting group because it is rather small compared to other protecting 
groups (e.g., trityl group) and this fact should reduce the risk of problems associated with 
the steric hindrance of the protecting group when alkylating the imidazolic C5 in the next 
step. To avoid side-reaction at the C2 position of the imidazolic ring, 23 was protected at 
the C2 position with a tert-butyldimethylsilyl (TBDMS) group, known to be stable in the 
presence of n-BuLi. By treatment of 23 with n-Buli in THF and subsequent addition of 
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TBDMS-chloride, we obtained 24 in excellent yield (92%).17 We then introduced an 
ethylenhydroxyl group at the C5 position by treating 24 with n-BuLi followed by addition of 
ethylene oxide, affording 25 in 56% yield.18 After tosylation of the hydroxyl group of 25, 
affording 26, we used the optimized conditions described above to promote an SN2 
reaction of 26 with pyrazole (27). Beside the desired product 28, we also obtained the 
partially deprotected product 29 in 20% yield (over two steps), presumably because of the 
presence of an excess of deprotonated pyrazole or the instability of 28 towards column 
chromatography. Given that we had envisaged a double deprotection as the next step, we 
treated the mixture of 28 and 29 with an ethanolic solution of HCl to obtain 30 in 84% yield. 
Finally, we obtained the desired fragment 14 in quantitative yield by treating 30 with LiAlH4. 
Finally, we thought to explore the possibility of combining fragments 13 and 14 in a single 
molecule (31) so as to fill part of the TDP-binding pocket and, at the same time, address 
the putative substrate-binding pocket (modeled pose not shown). A simplified version of 
31, compound 32, was synthesized as shown in Scheme 4. Benzyl chloride 21 and 30 
were reacted via an SN2 reaction yielding a mixture of two regioisomers in a 1: 3 ratio 
(according to 1H-NMR spectroscopy), which was very difficult to separate. The major 
regioisomer, presumably 33, could be isolated in 10% yield and was further reduced to 
yield product 32. The structure of 32 (and therefore of the previous intermediate), was 
confirmed by 1D- and 2D-NMR spectroscopy (COSY). 
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2.3.3 Biochemical evaluation of the synthesized fragments against D. radiodurans 
and M. tuberculosis DXS 
To evaluate the inhibitory potency of our modeled and synthesized fragments, we 
established and optimized a spectrophotometric assay, which consists of a coupled assay 
where the second enzyme of the MEP pathway, IspC, is used as auxiliary enzyme. In fact, 
in the DXS-catalyzed reaction, there are no species that can be monitored conveniently 
by spectrophotometric methods. In the assay, the effect of our fragments as inhibitors is 
investigated by determining the reaction velocity of the DXS- and IspC-catalyzed reactions 
over 30 minutes, by monitoring the disappearance of NADPH (converted to NADP+) at 340 
nm. We performed a preliminary titration of E. coli IspC to establish the optimal 
concentration of the auxiliary enzyme, so that the rate of the DXS-catalyzed reaction would 
not be affected by the concentration of IspC. Ideally, the compounds should be tested as 
stock solutions in water, which was impossible for most of our potential inhibitors. 
Therefore, we prepared stock solutions in DMSO at the highest concentration possible 
(ideally, 160 mM). A preliminary measurement to check the maximum DMSO concentration 
tolerated by both D. radiodurans and M. tuberculosis DXS was necessary. We established 
that D. radiodurans DXS tolerates up to 3% DMSO, while M. tuberculosis DXS tolerates 
up to 5% DMSO.  
By monitoring the activity of D. radiodurans DXS and E. coli IspC in Tris-HCl buffer at 
multiple pH values (pH = 5.0, 6.0 and 7.6), we found that the optimal conditions for 
performing the coupled assay consist in working at pH = 7.6, where both enzymes are 
sufficiently active. Moreover, especially DXS has a narrow pH window. In fact, at pH = 6.0, 
the activity of DXS is not measurable anymore, whereas IspC is still very active. Even 
though the modeling studies were performed with the crystal structure of D. radiodurans 
DXS as a model enzyme, we tested our molecules also against M. tuberculosis DXS, 
which has 68% sequence identity in the TDP-binding pocket with the model enzyme (vide 
supra). 
The results of the biochemical evaluation of our first-generation inhibitors, are summarized 
in Table 1. Fragments 4 and 5 are inactive against either DXS orthologues. As mentioned 
before, the fact that the ethylene linker of 4 in the modeled pose is not in an ideal zig-zag 
conformation, together with the fact that the ππ interaction with Phe398 is lost, might be 
responsible for its inactivity. As for 5, its inactivity is surprising and suggests that 5 is not 
an ideal starting point for further fragment-growing or optimization. 
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13 has a single-digit millimolar IC50 value against D. radiodurans DXS, while its analogue 
22 does not display any inhibitory activity, showing that the presence of the pyridyl nitrogen 
atom is essential. 14 resulted to be the most potent fragment of this series, with an IC50 of 
762 ± 199 μM against D. radiodurans DXS. Both 13 and 14, constitute optimal templates 
for further optimization, especially thanks to their LEs of 0.33 and 0.32, respectively. The 
fact that 32, in which 13 and 14 are linked, only shows 45% inhibition at 2000 μM against 
D. radiodurans DXS, illustrates how delicate fragment linking is in the absence of co-crystal 
structures at every step in the hit-to-lead optimization. Unfortunately, we did not have 
access to any crystallographic information. Thus, we decided to exploit NMR spectroscopy 
for validating the binding mode of 13. Before discussing this in detail, we will briefly discuss 
the utility of NMR spectroscopy in drug discovery and the background behind the NMR 
technique that we applied. 
 
Table 1. Biochemical evaluation of the first-generation fragments against D. radiodurans 
and M. tuberculosis DXS. 
Fragment IC50 (μM) [a] 
 D. radiodurans DXS M. tuberculosis DXS 
4 >2000 >2000 
5             >2000 >2000 
13 1810 ± 480 >2000 
14 762 ± 199 >2000 
22 >2000 >2000 
32 >2000[b] >2000 
[a] IC50 values were determined using a photometric assay 
using the program Dynafit.19 Full details of the biochemical-
assay conditions are provided in the experimental part. 
[b] 45% inhibition at 2000 μM. 
 
 
2.4 NMR spectroscopy in drug discovery 
NMR spectroscopy plays an essential role in the field of drug discovery and development. 
Instead of being considered as a mere alternative to crystallography, NMR spectroscopy 
has become, over the past decade, an established tool in drug discovery, both for the 
discovery and for the elucidation of the binding sites of high-affinity ligands for biologically 
relevant macromolecules, particularly when dealing with weak binders for which no 
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crystallographic information is available.20 A major advantage of NMR spectroscopy with 
respect to crystallography is that information about the binding mode in solution is 
obtained. In fact, the rigid nature of co-crystal structures can lead to misinterpretations of 
the interactions between the designed ligand and the protein.21 Whereas protein-observed 
NMR experiments are limited to small protein targets (Mw < 50 kDa), which can be 
isotopically labeled and purified in large amounts,22 ligand-observed NMR experiments 
require less, unlabeled protein and enable direct identification of the ligands as long as 
their chemical shifts in solution are known.23 
 
2.4.1 The STI methodology 
Recently, an innovative, fast and reliable ligand-based NMR methodology was developed 
by Griesinger and co-workers,24 extending the Interligand NOE for pharmachophore 
mapping (INPHARMA) methodology,25,26 to decipher the binding mode of a ligand in 
solution using a very low concentration of unlabeled protein (e.g., 30 μM). The latter aspect 
makes this technique available for all targets with a certain size (Mw > 30 kDa), including 
less established ones for which protein expression is often the bottleneck. The method 
covers a wide range of binding affinities (Kd from 1.0 μM to 2.0 mM), typically observed for 
weakly to moderately binding fragments. A combination of three NMR techniques is 
applied to elucidate the binding mode of a ligand or fragment. 
Saturation-Transfer Difference (STD)-NMR yields information on the protein-buried and 
water-exposed parts of the ligand.27 The STD-NMR spectrum is based on the nuclear 
Overhauser effect and relies on the fact that, for weak-binding ligands, there is exchange 
between the bound and the free ligand site. After acquiring a standard 1H-NMR spectrum 
of the ligand, one can saturate the protein signals by irradiating in a region of the spectrum 
that contains only resonances of the protein (typically between 0 and 1 ppm). The 
saturation transfer from the protein to the ligand occurs via the ligand protons that are in 
proximity of the protein.  The STD-NMR spectrum is obtained by subtracting the second 
spectrum from the first one. As a result, the protons which correspond to a part of the 
ligand being more buried into a certain pocket of the protein, will have a higher STD-NMR 
signal.28 
Transferred-NOE (trNOE) reveals the conformation of the ligand in its bound state. It is 
based on the fact that, while NOEs develop very slowly within the free ligand, NOEs within 
the bound ligand develop faster, thanks to the extensive spin diffusion via the protein 
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protons. Thus, once the ligand will have dissociated from the protein, it will still contain 
NOEs information characteristic of the bound state.29 
The INPHARMA methodology derives the relative binding mode of two ligands (A and B) 
interacting subsequently (and not simultaneously) with the same binding site. A reference 
ligand (ligand B), for which the binding mode is known, is necessary. The dissociation 
constants of both ligands to the receptor (T) has to be in the millimolar or micromolar range, 
so that enough exchange events between A and B can occur during the NMR mixing time. 
A NOE peak between a proton of ligand A (HA) and a proton of ligand B (HB) in the 
presence of the receptor T, originates from spin diffusion involving the receptor protons 
HT. Although the concept per se is very simple, a qualitative interpretation of the 
phenomenon, based on the simplified model as shown in Figure 6, can be misleading. In 
fact, complex theoretical calculations by using the full-relaxation-matrix approach are 
necessary given that spin diffusion among protein protons can generate intermolecular 
NOEs between ligands that are in contact with non-neighboring sites of the protein.25 
 
 
Figure 6. Schematic representation of the molecular principle underlying the INPHARMA 
method. The receptor is shown in light blue; the ligand for which the binding mode has to 
be determined (ligand A) is shown as a green sphere and the reference ligand is shown 
as a yellow sphere (ligand B). 
 
 
The methodology combining the three techniques described above is termed STI, referring 
to its three NMR components STD, trNOE and INPHARMA and holds the potential to 
represent an attractive alternative to protein crystallography in both FBD and structure-
based design (SBD) projects. An INPHARMA-based identification of the binding site of 
fragment-like binders for glycogen phosphorylase has been reported recently, which 
illustrates the potential of this method.30  
The STI methodology itself has been applied so far only retrospectively and it has been 
applied to successfully predict the binding modes of ligands to a few protein targets.24 
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2.5 Determination of the binding mode of fragments 13 and 14 in solution using the 
STI-NMR methodology 
As discussed in Section 2.3.3, we could not rely on crystallography for determining the 
binding mode of 13 and 14 within D. radiodurans DXS. However, realizing the importance 
of identifying their binding mode to further grow and optimize them in terms of their 
inhibitory potency, we decided to exploit NMR spectroscopy. In particular, we applied the 
novel STI methodology described in Section 2.4.1 to our project. 
A flowchart to illustrate the stepwise validation of the binding-mode by STI-NMR is shown 
in Figure 7. In the first stage, we performed docking studies for each ligand within the TDP-
binding site, using the FlexX docking module in the LeadIT suite.31  
 
 
Figure 7. Flowchart of the methodology, including the STI-NMR method, used to validate 
the binding mode of the fragments in solution. 
 
After generating typically 30 docking poses for each ligand, we clustered them to yield a 
set of representative and diverse possible binding modes. The top-ranked poses from 
each cluster according to HYDE,32, 33 which possessed acceptable torsional angles 
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according to Torsion Analyzer,34 were selected. For each pose, we back-calculated the 
spin-diffusion-based NMR parameters STD, trNOE and INPHARMA with the software 
spINPHARMA (www.inpharma.de) and scored the correlation between back-calculated 
and experimental data using the Pearson correlation coefficient to yield RSTD, RtrNOE 
and RINPHARMA. We then combined these to RSTI by averaging and we selected the 
structure pair with the highest score as the most accurate binding mode. In the first stage, 
we conducted STD experiments with ligands 13 and 14 (Figure 8a and 8b, respectively). 
Both molecules showed STD enhancement in the presence of D. radiodurans DXS, 
indicating that they do bind to the target protein. As expected, we observed no STD 
enhancement for the fragments in a buffer solution without DXS. The same observation 
holds true for trNOE peaks in a NOESY spectrum. For the third step of the methodology 
(INPHARMA), we chose deazathiamine 2 as a reference ligand for our studies. 
 
(a)       (b) 
 
Figure 8. Experimental STD data of ligands 13 (Figure 8a) and 14 (Figure 8b)  The 1D-
NMR spectrum with 1 mM of ligand 13 or 14  in the presence of 10 μM D. radiodurans 
DXS is shown in black and the STD spectrum in blue. Saturation was applied for 8 s at 
−0.5 ppm on a 400 MHz (13) or a 700 MHz (14) spectrometer (number of scans = 8; 
temperature = 293 K; time domain = 16384 points). 
 
Compound 2 is structurally related to the cofactor 1 and docking studies supported our 
assumption that it binds in the cofactor-binding pocket of DXS. Moreover, the experimental 
 48 
 
 Chapter 2 
determination of the Ki value for 2 (Ki = 151 ± 34 μM) confirmed that its mode of inhibition 
is competitive with respect to 1, making it a suitable reference ligand for the INPHARMA 
methodology. 
As introduced in Section 2.4.1, in order to observe INPHARMA peaks in a spectrum, the 
ligands must have an off-rate from the target, which is large enough to ensure that several 
exchange events can take place during the NOESY mixing time of several 100 ms. When 
both ligands target the same binding pocket, magnetization of the protons of the first 
compound will be transferred to the protein protons and back to the protons of the second 
compound, when it is bound. Whereas we recorded a NOESY spectrum of the ligand 
combination 2 and 13 and were able to clearly observe INPHARMA peaks (Figure 9a), we 
were unable to observe INPHARMA peaks for ligand combinations 2 with 14 and 13 with 
14.  
In parallel, we used the docking module FlexX to dock 13 and 14 into the crystal structure 
of D. radiodurans DXS. We generated 30 docking poses for each ligand and clustered 
them with an RMSD difference of 3 Å using GROMACS to yield a set of representative 
and diverse binding modes. From every cluster, we used the structure with the best 
calculated 'G value according to the scoring function HYDE in the LeadIT suite for the 
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Figure 9. a) NOESY spectrum of 2 and 13 in the presence of D. radiodurans DXS clearly 
shows trNOE (black) and INPHARMA (green) peaks. Peak assignment is indicated on the 
axes for 13 (black) and 2 (blue). b) Binding mode of 2 and 13 in the TDPbinding pocket of 
D. radiodurans DXS validated by the STI methodology. Deazathiamine (2) skeleton: C: 
purple. Inhibitor 13 skeleton: C: orange. 
 
We also docked deazathiamine (2) into the TDP-binding site of D. radiodurans DXS and, 
as expected, found the top-ranked poses to overlap with TDP, which we used as a 
reference for the INPHARMA calculations. We identified three different and representative 
binding modes by docking (Figure 10), all of them preserving the ππ-stacking interaction 
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with Phe398 observed for 1. Nevertheless, the hydroxyethylene tail seems to be rather 
flexible and adopts different orientations in the three poses, being involved in hydrogen 
bonds with various amino acids (His82, His51 or His 304).  
 
 
Figure 10. Schematic representation of the three top-scoring poses of deazathiamine (2) 
according to the docking studies performed with the the FlexX module of the LeadIT suite 
and after HYDE scoring. Mg2+ has not been included in the docking. The figure was 
generated with PoseView35 as implemented in the LeadIT suite. This holds also for other 
figures of this type. 
 
It has been observed before for another protein system that different binding modes of one 
ligand directly contribute to the spin diffusion and the NMR signals represent an average 
of them.24 In order to better understand the binding behavior of 2, we used all three 
representative binding poses as a starting point of a molecular dynamic (MD) simulation 
for 1 ns. It is remarkable that only one pose maintains its binding mode during the MD 
simulation (Figure 10, docked pose 2), confirming that this pose corresponds to the binding 
mode of 2 to D. radiodurans DXS in solution (Figure 9b). The best-scoring binding modes 
for 2 and 13 based on their RSTI are shown in Figure 9b. 
It is noteworthy that for ligand 13 the best scoring RSTI (0.52) binding mode (Figure 9b 
and Figure 11, docked pose 1) is very similar to the modeled one (Figure 4). In the other 
plausible binding mode proposed by the docking studies (RSTI = 0.36), 15 binds in the 
diphosphate pocket of 1 (Figure 11, docked pose 2) but displays negative RSTD and 
RINPHARMA values. The STI methodology was therefore able to clearly differentiate 
between both binding modes and allowed us to validate the modeled binding mode of 13. 
In the case of 14, we could only record STD and trNOE data. The absence of INPHARMA 
peaks could be explained by the small overlap between 14 and 2 that we observe in the 
top-scored docked poses (not shown). Owing to the lack of hydrogen-bonding interactions 
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and the inherently flexible ethylene linker, the imidazole moiety presumably adopts various 
conformational states. 
 
Figure 11. Schematic representation of the two top-scoring poses of 13 within 
D. radiodurans DXS obtained from docking studies. 
 
MD simulations for 1 ns of the two selected representative poses further confirmed this 
assumption. In fact, although the two poses are maintained during the simulation period, 
we observed several rotations of the imidazole moiety. The high degree of flexibility 
combined with the small overlapping area with 2 in the modeled and docked poses, are 
putatively the reasons why we only observed weak trNOE and no INPHARMA peaks. We 
attempted kinetic studies to determine whether 13 and 14 bind to D. radiodurans DXS in 
a competitive manner with respect to 1. Unfortunately, the data sets were of insufficient 
quality to allow us to draw any definite conclusions. However, the data set for 14 suggests 
a mixed mode of inhibition, which would be consistent with our modeled binding mode and 
could therefore explain why the STI methodology did not work in this case, given that 14 
only partially occupies the cofactor-binding pocket. 
Given that the validation of the binding mode within D. radiodurans DXS was possible just 
for 13, we focused our attention on the growing and optimization of fragment 13. 
 
2.6 Fragment growing and optimization of 13 
2.6.1 Modeling of some derivatives of 13 
On the way to improve the inhibitory potency of 13, we modeled and synthesized the 
compounds shown in Figure 12. Fragment 34 constitutes a regioisomer of 13 and we 
designed it so as to gain a hydrogen-bonding interaction with the side chain of Glu373, 
provided that the carboxylic acid is present in its protonated form. To circumvent the 
uncertainty related to the protonation state of the side chain of Glu373, we designed 
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compound 35. According to the modeled pose, the amino group of 35 should form two 
strong hydrogen bonds with the side chain of Glu373 – whether protonated or not – as well 
as with the backbone C=O of Pro347. 36 was modeled so as to introduce another 
hydrogen-bonding contact between the ligand and DXS, by introducing the hydroxyl group 
on the phenyl ring. In the modeled pose of 37 the trifluoromethyl group is involved in 
numerous lipophilic interactions with the side chains of Phe398, His124 and Ile371. It is 
also engaged in an electrostatic interaction with the positively charged guanidinium side 
chain of Arg401. For all the derivatives of 13 discussed above, all the other interactions of 
the original fragment 13 are preserved in the modeled poses.  
 
Figure 12. Modeled and synthesized derivatives of 13. 
 
A first attempt to explore the diphosphate-binding pocket was carried out by designing 38 
and 39, where an ethylene amino linker extends in that pocket, anchoring the protein via 
two additional-hydrogen bonding interactions. Moreover, fragment 40 was designed, were 
we introduced a sugar moiety so as to mimic the complex network of hydrogen-bonding 
interactions of the diphosphate moiety of 1. According to our modeling studies, a pentose 
fits better than a hexose in the diphosphate subpocket. In fact, hexoses would cause 
numerous clashes with the protein. Attempts to grow toward the putative substrate-binding 
pocket led to the design of 41 and 42 where, according to the modeled poses, a 
benzimidazole moiety is engaged in many hydrophobic contacts with the histidine-rich 
pocket of D. radiodurans DXS. 
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2.6.2 Synthesis of 3442 
We conveniently synthesized 37 and 41 via SN2 reactions of 20 or benzimidazole (43) with 
the commercially available benzyl bromide 44.  For the synthesis of 34, we used benzyl 
bromide 45, which was synthesized following a literature procedure from the 
corresponding carboxylic acid 46 via the alcohol 47, in an analogous way as for the 
synthesis of 13 (Scheme 5a).36, 37 For the synthesis of 36, we took advantage of the ability 
of 48 to spontaneously undergo a Michael addition with 20 and we obtained the desired 
product 36 in 53% yield (Scheme 5b) 
 
Scheme 5. (a) Generic scheme for the synthesis of 34, 37 and 41 via SN2 reactions; (b) 
Synthesis of 36. 
 
Fragments bearing one or two free amino groups, such as 35, 38, 39 and 42, were 
synthesized with analogous synthetic routes as shown for 13, but protection/deprotection 
steps involving the amino group(s) were necessary to avoid side reactions and to obtain 
the final products. As shown in Scheme 6, the protecting group of choice was a 
phthalimide, which we could remove in the last step of the synthesis by treatment with 
N2H4.H2O in MeOH. Due to the substitution pattern on 49, easily obtainable from 50,38 a 
mixture of two regioisomers was obtained for the final products 38a, b and 39a, b. The 
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synthesis of 39a, b was performed in a similar manner to the one of 38a, b, by reacting 44 
with 49 and finally deprotecting the amino group (synthesis not shown in Scheme 6, see 
experimental part for synthetic protocols). The synthesis of 35, 42 and 38a, b, involving 
compounds 5157a, b is shown in Scheme 6 and will not be discussed in detail. 
 
Scheme 6. Synthesis of fragments 35, 42 and 38 as a mixture of regioisomers 38a, b. 
 
We synthesized the sugar derivative 40 as shown in Scheme 7. The alcohol 58 was first 
protected with a TBDMS group to yield 59, which was then reacted with 44. We obtained 
the SN2 product 60 as a mixture of two inseparable regioisomers 60a, b in 2:1 ratio 
according to crude NMR. 60a, b was deprotected to yield 61a, b, which was subjected to 
 55 
 
 De novo fragment-based design of inhibitors of DXS guided by NMR spectroscopy 
a BF3.Et2O-promoted glycosylation with peracetylated β-D-ribofuranose (62). We could 
observe the formation of only one epimer (63a, b), presumably the β anomer, which is 
favored under these conditions.39 Deprotection of the acetyl groups, yielded the desired 
product as a mixture of the two regioisomers 40a, b, which could be separated by column 
chromatography only at this stage. The major product, consisting in 40a (Scheme 7) 
according to 1H-, 13C- and COSY experiments, was purified and tested in the biochemical 
assay. The minor product could not be isolated as a pure product and was therefore not 
tested. 
Scheme 7. Synthesis of the sugar derivative 40a. 
 
2.6.3 Biochemical evaluation of 3442 
As shown in Table 2, we observed only 20% inhibition and 0% inhibition at 2 mM for 34 
and 35 against D. radiodurans DXS, respectively. Addressing the side chain of Glu373 
seems therefore unreliable in terms of molecular recognition and addressing other amino 
acid residues in the TDP-binding site of DXS would appear to be a better strategy for SBD. 
36 and 37, where the imidazole part is kept constant and we exploit other substitution 
patterns on the left-hand side (LHS) of the molecule, also did not lead to any or weak 
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Table 2. Experimental IC50 values of synthesized derivatives of fragment 13. LEs are 
derived from experimentally determined IC50 values. 
Compound IC50 (μM) [a] 
 D. radiodurans 
DXS 
M. tuberculosis  
DXS 
   
34 >2000[b] >2000 
35 >2000 >2000 
36 >2000 >2000 
37 >2000[c]    >2000[c] 
38(a, b) 1200 ± 200 >2000 
39(a, b) >2000   ~ 2000[d] 
40a >2000[c] >2000 
41 595 ± 81            >600 
42 >1000 >1000 
[b] 20% inhibition at 2000 μM. 
[c] 40% inhibition at 2000 μM. 
[d] 55% inhibition at 2000 μM. 
 
To grow the fragment towards the diphosphate-binding pocket, we designed and tested 
38 as a mixture of two regioisomers (38a and 38b), which displays an IC50 value of 1.2 ± 
0.2 mM. A possible explanation of the higher inhibitory potency of 38 with respect to 35 
could be the capability of the aminoethylene linker to anchor 38 in a slightly different 
orientation with respect to 35, which might help the binding event to occur. This favorable 
anchoring both on the left- and right-hand sides of the molecule is probably responsible 
for the gain in potency. However, it is rather surprising that when testing 39 (also, as a 
mixture of two regioisomers, 39a, b), we observed no inhibition at 2 mM, given that its close 
analogue 37 shows weak inhibition at the same concentration. The fact that 40a resulted 
in only very weak inhibition of D. radiodurans DXS at 2000 μM was particularly 
disappointing, given that the ribose moiety of 40a fits the diphosphate subpocket of DXS 
very well, according to our modeling studies. As we will see and discuss more in detail in 
Chapter 4, the use of sugars as (di)phosphate mimics does not seem to be so trivial and 
straightforward. It might be that this part of the pocket has a certain degree of flexibility, 
which we cannot easily take into account during SBD. Moreover, it could also be that a 
more careful design of (di)phosphate bioisosteres, by taking into account, for instance, pKa 
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values, bond directionalities, lengths and dipole moments, is necessary to efficiently fill 
this subpocket. 
To increase the lipophilic contacts of 37, we expanded the imidazolyl ring into a 
benzimidazolyl moiety, leading to compound 41 (Figure 12), which interacts, according to 
our modeling studies, with Val80, His82 and Ile187 within D. radiodurans DXS. 41 (IC50 = 
595 ± 81 μM) is three times more potent than the original fragment 13. Not surprisingly, 
when replacing the imidazole moiety of 35 by a benzimidazole moiety (fragment 42, Figure 
12) we did not observe any inhibition for D. radiodurans DXS at 1000 μM. 
As one can see in Table 2, the inhibitory potencies of 34-42 against the two orthologues 
of DXS, are remarkably different. Besides 37, which displays 40% inhibition at 2000 μM 
against both D. radiodurans and M. tuberculosis DXS, 39a, b showed 55% inhibition at 
2000 μM against M. tuberculosis DXS, while being inactive against D. radiodurans DXS. 
Unfortunately, a rational optimization of fragments, which are active against the M. 
tuberculosis orthologue of DXS is even more challenging due to the absence of any 
structural information. Therefore, we decided to focus on the results obtained against the 
model enzyme, particularly on 41. The inhibitory potency of 41 is in the same range as that 
of the non-selective thiamine analogue deazathiamine (2; IC50 = 430 ± 68 μM), making 41 
an attractive and novel thiamine analogue. The fact that this fragment was designed de 
novo could facilitate and enable subsequent tuning of the selectivity over human thiamine- 
or TDP-binding targets. A further cycle of optimization using 41 as a template, should be 
aimed, in particular, at increasing the hydrophilicity of 41 while enhancing its inhibitory 
potency. Moreover, 41 has a LE of 0.24, which is below the lower threshold for LEs in FBD 
projects (LE = 0.3).40 Therefore, the next round of optimization should also focus on 
enhancing the LE of the optimized fragment. 
 
2.6.4 Validation of the binding mode of 41 using the STI methodology 
Before performing any further synthetic effort to optimize 41, the best fragment we 
obtained among all the derivatives tested, we established its binding mode within 
D. radiodurans DXS by applying once more the STI-NMR methodology.  
First, we recorded an STD spectrum of 41, which showed STD enhancement only in the 
presence of DXS, confirming the binding event. We observed the same in a trNOE 
spectrum (Figure 13a). In the subsequent NOESY spectrum of 41 and 17, we clearly 
observed INPHARMA peaks (Figure 13a), confirming that both compounds bind in the 
 58 
 
 Chapter 2 
same pocket. As described for 13, we generated three representative binding poses for 
41 by docking it within D. radiodurans DXS. The docked pose displaying the best RSTI 
score – and, at the same time, displaying the highest 'G value among the top-scoring 








Figure 13. (a) NOESY spectrum of inhibitors 41 and 2 in the presence of DXS clearly 
shows trNOE (black) and INPHARMA (green) peaks. Peak assignment is indicated on 
the axes for 41 (red) and 2 (purple). (b) Validated binding mode for 41 in the TDP-binding 
pocket of D. radiodurans DXS. Color code: inhibitor 41 skeleton: C: orange. (c) Modeled 
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Here, the left-hand side of 41 maintains the same interactions with D. radiodurans DXS 
with respect to the modeled pose, while the benzimidazolyl ring points into the histidine-
rich pocket rather than towards the diphosphate pocket as is the case for the modeled 
pose of 41. We did not observe the modeled pose of 41 (Figure 13c) among the 30 docked 
poses but it was included in the evaluation and, not surprisingly, received a lower RSTI 
score: this fact further validates the pose shown in Figure 13b for 41. 
It is worthwhile underlining that the binding pose validated with the STI approach differs 
from the pose obtained purely by modeling and that the structure-based fragment 
optimization of 41 based on the modeled pose alone would have led to fragment growing 
in the wrong direction. This observation confirms that the validation of the binding mode of 
the fragments in the first steps of the fragment-to-lead process is fundamental to render 
the process more efficient and less time- and material- consuming. 
 
2.7 Conclusions and outlook 
In conclusion, we have successfully applied the NMR-based STI methodology for the first 
time to a SBD project prospectively. Our findings show that the STI approach represents 
an attractive alternative to protein X-ray crystallography enabling SBD and FBD projects 
on targets for which a reliable crystallographic protocol is not available. A further 
advantage is that the binding mode in solution is derived. The STI methodology therefore 
holds the potential to find application in a wide range of medicinal-chemistry or chemical-
biology projects.  
In our de novo FBD of inhibitors of D. radiodurans DXS, the STI methodology was essential 
to validate the binding mode of the first promising fragment (13, IC50 = 1.8 ± 0.5 mM) and 
enabled us to focus our efforts on just one fragment and perform further fragment-growing 
and optimization leading to 41. Compound 41 is three times more potent than 13 (IC50 = 
595 ± 81 μM) and about as potent as deazathiamine (17), making 41 an attractive thiamine 
analogue with the potential for better selectivity over other thiamine- or TDP-dependent 
enzymes, which will have to be realized in future cycles of optimization. We investigated 
the binding mode of 41 using STI and found it to be different from the modeled one. The 
fact that the benzimidazole ring of 41 points toward the putative substrate-binding pocket, 
would allow for growing 41 into this pocket. Nevertheless, this is not trivial due to the fact 
that in the co-crystal structure of D. radiodurans DXS with TDP (PDB: 2O1X), this pocket 
is not defined, probably because of the absence of co-crystallized substrate(s). As we will 
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discuss in Chapter 4, some residues have been identified, which are fundamental for 
catalysis and substrate-binding and which could be targeted specifically. Moreover, 
molecular dynamics studies could also be helpful to guide the SBD in this part of the 
protein. 
As discussed in the introduction of this thesis, Freel Meyers and co-workers reported 
acetylphosphonates as low micromolar inhibitors of M. tuberculosis DXS 
(butylacetylphosphonate 64, IC50 = 4 ± 2 μM), with a competitive mode of inhibition with 
respect to pyruvate.41,42 Presumably, their mode of inhibition involves reaction with TDP to 
form the stable phosphonolactyl-TDP intermediate 65 (Figure 14), effectively trapping the 
enzyme at a predecarboxylation complex. As a follow up to the project presented in this 
Chapter, one could attempt the modeling and synthesis of compounds having the general 
scaffold 66, aimed at occupying both the TDP- and the substrate-binding pockets 
simultaneously. This would also enhance the solubility of 41. The synthetic strategy to get 
these scaffolds in hand could be the same as employed by the group of Freel Meyers: 
reacting the corresponding acyl chloride of 41 (compound 67) under mild conditions with 
commercially available tributyl phosphite via the Michaelis-Arbuzov reaction. The final 
compound, as its lithium salt, is obtained by treatment of the phosphonate ester with a 
stoichiometric amount of LiBr. 
 
Figure 14. Butylacetylphosphonate (64) is an inhibitor of M. tuberculosis DXS inhibitor; 65 
is the covalent adduct of 64 with TDP, which is presumably responsible for its inhibitory 
potency; 66 is the proposed scaffold which combines our modeled inhibitor 41 with 64. A 
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2.8 Experimental 
Modeling and Docking  
The X-ray crystal structure of D. radiodurans DXS in complex with TDP (PDB code: 2O1X) 
was used for our modeling.9 All the fragments were designed so as to occupy the TDP-
binding pocket or at least part of it. The energy of the system was minimized using the 
MAB force field as implemented in the computer program MOLOC,12 whilst keeping the 
protein coordinates fixed. After energy minimization of the designed fragments, all types 
of interactions (hydrogen bonds and lipophilic interactions) between the fragments and the 
protein were analyzed in MOLOC. For the docking studies, the three-dimensional structure 
of each compound was generated using the software CORINA43 and protonated with 
FCONV44 and subsequently docked into the TDP-binding pocket of D. radiodurans DXS 
by using the FlexX docking module in the LeadIT suite.31 To define a binding pocket for 
docking, we applied a standard procedure resulting in an enclosing volume utilizing the 
co-crystallized ligand TDP defined as the “reference ligand”. Every protein atom within a 
distance of 11 Å from any reference-ligand atom, was defined to be part of the binding site 
for FlexX. Given that the docking algorithm may deliver more than one pose per docking 
run, a maximum of 30 FlexX-scored solutions were retained, and subsequently re-scored 
with the HYDE module in LeadIT v.2.1.2.32,33 After careful visualization to exclude poses 
with significant inter- or intramolecular clash terms or unfavorable conformations and 
analysis of the selected poses with the program torsion analyzer,34 the resulting solutions 
were subsequently ranked according to their free energies of binding. A representative 
pose for every different binding mode with the highest binding energy was taken into 
account and was used to support the NMR studies. 
Construction of Expression Vectors pET22b-H6TBKDRDXS and pET22b-
H6TEVEKMTDXS 
A gene containing an N-terminal sequence encoding a hexahistidine tag and cleavage 
sites for TEV protease and enterokinase was adapted to the codon usage of Escherichia 
coli and has been synthesised by the custom synthesis service of GenScript (GenScript 
USA Inc., NJ, USA) and cloned into the expression vector pET22b+ by NdeI and HindIII. 
The resulting plasmids were electroporated into E. coli BL21(DE3) cells, affording the 
recombinant strains BL21(DE3)-pET22b-H6TEVEKDRDXS (acc. no. KJ462005; 
D. radiodurans) and BL21(DE3)-pET22b-H6TEVEKMTDXS (acc. no. KJ462006; 
M. tuberculosis). 
Purification of DXS from D. radiodurans and M. tuberculosis 
Cells of E. coli BL21(DE3) carrying plasmid pET22b-H6TEVEKDRDXS (for D. radiodurans 
DXS) or pET22b-H6TEVEKMTDXS (for M. tuberculosis DXS) were inoculated into LB 
medium supplemented with ampicillin (100 mg/mL) and cultivated in shaking flasks at 
37 oC until OD590 = 0.4. IPTG was added to 0.5 mM, and the cell culture was further 
incubated at 20 oC for 20 h. Cells were harvested by centrifugation (4000 rpm, 40 min, 
4 oC), washed once with aq. NaCl solution (0.9%) and resuspended in buffer A (50 mM 
Tris-HCl pH 8.0, 300 mM NaCl, 15 mM imidazole, 0.02% NaN3), 5 mL per 1 g of cells. Cells 
in buffer A were disrupted with French-Press, debris was removed by centrifugation, and 
the supernatant was applied to a Ni-chelating sepharose column (1 cm x 15 cm) 
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equilibrated with buffer A. The column was washed with buffer A until OD280 of the effluent 
came back to the base line and then developed with a gradient of imidazole (15 mM – 800 
mM). Fractions containing DXS were combined, transferred to buffer B (50 mM Tris-HCl 
pH 8.0, 100 mM NaCl, 5 mM DTT, 0.02% NaN3) using desalting column HiPrep 26/10 
Desalting (GE Healthcare), concentrated to 19 mg/mL (D. radiodurans DXS) or 1.1 mg/mL 
(M. tuberculosis DXS) using Amicon Stirred Ultrafiltration Cell (Amicon) equipped with 
polyethersulfone ultrafiltration membrane (pore size 10 kDa, Pall Life Sciences) and frozen 
at −80 oC for long-term storage. Isolated and purified DXS showed no measurable DXS 
activity unless enough external TDP was added. 
 
Photometric assay for kinetic studies of DXS 
Photometric assays were conducted in transparent flat-bottomed 96-well plates (Greiner 
Bio-One). Assay mixtures for the D. radiodurans DXS assay contained 100 mM Tris-HCl 
(pH 7.6), 4 mM MnCl2, 5 mM dithiothreitol (DTT), 0.5 mM NADPH, 1.2 μM TDP, 0.5 mM 
sodium pyruvate, 1.0 mM DL-glyceraldehyde 3-phosphate, 8.3 μM IspC and 0.41 μM 
D. radiodurans DXS. Assay mixtures for the M. tuberculosis DXS assay contained 100 mM 
Tris-HCl (pH 7.6), 5 mM MnCl2, 2 mM dithiothreitol (DTT), 0.5 mM NADPH, 20 μM TDP, 
0.5 mM sodium pyruvate, 0.5 mM DL-glyceraldehyde 3-phosphate, 2.0 μM IspC and 2.0 μM 
M. tuberculosis DXS. 
The tolerance of both DXS ortologues with respect to DMSO concentration was 
determined by measurement of the reaction velocity in the presence of different 
concentrations of DMSO. The activity of the enzyme was found to be stable in presence 
of up to 3% DMSO. The potential inhibitors for DXS were dissolved in DMSO so as to get 
160 mM solutions when possible. Their solubility in the assay buffer was tested prior to the 
inhibitory assay so as to get 2000 μM as the highest concentration tested when possible. 
Dilution series of the compounds tested typically covered the concentration range of 2000 
PM to 4.0 PM. The concentration range varied depending on the solubility of the organic 
molecule in DMSO and in the assay buffer. The reaction was started by adding 95 μL of 
buffer A (100 mM Tris-HCl (pH 7.6), 8 mM MnCl2, 10 mM dithiothreitol (DTT), 1.0 mM 
NADPH, 2.4 μM TDP, 1.0 mM sodium pyruvate, 4.1 μM IspC and 0.82 μM D. radiodurans 
DXS to 95 μL of a buffer solution (100 mM Tris-HCl (pH 7.6) containing the DMSO solution 
of inhibitor and DL-glyceraldehyde 3-phosphate (2 mM) (these values correspond to the 
D. radiodurans DXS assay). The reaction was monitored photometrically at room 
temperature at 340 nm using either a Synergy Mx (Biotek) or SpectraMax M5 (Molecular 
Dynamics) microplate reader. Initial rate values were evaluated with a nonlinear regression 
method using the program Dynafit.19 
The dissociation constant (Kd) for TDP-DXS complex was determined as follows. Dilution 
series (1:2) of TDP, covering the concentration range of 60 μM to 0.02 μM were prepared 
in buffer A (100 μL per test well). The reaction was started by adding 100 μL buffer B that 
did not contain TDP. The Kd values for TDP determined from the best fit of data to the 
reaction model with the program Dynafit19 are 114 ± 13 nM (D. radiodurans DXS) and 3.1 
± 0.3 μM (M. tuberculosis DXS). 
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The mode of inhibition for compound 2 was determined as described as follows. As in the 
assay for IC50 determination, reaction mixtures contained 100 mM Tris-HCl (pH 7.6), 4 mM 
MnCl2, 5 mM DTT, 0.5 mM NADPH, 0.5 mM sodium pyruvate, 2.05 μM E. coli IspC and 
0.41 μM D. radiodurans DXS. Both concentration of inhibitor and TDP were varied in the 
assay, giving the following concentration windows: inhibitor: 0–2000 μM; TDP: 0.25–6 μM. 
The reaction was started by the addition of DL-glyceraldehyde 3-phosphate to a final 
concentration of 1.0 mM. The velocity-[TDP] data were fitted for all inhibitor concentrations 
with a nonlinear regression method using the program DynaFit.19 Three inhibition models 
(competitive, uncompetitive and mixed) were considered for the calculation. Ki and Kis 
values, defined as inhibition constants for competitive and uncompetitive modes of 
inhibition, respectively, were obtained from the fit under consideration of the most likely 
inhibition model as described earlier.45 
General Experimental Details 
Starting materials and reagents were purchased from Aldrich, Acros, Alfa Aesar or Apollo 
Scientific. Yields refer to analytically pure compounds and have not been optimized. 
Compounds were synthesized and purified only by column chromatography, then tested 
as such. Compounds with activity were purified further (when necessary), and fully 
characterized prior re-testing. Compounds, which did not show any activity, were 
characterized only by 1H-NMR, 13C-NMR spectroscopy and high-resolution mass spectra 
(HR-MS). All solvents were reagent-grade and if necessary, dried and distilled prior to use. 
All reactions were run under a nitrogen atmosphere unless otherwise stated. Column 
chromatography was performed using silica gel (Silicycle® SiliaSepTM 40−63 μm). TLC was 
performed with silica gel 60/Kieselguhr F254. Solvents used for the column 
chromatography were dichloromethane, methanol, ethylacetate or pentane. 1H-NMR and 
13C-NMR spectra were recorded at 400 MHz on a Varian AMX400 spectrometer (400 MHz 
for 1H, 101 MHz for 13C, 376 MHz for 19F) at 25 oC. Chemical shifts (δ) are reported (ppm) 
relative to the residual solvent peak (CHCl3, 1H = 7.24; 13C = 77.23. CD3OD, 1H = 3.31; 13C 
= 49.15). Splitting patterns are indicated as (s) singlet, (d) doublet, (t) triplet, (q) quartet, 
(m) multiplet, (br) broad. Coupling constants (J) are given in Hertz (Hz). HR-MS were 
recorded with an LTQ Orbitrap XL (Thermo Fisher Scientific) mass spectrometer, using 
ESI (or APCI or APPI) as ionization source. FT-IR were measured on PerkinElmer FT-IR 
spectrometer. Melting points (Mp) were measured with a Buchi melting point B-545. 
Compounds 7,13,46 10,14 11,14 23,16 24,17 25,18 45,36,37 47,36,37 49,38 5947,48 were prepared 
according to literature procedures and their spectral data are consistent with the literature. 
 
General procedure for SN2 reaction (GP1) 
To a solution of the nucleophile (1 eq.) in dry DMF (1.0 mL per 0.15 mmol) at 0 oC, the 
electrophile (benzyl chloride or benzyl bromide, 1−1.2 eq.) was added dropwise. The 
reaction mixture was left to warm up and stir at room temperature for 16 h. DMF was 
removed in vacuo, and the residue was purified by column chromatography. 
General procedure for phthalimide deprotection (GP2) 
A solution of the phthalimide-protected amine (1 eq.) in MeOH (1.0 mL per 0.017 mmol) 
was treated with N2H4·H2O (50−60% solution, 11.4−17.0 eq.), and the mixture was left to 
 64 
 
 Chapter 2 
stir at room temperature for 16 h. MeOH was removed in vacuo and the crude was 
extracted with EtOAc (3x), the organic layers dried over Na2SO4, filtered and concentrated 
in vacuo. Alternatively, the crude was dissolved in water and the solution acidified 
(according to pH paper) by adding aq. HCl (1N); the aqueous layer was extracted with 
EtOAc (3x) and subsequently basified by treatment with aq. NaOH (1N) (according to pH 
paper). After extraction with EtOAc (3x) and DCM/iPrOH (3:1, 3x), the organic layers were 
concentrated in vacuo. The residue was purified by column chromatography. 
 
6-(2-(Thiophen-2-yl)ethyl)pyridin-2-amine (4)  
To a solution of 8 (33 mg, 0.16 mmol) in EtOH (2.0 mL), was added Pd/C 
(10%). The mixture was left to stir for 16 h under H2 in an autoclave 
(40 bar), then filtered through a pad of celite and concentrated in vacuo. 
Purification by CC (SiO2; toluene/Et2O, 4:1) afforded 4 as a yellow oil (23 
mg, 72%). 1H-NMR (400 MHz, CDCl3): δ=7.33 (t, J = 7.7, 1H), 7.11 (d, J 
= 5.1, 1H), 6.90 (dd, J = 5.0, 3.4, 1H), 6.80 (d, J = 3.4, 1H), 6.49 (d, J = 7.3, 1H), 6.34 (d, 
J = 8.1, 1H), 4.41 (br. s, 2H), 3.23 (t, J = 8.0, 2H), 2.97 (t, J = 8.0 , 2H). 13C-NMR (400 
MHz, CDCl3): 138.3 (2C), 126.9, 124.5, 123.2, 113.2, 106.4, 40.3, 30.0 (2 quaternary 
carbons not visible). HR-MS (APCI): calculated for C11H13N2S [M+H]+: 205.0794; found: 
205.0793. IR: 3463, 3314, 3177, 2922, 1597, 1575, 1461, 1327, 1161, 987.0, 787.5, 691.9. 
(1-((2-Aminopyridin-3-yl)methyl)-1H-indol-6-yl)methanol (5)  
To a solution of 12 (41 mg, 0.16 mmol) in dry THF (4.0 mL) at 0 °C, LiAlH4 
(12 mg, 0.32 mmol) was added in small portions, and the mixture was left 
to stir at 0 °C for 2.5 h. The reaction was quenched by the sequential 
addition of H2O (0.2 mL), aq. NaOH (10%, 0.3 mL) and H2O (0.4 mL) and 
filtered. The filter was washed with CH2Cl2/iPrOH (3:1) and the filtrate 
transferred to a separatory funnel were the aqueous phases were extracted 
with CH2Cl2/iPrOH (3:1, 3 x 8 mL). The organic phases were combined, washed with sat. 
aq. NaCl solution (3 x 8 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford 
5 as a yellow solid (40 mg, quant.).; 1H-NMR (400 MHz, CD3OD): δ=7.82 (d, J = 5.0, 1H), 
7.57 (d, J = 8.1, 1H), 7.27 (s, 1H), 7.21 (d, J = 3.1, 1H), 7.08 (d, J = 8.1, 1H), 6.62 (d, J = 
7.4, 1H), 6.52 (d, J = 3.0, 1H), 6.48 (dd, J = 7.2, 5.4, 1H), 5.22 (s, 2H), 4.65 (s, 2H). 
13C- NMR (400 MHz, CD3OD): 157.7, 147.0, 137.9, 136.8, 136.6, 129.9, 129.8, 122.0, 
120.6, 119, 114.7, 109.4, 102.92, 66.1, 46.6. HR-MS (APCI): calculated for C15H16N3O 
[M+H]+: 254.1288; found: 254.1288. Mp = 161163 °C. 
6-(Thiophen-2-ylethynyl)pyridin-2-amine (8)  
To a degassed solution of 2-bromo thiophene (72 μL, 0.74 mmol) and 7 
(100 mg, 0.846 mmol) in a mixture of freshly distilled Et3N and THF (1:2, 
7.8 mL: 5.2 mL), [PdCl2(PPh3)2] (37 mg, 0.052 mmol) and CuI (13 mg, 
0.068 mmol) were added. The reaction was left to stir at room 
temperature for 16 h. The resulting mixture was filtered through a plug of 
silica gel, washed with 5% MeOH in CH2Cl2 and concentrated in vacuo. 
Purification by CC (SiO2; CH2Cl2/EtOAc, 97:3) afforded 8 as an orange solid (30 mg, 20%). 
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1H-NMR (400 MHz, CD3OD): δ=7.49 (dd, J = 5.2, 1.1, 1H), 7.45 (t, J = 7.9, 1H), 7.35 (dd, 
J = 3.7, 1.1, 1H), 7.07 (dd, J = 5.2, 3.7, 1H), 6.81 (s, 1H), 6.57 (s, 1H). 13C-NMR (400 MHz, 
CD3OD): 161.0, 139.5, 134.2, 129.7, 128.6 (2C), 123.5, 117.6, 110.7, 82.5 (2C). HR-MS 
(APCI): calculated for C11H9N2S [M+H]+: 201.0481; found: 201.0482. Mp = 117118 °C. 
IR: 3468, 3291, 3150, 3106, 2924, 2202, 1620, 1587, 1563, 1456, 1414, 1218, 853, 830, 
788, 700. 
Methyl 1-((2-aminopyridin-3-yl)methyl)-1H-indole-6-carboxylate (12)  
A solution of methyl 1H-indole-6-carboxylate (308 mg, 1.76 mmol) in 
anhydrous DMF (10 mL) was cooled down to 0 °C. NaH (47 mg, 1.9 mmol) 
was added, and the solution was left to stir at 0°C for 30 min. A solution of 
11 (250 mg, 1.76 mmol) and tetrabutyl ammonium iodide (130 mg, 
0.352 mmol) in anhydrous DMF (8.0 mL) was added dropwise over 10 min 
and the mixture was let warm up to room temperature and stirred for 16 h. 
The reaction was then quenched with sat. aq. NH4Cl solution (5 mL), transferred to a 
separatory funnel and extracted with EtOAc (3 x 8 mL). The organic phases were 
combined, washed with sat. aq. NaCl solution (3 x 8 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by CC (SiO2; EtOAc/pentane, 60:40 to EtOAc/pentane: 
100:0 to CH2Cl2/MeOH, 95:5) afforded 12 as a yellow solid (95 mg, 20%).1H-NMR 
(400 MHz, DMSO-d6): δ=8.01 (s, 1H), 7.86 (dd, J = 5.0, 1.8, 1H), 7.70 (d, J = 3.1, 1H), 
7.68 (d, J = 0.8, 1H), 7.67 (d, J = 1.3, 1H), 6.64 (dd, J = 3.1, 0.9, 1H), 6.546.57 (m, 1H), 
6.47 (dd, J = 7.4, 5.1, 1H), 6.31 (br. s, 2H), 5.36 (s, 2H), 3.82, (s, 3H). 13C-NMR (400 MHz, 
DMSO-d6): 167.5, 156.5, 145.7, 135.6, 135.3, 133.6, 132.4, 123.0, 121.0, 120.4, 112.9, 
112.3, 102.1, 52.3, 45.6, 31.1. HR-MS (APCI): calculated for C16H16N3O2 [M+H]+: 
282.1237; found: 282.1238. Mp = 194195 °C. 
3-((1H-Imidazol-1-yl)methyl)-5-methoxypyridine (13) 
A dry flask was charged with imidazole (20) (12 mg, 0.18 mmol) and 
anhydrous DMF (1.0 mL). NaH (60% dispersion in mineral oil, 15 mg, 
0.38 mmol) was added, and the mixture was stirred at room 
temperature for 1 h. 19 (38 mg, 0.20 mmol) was added, and the 
mixture was allowed to stir at room temperature for 16 h. The solvent was removed in 
vacuo, and the crude was purified by CC (SiO2; CH2Cl2/MeOH, 1:4) to afford 13 as a yellow 
oil (23 mg, 66%). 1H NMR (400 MHz, CDCl3): δ=8.25 (d, J = 2.7, 1H), 8.10 (d, J = 1.6, 1H), 
7.54 (s, 1H), 7.09 (s, 1H), 6.88 (s, 1H), 6.85 (s, 1H), 5.10 (s, 2H), 3.79 (s, 3H). 13C NMR 
(101 MHz, CDCl3): δ= 156.0, 140.7, 137.7 (2C), 132.4, 130.3, 119.1 (2C), 55.6, 48.1. HR-
MS (ESI) calcd for C10H12N3O [M+H]+: 190.0975; found: 190.0982. IR: 3118, 3058, 2926, 
2624, 1670, 1592, 1472, 1433, 1293, 1199, 1129, 1053, 1018, 878, 829, 799, 759, 720, 
704, 637, 598, 589, 544, 519. 
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(1-(2-(1H-Imidazol-5-yl)ethyl)-1H-pyrazole-3,5-diyl)dimethanol (14) 
A suspension of LiAlH4 (16 mg, 0.42 mmol) in anhydrous THF (2.0 mL) 
was cooled to 5 ºC. A solution of 30 (40 mg, 0.13 mmol) in anhydrous 
THF (1.5 mL) was added dropwise, and the mixture was stirred at 5 ºC 
for 36 h. The mixture was quenched with sequential addition of H2O 
(16 μL), aq. NaOH solution (15%, 32 μL) and H2O (48 μL), filtered 
through paper, and the filter washed with MeOH (3 mL). The filtrate was 
concentrated in vacuo, and the residue was purified by CC (SiO2; CHCl3/MeOH/H2O, 
5:5:1) to afford 14 as a colorless oil (29 mg, quant.). 1H NMR (400 MHz, CD3OD): δ=7.64 
(s, 1H), 6.72 (s, 1H), 6.19 (s, 1H), 4.54 (s, 2H), 4.37 (s, 2H), 4.33 (t, J = 7.1, 2H), 3.09 (t, 
J = 7.1, 2H). 13C NMR (101 MHz, CD3OD): δ=153.0, 145.2, 136.3, 135.6, 118.2, 105.2, 
59.0, 55.4, 50.3, 29.2. HR-MS (ESI) calcd for C10H15N4O2 [M+H]+: 223.1190, found: 
223.1187. IR: 3204, 2920, 2877, 1680, 1570, 1456, 1435, 1404, 1360, 1317, 1204, 1179, 
1140, 1086, 1017, 953, 801, 721, 661, 624. 
Methyl 5-methoxynicotinate (17) 
A round-bottomed flask was charged with 16 (600 mg, 4.31 mmol) 
and toluene/MeOH (4:1, 175 mL). Trimethylsilyldiazomethane (2 M in 
Et2O, 8.6 mL, 17 mmol) was added, and the mixture was allowed to 
stir at room temperature for 16 h. The solvent was removed in vacuo, 
and the crude mixture was purified by CC (SiO2; EtOAc/toluene, 1:4) to afford 17 as a 
beige solid (719 mg, quant.). 1H NMR (400 MHz, CDCl3): δ=8.76 (d, J = 1.6, 1H), 8.41 (d, 
J = 2.9, 1H), 7.70 (dd, J = 2.9, 1.6, 1H), 3.89 (s, 3H), 3.84 (s, 3H). 13C NMR (101 MHz, 
CDCl3): δ=164.8, 155.2, 141.4, 140.7, 126.2, 120.3, 55.4, 52.0. Mp = 61−63 ºC. HR-MS 
(ESI) calcd for C8H10NO3 [M+H]+: 168.0662, found: 168.0655. IR: 2923, 2473, 1726, 1580, 
1504, 1455, 1434, 1389, 1310, 1237, 1159, 1105, 1024, 996, 874, 802, 765, 728, 690. 
 
(5-Methoxypyridin-3-yl)methanol (18) 
A dry flask was charged with 17 (30 mg, 0.18 mmol) and CH2Cl2 (1.0 mL). 
The mixture was cooled down to –78 ºC, and DIBAL-H (1 M in CH2Cl2, 
0.57 mL, 0.57 mmol) was added. The mixture was allowed to stir at 0 ºC 
for 16 h, then quenched with a sat. aq. sodium tartrate solution (1.0 mL). 
The mixture was diluted with CH2Cl2 (5.0 mL) and stirred for 1 h. The 
layers were separated, and the aqueous phase was washed with CH2Cl2 (3 x 5.0 mL). The 
organic layers were dried over MgSO4, filtered and concentrated in vacuo to afford 18 as 
a yellow oil (24 mg, 97%). 1H NMR (400 MHz, CDCl3): δ=8.12 (s, 1H), 8.07 (s, 1H), 7.25 
(s, 1H), 4.67 (s, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, CD3OD): δ=158.0, 140.8, 140.2, 
137.0, 121.0, 62.5, 56.3. HR-MS (ESI) calcd for C7H10NO2 [M+H]+: 140.0706, found: 
140.0697. 
1-(3-Methoxybenzyl)-1H-imidazole (22) 
A dry flask was charged with imidazole (43 mg, 0.64 mmol) in 
anhydrous DMF (1.0 mL). NaH (60% dispersion in mineral oil, 28 mg, 
0.70 mmol) was added, and the mixture was stirred at room 
temperature for 1 h. 58 (100 mg, 0.639 mmol) was added, and the 
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mixture was allowed to stir at 25 °C overnight. The solvent was removed in vacuo, and the 
crude mixture was purified by column chromatography (SiO2, EtOAc/toluene, 1:1) to afford 
a colorless oil (100 mg, 83%). 1H NMR (CDCl3, 400 MHz) δ=7.53 (s, 1H), 7.26 (t, J = 7.9, 
1H), 7.08 (s, 1H), 6.90 (s, 1H), 6.84 (dd, J  = 8.3, 2.5, 1H), 6.73 (dd, J  = 7.6, 0.6, 1H), 6.66 
(s, 1H), 5.09 (s, 2H), 3.77 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ=160.0, 137.7, 137.4, 
130.0, 129.8, 119.4, 119.3, 113.4, 113.0, 55.2, 50.7. HR-MS (ESI) calcd for C11H13N2O: 
189.1023 ([M+H+]), found 189.1030. IR: 3373, 3109, 3004, 2942, 2837, 1602, 1587, 1505, 
1491, 1456, 1438, 1391, 1350, 1283, 1262, 1229, 1152, 1107, 1075, 1049, 996, 964, 906, 




To a solution of 25 (50 mg, 0.15 mmol) in CH2Cl2 (1.4 mL), 
cetrimonium bromide (3 mg, 0.01 mmol) and an aq. solution of 
NaOH (50%, 0.20 mL) were added. After that, a solution of p-
toluensulfonyl chloride (35 mg, 0.18 mmol) in CH2Cl2 (0.20 mL) was 
added, and the mixture was allowed to stir at room temperature for 
16 h. The layers were separated, and the organic phase was washed with H2O (3 x 1.0 
mL) and a sat. aq. NaCl solution (1 x 1.0 mL), dried over MgSO4, filtered and concentrated 






A dry flask was charged with diethyl 1H-pyrazole-3,5-
dicarboxylate (27)  (3.18 g, 15.0 mmol) in anhydrous DMF 
(50 mL). NaH (60% dispersion in mineral oil, 570 mg, 
14.3 mmol) was added, and the suspension was stirred at 
room temperature for 30 min. A solution of 26 (3.66 g, 7.50 
mmol) in DMF (50 mL) was added dropwise, and the mixture 
was stirred at room temperature for 16 h. After quenching with 
a sat. aq. NaCl solution (10 mL), the crude was extracted with 
Et2O (3 x 10 mL) and concentrated in vacuo. Purification by 
CC (SiO2; EtOAC/toluene, 1:5) afforded 28 as a colorless oil 
(2.20 g, 56%). 1H NMR (400 MHz, CDCl3): δ=7.28 (s, 1H), 
6.75 (s, 1H), 4.90 (t, J = 7.1, 2 H), 4.38 (q, J = 7.1, 2H), 4.27 (q, J = 7.0, 2H), 3.35 (t, J = 
7.0, 2H), 2.80 (s, 6H), 1.34 (m, 6H), 0.95 (s, 9H), 0.33 (s, 6H). 13C NMR (101 MHz, CDCl3): 
δ=161.6, 159.1, 156.0, 142.7, 134.1, 130.5, 130.3, 114.1, 61.7, 61.4, 50.8, 37.9 (2C), 27.4 
(3C), 26.1, 18.5, 14.5, 14.3, −3.5 (2C). HR-MS (ESI) calcd for C22H38N5O8SSi [M+H]+: 
528.2307, found: 528.2296.   
The partially deprotected compound 29 was also isolated as a yellow oil (1.20 g, 20%). 
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1H NMR (400 MHz, CDCl3): δ=7.83 (s, 1H), 7.27 (s, 1H), 6.60 (s, 1H), 4.93 (t, J = 6.9, 2H), 
4.37 (q, J = 7.1, 2H), 4.26 (q, J = 7.1, 2H), 3.34 (t, J = 6.9, 2H), 2.87 (s, 6H), 1.30−1.38 (m, 
6H). 13C NMR (101 MHz, CDCl3): δ=161.6, 159.1, 142.8, 138.7, 136.7, 134.3, 129.7, 128.1, 
114.1, 61.8, 61.4, 50.7, 38.2, 26.2, 14.5, 14.3. HR-MS (ESI) calcd for C16H24N5O6S [M+H]+: 
414.1442, found: 414.1535. IR (cm−1): 3133, 2982, 2939, 1718, 1528, 1464, 1440, 1418, 
1388, 1260, 1213, 1173, 1149, 1084, 1028, 964, 904, 848, 766, 726, 652, 589, 515. 
Diethyl 1-(2-(1H-imidazol-5-yl)ethyl)-1H-pyrazole-3,5-dicarboxylate (30) 
A dry flask was charged with 28 (170 mg, 0.322 mmol) in HCl (1.25 M 
in EtOH, 5.8 mL). The mixture was stirred at room temperature for 
16 h, and the solvent was removed in vacuo. The crude mixture was 
taken up in EtOAc (5 mL) and washed with a sat. aq. NaHCO3 
solution (3 x 4.0 mL). The organic phase was dried over MgSO4, 
filtered and concentrated in vacuo to afford the product as an off-
white solid (70 mg, 68%). 1H NMR (400 MHz, CD3OD): δ=7.57 (s, 1H), 7.23 (s, 1H), 6.70 
(s, 1H), 4.85 (t, J = 7.0, 2H), 4.33 (two overlapping quartets, J = 7.2, 4H), 3.13 (t, J = 7.0, 
2H), 1.36 (two overlapping triplets, 6H, J=7.2). 13C NMR (101 MHz, CD3OD): δ=163.1, 
160.2, 143.4, 136.4, 135.6, 134.8, 118.4, 114.4, 62.8, 62.4, 53.4, 29.2, 14.7, 14.6. HR-MS 
(ESI) calcd for C14H19N4O4 [M+H]+: 307.1401, found: 307.1400. IR: 3337, 3128, 2985, 
2873, 2638, 1721, 1578, 1528, 1471, 1447, 1384, 1366, 1334, 1303, 1261, 1212, 1166, 




To a suspension of LiAlH4 (3 mg, 0.08 mmol) in anhydrous THF 
(1.0 mL) at 5 °C, a solution of 33 (9 mg, 0.02 mmol) in anhydrous 
THF (2.0 mL) was added dropwise. The reaction mixture was 
allowed to stir for 16 h, quenched with sequential addition of 
H2O, an aq. solution of NaOH (10%), and H2O, filtered over a 
paper filter and washed with MeOH. The filtrate was 
concentrated in vacuo and purified by column chromatography (SiO2, CH2Cl2/ MeOH, 9:1) 
to afford 32 as a transparent oil (4 mg, 60%). 1H NMR (CDCl3, 400 MHz): δ=7.36 (s, 1H), 
7.26 (t, J = 7.9, 1H), 6.83 (dd, J  = 8.3, 2.4, 1H), 6.65 (d, J = 7.6, 1H), 6.56 (s, 1H), 6.54 (s, 
1H), 6.09 (s, 1H), 4.94 (s, 2H), 4.59 (s, 2H), 4.55 (s, 2H), 4.44 (t, J = 6.5, 2H), 3.77 (s, 3H), 
3.12 (t, J = 6.5, 2H). 13C NMR (CDCl3, 100 MHz): δ=160.0, 151.2, 143.4, 138.8, 137.3, 





A dry flask was charged with 30 (65 mg, 0.21 mmol) in 
anhydrous DMF (6 mL). NaH (60% dispersion in mineral oil, 
10 mg, 0.25 mmol) was added, and the mixture was allowed 
to stir at room temperature for 1 h. A solution of 21 (31 μL, 
0.21 mmol) in anhydrous DMF was added dropwise, and 
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the mixture was allowed stir at room temperature for 16 h. The solvent was concentrated 
in vacuo, the crude reaction mixture was taken up in CH2Cl2 and filtered through Celite. 
The filter was washed with a mixture of CH2Cl2/MeOH (90:10), and the second filtrate was 
concentrated in vacuo to afford a crude product, which was used in the next step without 
any further purification. The presence of the product was confirmed by 1H NMR (CDCl3, 
400 MHz) δ=7.45 (s, 1H), 7.307.32 (m, 1H), 7.26 (t, J = 8.16, 1H), 6.85 (dd, J=8.2, 2.4, 
1H), 6.68 (d, J = 7.5, 1H), 6.64 (s, 1H), 6.59 (s, 1H), 4.99 (s, 2H), 4.90 (t, J = 8.0, 2H), 4.39 
(q, J = 7.1, 2H), 4.32 (q, J = 7.1, 2H), 3.78 (s, 3H), 3.12 (t, J = 8.0, 2H), 1.341.41 (m, 6H). 
 
4-((1H-Imidazol-1-yl)methyl)-2-methoxypyridine (34) 
Compound 34 was synthesized according to GP1, starting from 4-
(bromomethyl)-2-methoxypyridine (45, 15 mg, 0.074 mmol) and 
imidazole (20) (5 mg, 0.07 mmol) in anhydrous DMF (0.5 mL). The 
mixture was stirred at room temperature for 16 h and concentrated in 
vacuo. Purification by CC (SiO2; 4% MeOH in CH2Cl2) afforded 19 as a transparent oil 
(6 mg, 48% yield over two steps). 1H NMR (400 MHz, CDCl3): δ=8.11 (d, J = 5.3, 1H), 7.63 
(s, 1H), 7.13 (s, 1H), 6.90 (s, 1H), 6.59 (d, J = 5.3 Hz, 1H), 6.43 (s, 1H), 5.08 (s, 2H), 3.90 
(s, 3H). 13C NMR (101 MHz, CDCl3): δ=165.1, 148.1, 147.9, 137.8, 130.3, 119.7, 115.0, 
109.0, 53.8, 49.7. HR-MS (ESI) calcd for C10H11N3O [M+H]+: 190.0975, found: 190.0975. 
IR (cm−1): 3379, 3112, 2949, 1614, 1565, 1451, 1399, 1316, 1292, 1230, 1155, 1044, 990, 
818, 774, 751, 663. 
3-((1H-Imidazol-1-yl)methyl)-5-methoxyaniline (35) 
Compound 35 was synthesized according to GP2, starting from 55 
(6 mg, 0.02 mmol) and N2H4·H2O (50−60% solution, 19 μL, 0.19 mmol) 
in MeOH (1.0 mL). Purification by CC(SiO2; CH2Cl2/MeOH, 95:5 to 
CH2Cl2/MeOH, 92:8) afforded 35 as a white solid (4 mg, 59% over two 
steps). 1H NMR (400 MHz, CDCl3): δ=7.55 (s, 1H), 7.08 (s, 1H), 6.91 
(s, 1H), 6.14 (s, 1H), 6.08 (s, 1H), 5.99 (s, 1H), 4.96 (s, 2H), 3.71 (s, 3H). 13C NMR (101 
MHz, CDCl3): δ=161.5, 148.5, 138.7, 137.9, 129.8, 119.8, 106.5, 103.4, 100.5, 55.4, 51.1. 
HR-MS (ESI) calcd for C11H14N3O [M+H]+ : 204.1131, found: 204.1130. IR (cm−1): 3345, 
3214, 2925, 2852, 1508, 1472, 1358, 1284, 1230, 1172, 1107, 1078, 1057, 914, 835, 749, 
688, 664. Mp = 111–115 ºC. Purity by HPLC > 94% (HPLC conditions: column Astec 
Chirobiotic T 5 μ, 250 mm x 4.6 mm; flow rate 0.5 mL min−1). 
2-((1H-Imidazol-1-yl)methyl)-6-methoxyphenol (36) 
A mixture of 48 (111 mg, 0.720 mmol) and 20 (123 mg, 1.81 mmol) 
in CH3CN was refluxed for 16 h. The solvent was evaporated and 
purification by CC (SiO2; CH2Cl2/MeOH, 96:4 to 93:7) afforded 36 as 
a white solid (78 mg, 53%). 1H NMR (400 MHz, CDCl3): δ = 7.61 (s, 
1H), 7.03 (s, 1H), 6.97 (s, 1H), 6.836.87 (m, 2H), 6.65 (dd, J = 7.1, 1.6, 1H), 5.12 (s, 2H), 
3.86 (s, 3H). 13C NMR (101 MHz, CDCl3): δ = 146.9, 144.0, 137.6, 128.8, 122.4, 121.4, 
120.1, 119.7, 111.0, 56.3, 45.9. HR-MS (ESI) calcd for C11H13N2O2 [M+H]+: 205.0972, 
found: 205.0965.  
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1-(3-(Trifluoromethoxy)benzyl)-1H-imidazole (37) 
37 was synthesized according to GP1, starting from 1-
(bromomethyl)-3-(trifluoromethoxy)benzene (44, 95 μL, 0.59 mmol) 
and imidazole (20, 40 mg, 0.59 mmol) in anhydrous DMF (3.0 mL). 
The mixture was stirred at room temperature for 16 h and 
concentrated in vacuo. Purification by CC (SiO2; EtOAc/pentane, 4:1) afforded 37 as a 
transparent oil (86 mg, 63%). 1H NMR (400 MHz, CDCl3): δ=7.59 (s, 1H), 7.37 (t, J = 8.0, 
1H),  7.17 (d, J = 8.2, 1H), 7.11 (s, 1H), 7.04 (d, J = 7.7, 1H), 6.98 (s, 1H), 6.89 (s, 1H), 
5.14 (s, 2H). 13C NMR (101 MHz, CDCl3): δ=149.9, 138.7, 137.6, 130.7, 130.1, 125.6, 
121.8, 120.9, 119.9, 119.5, 50.4. 19F NMR (376 MHz, CDCl3): δ=57.9. HR-MS (ESI) calcd 
for C11H10F3N2O [M+H]+: 243.0740, found: 243.0733. IR (cm−1): 1592, 1506, 1449, 1253, 
1211, 1156, 1107, 1076, 1030, 1003, 907, 865, 800, 737, 701, 662, 629. 
3-((4-(Aminomethyl)-1H-imidazol-1-yl)methyl)-5-methoxyaniline (38a) and 3-((5-(2-
Aminoethyl)-1H-imidazol-1-yl)methyl)-5-methoxyaniline (38b) 
The mixture of 38a and 38b was synthesized 
according to GP2, starting from 57a and 57b 
(11 mg, 0.022 mmol) and N2H4·H2O (50−60% 
solution, 39 PL, 0.37 mmol) in MeOH (1.3 mL). 
Purification by CC (SiO2; CH2Cl2/MeOH, 87:13 
to CHCl3/MeOH/NH3, 2:1.5:0.7) afforded the 
mixture of the two regioisomers 38a and 38b as a yellow solid (15 mg, 17% over two steps, 
1:0.3 ratio, 38a: 38b). 1H NMR (400 MHz, CD3OD): δ=7.66 (s, 1H, 38b), 7.63 (s, 1H, 38a), 
6.88 (s, 1H, 38a), 6.81 (s, 1H, 38b), 6.24 (s, 1H, 38a), 6.21 (s, 1H, 38b), 6.17 (s, 1H, 38a), 
6.13 (s, 1H, 38a), 6.02 (s, 1H, 38b), 6.00 (s, 1H, 38b), 5.05 (s, 2H, 38b), 4.97 (s, 2H, 38a), 
3.70 (s, 3H, 38a), 3.69 (s, 3H, 38b), 2.93 (t, 2H, 38a), 2.76−2.65 (m, 2H, 38a + 4H, 38b). 
13C NMR (101 MHz, CD3OD): δ= 168.8, 162.7, 151.2, 151.0, 140.3, 140.2, 140.2, 139.4, 
138.6, 127.1, 118.3, 108.2, 107.2, 104.2, 103.2, 101.5, 101.2, 101.2, 55.7, 55.6, 52.0 (2C), 
42.1, 41.3, 31.1, 28.0. HR-MS (ESI) calcd for C13H19N4O[M+H]+: 247.1553, found : 
247.1553. 
 
2-(1-(3-(Trifluoromethoxy)benzyl)-1H-imidazol-4-yl)ethan-1-amine (39a) and 2-(1-(3-
(trifluoromethoxy)benzyl)-1H-imidazol-5-yl)ethan-1-amine (39b) 
The mixture of products 39a, b was synthesized according to GP1 
starting from 44 (40 μL, 0.25 mmol) and 49 (60 mg, 0.25 mmol) in 
anhydrous DMF (1.7 mL). The mixture was stirred at room 
temperature for 16 h and concentrated in vacuo. The residue was 
taken up in CH2Cl2 and filtered through Celite. The filter was 
washed with a mixture of CH2Cl2/MeOH (95:5), and the second 
filtrate was concentrated in vacuo to afford a crude product, which 
was used in the next step without any further purification. 
The final products were obtained by treating the crude (30 mg, 
0.072 mmol) with N2H4·H2O (50−60% solution, 43 μL, 0.43 mmol) 
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in MeOH (2.0 mL), according to GP2. The product was obtained as a yellow oil (21 mg, 
30% over two steps) as a mixture of two regioisomers in a 1:0.2 ratio (39a and 39b, 
presumably) according to 1H-NMR. 1H-NMR (400 MHz, CD3OD): δ=7.74 (s, 1H, 39b), 7.71 
(s, 1H, 39a), 7.47 (t, J = 8.0, 1H 39a, 1H 39b), 7.257.24 (m, 2H, 39a; 1H, 39b), 7.15 (s, 
1H, 39a), 7.10 (d, J = 8.0, 1H, 39b), 7.00 (s, 1H, 39b), 6.93 (s, 1H, 39a), 6.87 (s, 1H, 39b), 
5.30 (s, 2H, 39b), 5.23 (s, 2H, 39a), 2.92 (t, J = 7.1, 2H, 39a), 2.76 (t, J = 7.2, 2H, 39b), 
2.70 (t, J = 7.1, 2H, 39a), 2.62 (t, J = 7.2, 2H, 39b). 13C-NMR (101 MHz, CD3OD): δ=140.7, 
138.9, 138.2, 131.8 (2C), 127.5, 121.7, 121.3, 118.6, 51.0, 40.4, 26.5 (CF3OC- not visible; 
the reported signals correspond to 39a; signals corresponding to 39b are not visible). 19F 
NMR (376 MHz, CDCl3): δ=59.5, 77.0. HR-MS (ESI) calcd for C13H15F3N3O [M+H]+: 
286.1162 found: 286.1164. 
(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-((1-(3-(trifluoromethoxy)benzyl)-1H-imidazol-4-
yl)methoxy)tetrahydrofuran-3,4-diol (40a) 
Compound 40a was prepared in a four-step 
procedure (ad) and could only be isolated from 
the corresponding regioisomer 40b in the fourth 
step.  
(a) 60a, b was prepared according to GP1, starting from 44 (420 mg, 1.65 mmol) and 
59 (350 mg, 1.65 mmol) in anhydrous DMF (10 mL). The mixture was stirred at 
room temperature for 16 h and concentrated in vacuo. The residue was taken up 
in CH2Cl2 and filtered through Celite. The filter was washed with a mixture of 
CH2Cl2/MeOH (95:5), and the second filtrate was concentrated in vacuo to afford 
60a, b as a crude product (128 mg, 20% crude yield), consisting of a 2:1 mixture 
of 60a and 60b according to 1H-NMR, which was used in the next step without any 
further purification. 
(b) 60a, b (23 mg, 0.060 mmol) was dissolved in THF (0.4 mL) and cooled down to 
0 °C. The solution was treated with TBAF (1 M solution in THF, 0.07 mL, 0.07 mmol) 
and was left to warm to room temperature over 1.5 h. Sat. aq. NH4Cl solution (1 mL) 
and CH2Cl2 were added (1 mL). The organic phase was washed with sat. aq. NH4Cl 
solution (2 x 2 mL), sat. aq. NaCl solution (2 x 2 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was taken up in CH2Cl2 and filtered 
through Celite. The filter was washed with a mixture of CH2Cl2/MeOH (94:6), and 
the second filtrate was concentrated in vacuo to afford 61a, b as a crude product 
(16 mg, 95%), which was used in the next step without any further purification. 
(c) To a solution of D-ribose pentaacetate (62, 70 mg, 0.22 mmol) in dry CH2Cl2 
(0.5 mL) at 0 °C, 61a, b (20 mg, 0.073 mmol) and BF3.Et2O (45 μL, 0.37 mmol) 
were added. The mixture was left to warm to room temperature and after 3 h full 
conversion was observed and sat. aq. NaHCO3 (1 mL) was added. The quenched 
mixture was left to stir for 10 min, and the organic layers were extracted with CH2Cl2 
(3 x 2 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
taken up in CH2Cl2 and filtered through Celite. The filter was washed with a mixture 
of CH2Cl2/MeOH (99:1), and the second filtrate was concentrated in vacuo to afford 
63a, b as crude product (26 mg, 72% crude yield), which was used in the next step 
without any further purification. 
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(d) To a solution of 63a, b (160 mg, 0.310 mmol) in dry MeOH (1.7 mL), NaOMe was 
added (2 M in MeOH, 0.15 mL, 0.30 mmol) and the mixture was left to stir at room 
temperature for 35 min. Amberlite IR120 (hydrogen form) was added, the mixture 
was stirred for an additional 10 min and then filtered through a paper filter. The 
filter was washed with MeOH (5 mL), and the filtrate was concentrated in vacuo 
and purified by CC (SiO2; CH2Cl2/MeOH, 95:5 to 90:10). The major regioisomer 
(40a) was obtained as pure compound and characterized. 1H-NMR (400 MHz, 
CD3OD): δ=7.75 (s, 1H), 7.47 (t, J = 8.0, 1H), 7.24 (d, J = 8.0, 2H), 7.19 (s, 1H), 
7.13 (s, 1H), 5.25 (s, 2H), 4.93 (s, 1H), 4.63 (d, J = 12.0, 1H), 4.43 (d, J = 12.0, 
1H), 4.10 (dd, J = 7.0, 4.8, 1H), 3.95 (td, J = 6.4, 3.2, 1H), 3.90 (d, J = 4.8, 1H), 
3.74 (dd, J = 12.0, 3.2, 1H), 3.57 (dd, J = 12.0, 6.4, 1H). 13C-NMR (101 MHz, 
CD3OD): δ=151.0, 141.2, 140.1, 139.1, 131.9, 127.5, 121.8, 121.4, 120.1, 107.9 
(2C), 85.2, 76.5, 72.6, 64.8, 63.6, 51.0. 19F NMR (376 MHz, CDCl3): δ=59.4. HR-
MS (ESI) calcd for C17H20F3N2O6 [M+H]+: 405.1268, found: 405.1261. 
1-(3-(Trifluoromethoxy)benzyl)-1H-benzo[d]imidazole (41) 
Compound 41 was synthesized according to GP1, starting from 1-
(bromomethyl)-3-(trifluoromethoxy)benzene (44, 55 μL, 0.34 mmol) 
and benzimidazole (43, 40 mg, 0.34 mmol) in anhydrous DMF 
(2.3 mL). The mixture was stirred at room temperature for 16 h and 
concentrated in vacuo. Purification by CC (SiO2; EtOAc/pentane, 4:1) afforded 41 as a 
white solid (53 mg, 54%). 1H NMR (400 MHz, CD3OD): δ=8.34 (s, 1H), 7.72−7.70 (m, 1H), 
7.45−7.41 (m, 2H), 7.31−7.36 (m, 1H), 7.23 (s, 1H), 7.23−7.19 (m, 3H), 5.57 (s, 2H). 13C 
NMR (101 MHz, CD3OD): δ=151.0, 145.1, 144.1, 140.5, 131.9, 127.1, 124.8, 124.1, 123.3, 
121.7, 121.1, 120.7, 120.4, 111.9, 49.0. 19F NMR (376 MHz, CDCl3): δ=59.5.HR-MS (ESI) 
calcd for C15H12F3N2O [M+H]+: 293.0896, found: 293.0898. IR (cm−1): 3088, 1615, 1592, 
1484, 1459, 1445, 1383, 1366, 1092, 1007, 984, 947, 926, 887, 870, 808, 778, 703, 634, 
616, 582, 574, 534, 471. Mp = 45–47 ºC. Purity by HPLC > 99% (HPLC conditions: column 
Waters Xterra MS C8 AD-RH 5 μ, 150 mm × 4.6 mm; flow rate 0.5 mL min−1; wavelength 
265 nm; temperature 23 °C; gradient method, acetonitrile (0.1% TFA)/water (0.1% TFA) 
10:90 to 95:5 for 65 min.) 
3-((1H-Benzo[d]imidazol-1-yl)methyl)-5-methoxyaniline (42) 
42 was synthesized according to GP2, starting from 56 (20 mg, 
0.052 mmol) and N2H4·H2O (50−60% solution, 29 μL, 0.31 mmol) in 
MeOH (1.7 mL). The product was obtained as a pale yellow solid 
(15 mg, 35% over two steps). 1H-NMR (400 MHz, CD3OD): δ = 8.22 
(s, 1H), 7.687.66 (m, 1H), 7.467.44 (m, 1H), 7.28-7.25 (m, 1H), 6.22 
(t, J = 2.0, 1H), 6.16 (dd, J = 6.4, 2.0, 2H), 5.33 (s, 1H), 3.68 (s, 1H). 13C-NMR (101 MHz, 
CD3OD): δ=162.8, 151.1, 139.6 (2C), 124.4, 123.7, 120.2 (2C), 112.4 (2C), 107.9, 104.0, 
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 (3-Amino-5-methoxyphenyl)methanol (52) 
LiAlH4 (273 mg, 7.19 mmol) was added to a dry flask and cooled down 
to 0 ºC, then dry THF (5.0 mL) was slowly added. A suspension of 51 
(800 mg, 4.79 mmol) in anydrous THF (8.0 mL) was added dropwise, 
and the reaction mixture was heated to reflux for 16 h. After cooling to 
0 ºC, water (0.3 mL), an aq. NaOH solution (15%, 0.3 mL) and water 
(0.9 mL) were subsequently added, and the mixture was left to stir at room temperature 
for 1 h. After dilution with CH2Cl2, the mixture was filtered through Celite and concentrated 
in vacuo. The crude was used in the next step without any further purification. 
2-(3-(Hydroxymethyl)-5-methoxyphenyl)isoindoline-1,3-dione (53) 
A mixture of 52 (129 mg, 0.842 mmol), phthalic anhydride (124 mg, 
0.837 mmol) and pyridine (4.2 mL) was stirred at 80 ºC for 3 h. The 
reaction mixture was then cooled down, diluted with CH2Cl2 (20 mL) and 
washed with a sat. aq. CuSO4 solution until a blue color appeared in the 
aqueous phase. The organic phase was washed with water (2 x 10 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. Purification by CC 
(SiO2; EtOAc/pentane, 2:3) afforded 53 as a white solid (605 mg, 68%). 
1H NMR (400 MHz, CDCl3): δ=7.94−7.92 (m, 2H), 7.79−7.76 (m, 2H), 6.99 (s, 1H), 6.97 
(s, 1H), 6.87 (s, 1H), 4.71 (s, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, CDCl3): δ=167.4 (2C), 
160.5, 143.6, 134.7 (2C), 132.9, 131.9 (2C), 124.0 (2C), 117.4, 112.4, 111.9, 65.0, 55.8. 
HR-MS (ESI) calcd for C16H14NO4 [M+H]+: 284.0917, found: 284.0913. IR (cm−1): 1766, 
1712, 1603, 1467, 1391, 1346, 1281, 1197, 1159, 1116, 1032, 985, 954, 921, 896, 844, 
795, 745, 712, 685, 671, 637, 530. Mp = 168–171 ºC. Anal. calculated for C16H13NO4 
(283.28): C 67.84, H 4.63, N 4.94; found: C 67.67, H 4.72, N 5.06. 
2-(3-(Bromomethyl)-5-methoxyphenyl)isoindoline-1,3-dione (54) 
A solution of 53 (10 mg, 0.035 mmol) in CH2Cl2 (0.8 mL) was treated with 
SOBr2 (3.3 μL, 0.042 mmol) and the reaction mixture was left to stir at 
room temperature. After 1 h, more SOBr2 (3.3 μL, 0.042 mmol) was added 
given that the reaction was not complete. After 6 h, more SOBr2 was 
added (3.3 μL, 0.042 mmol), and the reaction mixture was left to stir at 
room temperature for 16 h. After quenching with sat. aq. NH4Cl (1 mL), 
the organic layers were washed with H2O (2 x 1.5 mL) and sat. aq. NaCl 
solution (1 x 1.5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The resulting 
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2-(3-((1H-Imidazol-1-yl)methyl)-5-methoxyphenyl)isoindoline-1,3-dione (55) 
Compound 55 was synthesized according to GP1, starting from 54 
(11 mg, 0.032 mmol) and imidazole (20, 2 mg, 0.03 mmol) in 
anhydrous DMF (0.2 mL). The mixture was stirred at room 
temperature for 16 h and concentrated in vacuo. The residue was 
taken up in CH2Cl2 (2.0 mL) and filtered through Celite. The filter was 
washed with a mixture of CH2Cl2/MeOH (95:5) and the second filtrate 
was concentrated in vacuo to afford a crude product, which was used 
in the next step without any further purification. 
 
2-(3-((1H-benzo[d]imidazol-1-yl)methyl)-5-methoxypheyl)-isoindoline-1,3-dione (56) 
56 was synthesized according to GP1, starting from 54 (63 mg, 
0.18 mmol) and benzimidazole (43, 20 mg, 0.17 mmol) in anhydrous 
DMF (1.1 mL). The mixture was stirred at room temperature for 16 h 
and concentrated in vacuo. The residue was taken up in CH2Cl2 and 
filtered through Celite. The filter was washed with a mixture of 
CH2Cl2/MeOH (97:3), and the second filtrate was concentrated in 
vacuo to afford a crude product, which was used in the next step 
without any further purification. The presence of the product was confirmed by HR-MS 






57a and 57b were synthesized 
according to GP1, starting from 54 
(136 mg, 0.393 mmol) and 49 (86 mg, 
0.36 mmol) in anhydrous DMF (2.4 mL). 
The mixture was stirred at room 
temperature for 16 h and concentrated 
in vacuo. The residue was taken up in 
CH2Cl2 (4.0 mL) and filtered through 
Celite. The filter was washed with a 
mixture of CH2Cl2/MeOH (95:5) and the 
second filtrate was concentrated in 
vacuo to afford a crude mixture of 57a 
and 57b (ratio 1 : 0.2), which was used in the next step without any further purification. 
The formation of the products was confirmed by 1H-NMR, 13C-NMR and HR-MS. 1H NMR 
(400 MHz, CDCl3): δ= 7.91−7.62 (m, 8H, 57a; m, 8H+1H, 57b) 7.51 (s, 1H) 6.90 (s, 1H, 
57a; s, 1H 57b), 6.79 (s, 1H 57a), 6.77 (s, 1H, 57b), 6.70 (s, 1H, 57a), 6.65 (s, 1H, 57b), 
6.62 (s, 1H, 57a), 5.22 (s, 2H, 57b), 5.03 (s, 2H, 57a), 3.91 (t, J = 7.1, 2H 57a), 3.80 (t, J 
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= 7.4, 2H, 57b), 3.76 (s, 3H, 47a), 3.75 (s, 3H, 47b), 2.93−2.87 (m, 2H, 57a; 2H, 47b). 13C 
NMR (400 MHz, CDCl3): δ=168.4 (2C, 57a), 168.2 (2C, 57b), 167.2 (2C, 57a), 167.1 (2C, 
57b), 160.8 (57b), 160.6 (57a), 139.4 (57b), 138.5 (57a), 138.1 (57b), 137.1 (57a),  134.7 
(4C, 57a), 134.7 (4C, 57b), 134.2 (4C, 57b), 133.9 (4C, 57a), 133.5 (57b), 133.4 (57a), 
132.2 (57a), 132.0 (57b), 131.7 (57a, 57b), 124.0 (2C, 57a), 123.9 (2C, 57b), 123.5 (2C, 
57b), 123.3 (2C, 57a), 117.6 (57a), 117.3 (57b), 112.9 (57a), 112.4 (57b), 112.2 (57b), 
112.1 (57a), 55.7 (57a, 57b), 50.7 (57a), 50.7 (57b), 38.0 (57a), 36.7 (57b), 29.8 (57b), 
27.3 (57a). HR-MS (ESI) calcd for C29H22N4O5 [M+H]+: 507.1663, found: 506.1658. 
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Development of peptidic inhibitors of the 
anti-infective target DXS by phage display 
 
In this chapter, we will describe how we discovered the first peptidic inhibitors of DXS by 
using phage display. An IC50 value of 9.5 ± 2 μM against Deinococcus radiodurans DXS 
was achieved and an Ala scan revealed essential features of the amino acid sequence 
(i.e., a Ser-Ser-Ser motif) responsible for its inhibitory activity that can be optimized in 
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 Chapter 3 
3.1 Peptides as therapeutic agents 
For many years, peptides have been considered to be poor drug candidates and still 
nowadays they partially suffer from a “deficit in image”.1 The main limitations attributed to 
the development of peptides as therapeutic agents involve low oral bioavailability, short 
half-life caused by their rapid degradation by proteolytic enzymes, rapid clearance 
(particularly in the liver and the kidneys) and poor ability to cross physiological barriers 
because of their remarkable hydrophilic character.2,3 Moreover, the costs for large-scale 
production of peptides are still higher than for small molecules, although considering the 
cost of the total drug-development process, the differences are not so significant, given 
that peptides generally have a higher clinical success rate.4,5 Furthermore, standard 
peptide sequences composed of natural amino acids (aa) are, besides few exceptions, 
worse drug candidates than small organic molecules, given their intrinsic physicochemical 
properties and pharmacokinetic profiles. 
The development and optimization of peptides as therapeutic agents has been hampered 
by difficulties in their synthesis, routes of administration and quantitative detection once 
administered but thanks to advances in chemistry, biochemistry, chemical biology and 
drug formulation and delivery, most of these limits have been overcome. As a result, over 
the past decade or so, the use of peptides as drug candidates is being increasingly 
encouraged and pursued, with some of them having reached the market (Table 1).  
Table 1. Three examples of marketed peptide-based drugs. 
Exanatide (Byetta®) Enfuvirtide (Fuzeon®) Buserelin acetate 
(Bigonist®) 
Amylin Pharms, Eli Lilly Roche Sanofi-Aventis 
39 aa, antidiabetic agent 36 aa, anti-HIV 9 aa, advanced prostate 
cancer 
 
As can be seen in Table 1, the size of a peptide-based drug can vary a lot. On the one 
hand, efficient target recognition can, in fact, occur also with very few residues. On the 
other hand, peptides that are 3040 residues long can enable the binding of very wide 
binding grooves. 
Peptides certainly have several advantages over small, organic molecules, for example 
the risk of systemic toxicity is reduced, given that their degradation products are amino 
acids. Moreover, thanks to their short half-life, few peptides accumulate in tissues, with a 
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reduced risk of complications caused by their metabolites.1 One of the main advantages 
of the use of peptides rather than small, organic molecules is that they can be tuned so as 
to reach extremely high selectivities toward their targets, explaining their elevated success 
rates in clinical trials.6 
Thanks to the availability of a wide range of synthetic protocols, both amide bonds and 
side chains of the amino acid sequences can be modified so as to develop peptides 
resistant to proteolytic degradation.7 More complex modifications might involve, for 
example, the insertion of a knotted Cys core, which endows the peptide with an exceptional 
thermal and proteolytic stability.8 Several strategies for improving the drug penetration 
through biological barriers have been developed, which include the incorporation of 
positively charged amino acids at the terminal positions (although polycations might 
destroy mammalian membranes)9 or the conjugation of the peptide to a ligand of cell-
surface receptors, such as a carbohydrate receptor, which results in the incorporation of 
sugar moieties in the amino acid sequence.10 
A lot of scientific effort has been put into improving the bioavailability of peptide 
therapeutics, which has been (and is) one of the main topics of discussion among drug 
developers and pharmaceutical companies. However, as Otvos and Wade remark, 
“peptide drugs do not necessarily need to be orally available”: many peptide-based drugs 
such as insulin or amylin are currently available in patient-friendly packaging ready for 
subcutaneous self-administration.4 Many peptides can be efficiently formulated for 
intranasal administration as well.11 
 
3.2 Phage display as a powerful tool for the identification of potential peptide-based 
drugs. 
Phage display is a biological technique introduced by Smith in 198512 and the phage-
display process is depicted in Figure 1. First, a population of filamentous bacteriophages 
(commonly referred to as phages, which are viruses that can replicate within bacteria) is 
engineered with different genes encoding different fusion proteins (Figure 1, step a). To 
do so, randomized cDNA sequences are inserted into the genome of the phage, 
specifically into a gene encoding for the phage’s coat protein, causing the phage to 
express the peptide fused with one of the phage’s coat proteins on its surface. The most 
important coat proteins for the display of peptides on the surface of phages are pIII (minor 
coat protein) and pVIII (major coat protein), the former being more widely used, given the 
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higher avidity effect of pVIII, which leads to the selection of peptides with lower affinities 
(Kd = 10100 μM) than the ones selected using pIII proteins (Kd = 110 μM). When no 
information is available about key features to be exploited for the target–peptide 
recognition process (e.g., key amino acid motifs), randomized libraries are generated, 
ranging from six to 30 residues. The optimal length required for a randomized library is 
difficult to establish and predict given that it depends on many variables but it is a key for 
the success of the phage-display process. As a result, as much information as possible 
about the protein target, the specific pocket and other known inhibitors of the target should 
be collected before starting a phage-display project. 
Once a library of phages – displaying different peptides – has been created, the library is 
exposed to the target (Figure 1, step b), those phages that bind the desired target are 
selected, while the non-binders are washed away (Figure 1, step c).13 Once the non-
binders have been removed, the other phages will be eluted (Figure 1, step d) and 
amplified in bacterial cells (Figure 1, step e). This cycle is repeated several times so as to 
amplify the library of the selected phages, helping to select binders with stronger affinity 
and to reduce the number of non-specific binders. Finally, the specifically bound phages 
are eluted and isolated. The primary structure of the displayed peptides is identified 
through DNA sequencing.14 
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Phage display has been used as a powerful tool in drug discovery15 but also in 
nanostructured electronics,16 agriculture17 and neurobiology.18 In drug discovery, its 
success is due to its advantages over traditional random screening methods: an enormous 
variety of peptides is generated and screened against the target, without the need to 
synthesize and purify them individually, making phage display very cheap, simple and 
effective, given that it relies on established biochemical methods. Several peptides, 
discovered by phage display, have been marketed as drugs or are currently in clinical 
trials.19  
It should be noted that phage display might lead to the identification of binders of a specific 
target, which do not necessarily translate into inhibitors. The inhibitory potency of the 
selected peptide-binders should therefore be tested in vitro against the target at a later 
stage. Moreover, phage display delivers hits, which do not have drug-like properties of a 
lead compound yet, but have to be further optimized in terms of their potency and 
especially in terms of their pharmacokinetic properties, as discussed in Section 3.1. For 
example, the sequence of peginesatide (hematide®), currently in Phase III clinical trials 
for the treatment of anemia associated with chronic kidney diseases, was originally 
discovered by phage display20 but had to be further optimized so as to enter the next stage 
of the drug-discovery process: PEGylation of its amino acid chain improved several 
properties such as solubility, stability, increased resistance to proteolysis and increased 
plasma half-life.21,22 
 
3.3 Exploiting phage display as a tool for the identification of peptidic inhibitors of 
DXS 
All inhibitors of DXS reported in the literature to date are small, organic molecules and, to 
our knowledge, there is no report on peptidic inhibitors of this enzyme. Therefore, we 
decided to use phage display for the identification of peptidic hits. For the phage-display 
protocol, we used the model enzyme D. radiodurans DXS, given that it is more stable than 
M. tuberculosis DXS. In fact, in a preliminary study, we checked the stability of 
D. radiodurans DXS both at 4 °C and at room temperature by monitoring its activity for up 
to 37 hours using a coupled enzyme activity assay. The assay employs IspC as the 
auxiliary enzyme, to enable spectrophotometrical monitoring of the consumption of 
NADPH. We observed no loss in activity even after 37 hours at room temperature. From 
these initial tests we concluded that D. radiodurans DXS is sufficiently stable to act as a 
target during the phage-display process. 
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3.4 The phage-display protocol 
During the first step, we screened a fully random M13 bacteriophage peptide library to 
specifically detect sequences, which are able to bind any part of the surface of D. 
radiodurans DXS. The first phage-display selection protocol was carried out using the 
commercially available M13 library PhD12 (NEB E8111L), consisting of M13 phages 
expressing a 12aa peptide at the N-terminus of each coat protein pIII. A small linker Gly-
Gly-Gly-Ser was inserted between the peptide and the coat protein to increase the 
conformational freedom of the exposed peptides and to minimize the contribution of the 
protein pIII to the overall binding event. The schematic sequence of this library is N-term-
X12-GGGS-pIII-C-term. We chose to start by screening libraries containing 12aa peptides 
because this constitutes a good starting point and a compromise between having too long 
peptides – which could get stuck by binding at the surface of the protein – and too short 
peptides – which would not be able to penetrate into the pocket we aim to target. Moreover, 
given that for E. coli cells – the most common hosts used for bacterial surface display – 
the transformation efficiency is typically 109, it does not make sense to start exploring 
libraries of longer peptides, such as 20aa, which would give rise to very high theoretical 
complexities (2020 possible sequences in the case of a 20aa library). In fact, only a very 
small fraction of the theoretical library would be explored in this case. 
We designed a phage-display protocol where the phages are incubated in solution with 
D. radiodurans DXS. After incubation, magnetic beads are added to allow for the recovery 
of the target protein-phage complex. In principle, one could add the magnetic beads right 
from the beginning of the protocol and incubate a solution containing the protein, the 
phages and the beads. Nevertheless, the risk of selecting phages, which bind to the beads 
rather than to the target protein, is much higher in this case, due to the prolonged contact 
time of the beads and the phages during incubation. In order to reduce this risk, we decided 
to not use this protocol. Moreover, we used a two-step selection approach to identify 
peptide binders (Table 1): we used two types of magnetic beads and several elution buffers 
to avoid background-selection bias (Figure 2). Analysis of the selected peptides enabled 
us to design a new and more stringent library for the second selection step in which we 
screened for sequences that specifically bind to the cofactor-binding site of D. radiodurans 
DXS, namely the thiamine diphosphate (TDP)-binding site. We used a solution of TDP as 
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Table 2. Overview of the phage-display protocols used for the first and second selection. 
 Phage Display I Phage display II 
Library X12GGGS XSSX9GGGS 
Competitors None Wild-type M13 
Rounds I and II 
Target Desthiobiotin-DXS His-tag-DXS 
Solid support Streptavidin-coated 
beads 
Nickel-coated beads 
Eluent Biotin TDP 
Round III 
Target His-tag-DXS Not performed 
Solid support Nickel-coated beads Not performed 
Eluent Imidazole Not performed 
 
Given that unspecific binders are often present after the second round of selection, we 
added wild-type M13 phages as competitors: wild-type phages efficiently compete with 
virus particles expressing the peptide library for unspecific phage–target interactions and 
they can be easily filtered out during post-sequencing analysis. Both measures decrease 




Figure 2. Two-step selection of DXS inhibitors. (a) Schematic representation of the 
streptavidin-coated beads used during rounds I and II of the first selection step to retain 
desthiobiotin-modified DXS and the phages that are bound to it (phages not shown). (b) 
Schematic representation of the nickel-beads used during round III of the first selection 
step and rounds I and II of the second selection step to retain DXS that has an N-terminal 
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3.5 First phage display 
As mentioned above, a commercially available M13 library PhD12 (NEB E8111L) was used 
for the first phage-display selection against D. radiodurans DXS. After three rounds of 
selection, the analysis of the sequences obtained clearly shows that a true selection 
occurred: we found several sequences to be repeated multiple times indicating their 
enrichment in the population (Table 2). However, there is no strong evidence of any 
consensus motif that would suggest a specific selection of binders targeting one particular 
region of D. radiodurans DXS. We took the four most prevalent sequences (P1 ̶ P4, Table 
2) and tested the synthesized peptides for their inhibitory activity against D. radiodurans 
DXS. 
The peptides were dissolved in DMSO (P1 and P2) or water (P3 and P4), and their 
inhibitory activities against D. radiodurans DXS were tested. To not miss out on potential 
slow binders, we investigated the influence of incubating the peptides with D. radiodurans 
DXS in Tris-HCl buffer (pH = 7.6) for 30 hours both at room temperature and at 4 °C.  
 










07AJ42 VNHEYKLHSIKY  07AJ68 ELQIGSWRMPPM  
07AJ43 TAELYPDLQSSQ P2 (x) 06DB70 SERLMTPPKLFR  
07AJ47 DDTYPSRPVYLK  07AJ71 MTHKQMHKHHGL  
07AJ52 DLYLSHGAPPQH  07AJ72 LVSLTPPWINVD  
07AJ53 HVTHNITNESNS  07AJ73 SSAQMNLNTFLN P13 
07AJ55 ARMTFSQMSPHT  06DB52 PVNKQHTSLQNN P1 (x2) 
07AJ59 TGSIRPKLHASP  06DB54 LGSHNIRLGEGS  
07AJ60 MSSRSRPHINSL P3 (x3) 06DB58 YPHPIRQNFFAY  
07AJ61 QLARMSSLHVPM  06DB61 KSHTENSFTNVW  
07AJ63 EDARRPPTSTEH P4 (x4) 06DB62 KLPPMNSDSMVW  
07AJ64 SHEISRITAVSK  06DB68 HMNAHLTFQSAI  
07AJ67 VDMVTKQLLEYP  06DB69 DAVKTHHLKHHS  
[a] Sequencing file identification number. 
[b] Peptide sequences were generated by translating the sequenced DNA considering the “amber 
mutation” codon usage i.e., the co-don TAG is translated with the amino acid Gln.  
[c] Peptide IDs (P1, P2, P3, P4) are assigned to every sequence tested. [d] The values in brackets 
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We noticed that the peptides dissolved in DMSO gave better results when incubated at 
4 °C, whereas peptides dissolved in water showed the maximum inhibition at room 
temperature. The best results were obtained for P2 (50% of inhibition at 1000 μM after 30 
hours incubation at 4 °C) and particularly P3 (47% of inhibition at 250 μM, after 30 hours 
incubation at room temperature) (Table 4). Both P2 and P3 contain two adjacent Ser 
residues in the sequence: this Ser-Ser motif might function as a fingerprint for the 
recognition of the TDP-binding pocket of D. radiodurans DXS. Some preliminary modeling 
studies aimed at rationalizing the role of the Ser-Ser-(Ser) motif will be shown in Section 
3.7. 
 
Table 4. List of peptides selected from the first phage display and their inhibitory 







  IC50 (μM) [b] % of inhibition 
r. t. [b] 
% of inhibition 
4 °C[b] 
P1 DMSO >1000 0% at 1000 μM 30% at 1000 μM 
P2 DMSO >1000 0% at 1000 μM 50% at 1000 μM 
P3 H2O >250 47% at 250 μM 0% at 250 μM 
P4 H2O >1000 30% at 1000 μM 30% at 1000 μM 
[a] Peptides were incubated in Tris-HCl buffer (pH = 7.6) with D. radiodurans DXS for 
30 hours at room temperature and/or 4 °C. 
[b] IC50 values and percentage of inhibition were determined using a 
spectrophotometric assay. The values reported in the table correspond to the 
maximum concentration of the peptide, which was soluble in the assay conditions.  
[c] P1P4 are amidated at the C-terminus. 
[d] It refers to the solvent (H2O or DMSO) used to prepare the stock solutions. When 
DMSO was used, the biochemical evaluation of IC50 was carried out according to the 
tolerance of DXS with respect to DMSO (up to 3%), determined as described in the 
Chapter 3.10.  
 
3.6 Second phage display 
We performed a second phage-display selection using a custom-made library taking into 
account the Ser-Ser motif. After the selection, the eluted phages were sequenced, and the 
results are shown in Table 5. The list contains some sequences that were present in the 
initial library, such as A10, A06, A01 and D02. Whereas A10 is a non-specific protein 
binder that we have found several times in other displays,23 A06 is repeated several times 
and so it may be a DXS binder not discovered during the first display. The last two 
sequences (A01 and D02) might be contaminants given that they are not repeated. 
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Focusing on the sequences containing the Ser motif, we can see that some of them are 
repeated (e.g., P9), whereas others are not repeated but contain some recurring motifs 
like the presence of additional Ser residues and multiple aromatic amino acids within the 
sequence (marked in bold and underlined in Table 5). Moreover, we observed that all the 
peptides contain at least one Pro residue, preferentially in the central part of the sequence, 
which might play a role in defining conformational preferences. 
 
Table 5. Peptide sequences obtained after the second phage display. 
Sequence 
ID 




Sequence[a, b] Peptide 
ID[c] 
A01 KAIRTRGKRPQY  B12 VSSSIFPIALPD P11 
A02 YSSTIYTPTAVG P5 C02 HSSPVQTDWITV P9 
(x4) 
A03 GSSLLYSGSGPA P6 D02 THPSTKVPGTPA  
A06 MAIPTRGKMPQY P12  
(x8) 
E05 ASSVISPRWLLW  
A10 ALWPPNLHAWVP[d]  E07 ALWPPNLHAWVP[d]  
A11 SSSPVAWALAMR P7 F09 TSSAAAPYYSPP  
B02 HSSPPFPWLLVT P10 G05 VSSMKGPTLSTN  
B07 DSSSGLYRPLS P8 H06 DSSTWLFLSSYR  
[a] Peptide sequences were generated by translating the sequenced DNA considering the “amber 
mutation” codon usage, i.e., the codon TAG is translated with the amino acid Gln [b] Additional Ser 
residues and aromatic residues are in bold and underlined. [c] The values in brackets correspond to the 
times the sequence has been found to be repeated. [d] Indicates a contaminant sequence, which non-
specifically recognizes any protein. 
 
We investigated a set of new peptides obtained from the second phage display, including 
the sequence 07AJ73 (P13) from the first round of phage display, considering that it 
contains a Ser-Ser motif at the N-terminus of the sequence. We tested the corresponding 
peptides (Table 6, P5P12, P13) for their inhibitory activity against D. radiodurans DXS. 
Biochemical evaluation of P7 resulted in an IC50 of 13 ± 3 μM, while the other peptides did 
not show any inhibition or very weak inhibitory activity (e.g., P10, 20% inhibition at 1000 
μM). As for the biochemical evaluation of the peptides originating from the first round of 
phage display, we included an incubation step not to miss out on potential slow binders, 
enabling us to confirm the inhibitory potency of P7 (IC50 = 62 ± 13 μM after 30 hours 
incubation at 4 °C) and to identify P13 as a double-digit micromolar inhibitor of D. 
radiodurans DXS (IC50 = 49 ± 11 μM). The accurate concentration of P7 in solution was 
determined by UV spectrophotometry taking advantage of the fact that P7 contains a single 
Trp residue. As a consequence, the IC50 dropped down to 9.5 ± 2 μM. Unfortunately, it was 
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not possible to determine the accurate concentration of P13 in solution by absorbance 
measurements, due to the absence of Trp or Tyr residues in the amino acid sequence. 
 
Table 6. List of peptides selected from the second phage display and their inhibitory 











P5 DMSO >1000 - >1000[c] 
P6 DMSO >1000 - >1000[d] 
P7 H2O 13 ± 3 
    (9.5 ± 2)[f] 
- 62 ± 13 
P8 H2O >500 >1000 - 
P9 H2O >500 >500 - 
P10 DMSO >1000[c] - >500 
P11 DMSO >1000 - >1000 
P12 H2O >1000 >1000 - 
P13 DMSO >50 - 49 ± 11 
[a] Peptides were incubated in Tris-HCl buffer (pH = 7.6) with D. radiodurans DXS 
for 30 hours at room temperature and/or at 4 °C.  
[b] IC50 values and percentage of inhibition were determined using a 
spectrophotometric assay. The values reported in the table correspond to the 
maximum concentration of the peptide, which was soluble in the assay 
conditions.  
[c] 20% inhibition at 1000 μM. 
[d] 40% inhibition at 1000 μM. 
[e] P5P13 are not amidated at the C-terminus.  
[f] IC50 value determined based on the accurate concentration of P7 in the stock 
solution, as determined by absorbance measurements. 
[g] It refers to the solvent (H2O or DMSO) used to prepare the stock solutions.  
 
Comparing the sequences of the two most successful peptides, P7 (containing a Ser-Ser-
Ser motif) and P13 (containing a Ser-Ser motif), it is clear that the Ser residues at the N-
terminus are essential for their inhibitory potency. It is important that the sequence starts 
with the Ser motif. In fact, peptides bearing a different amino acid at the N-terminus, right 
before the Ser motif, (e.g., P5, P6, P8), display no inhibition or very weak inhibition of 
D. radiodurans DXS. The use of a coupled spectrophotometric assay, requires a follow-up 
assay with the auxiliary enzyme, IspC. Therefore we tested P7 for its inhibitory potency 
against E. coli IspC and found that it has an IC50 value of 398 ± 61 μM. The fact that P7 
acts both as an inhibitor of DXS and of IspC, can be considered an advantage. In fact, the 
possibility of targeting multiple enzymes of the MEP pathway with one compound looks 
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very appealing for the development of novel drugs, potentially able to overcome drug-
resistance.24 
 
3.7 Rationalization of the binding mode – Ala scan 
To elucidate the contribution of each amino acid residue, we performed an Ala scan of P7, 
which displays low micromolar activity against D. radiodurans DXS also without pre-
incubation. The nine peptides corresponding to the systematic replacement of non-Ala 
residues with Ala, (P7bl, Table 7) were synthesized and tested in vitro against 
D. radiodurans DXS without pre-incubation. To verify the influence of the free C-terminus, 
we also tested the C-amidated derivative of P7 (P7a, Table 7). Given that some derivatives 
of P7 were insoluble in water even at very low concentration, we decided to use them as 
stock solutions in DMSO. To start with, we tested the reference peptide P7 in DMSO so 
as to have a reference value for its inhibitory activity in both solvents. We found its IC50 
against D. radiodurans DXS to be higher (IC50 = 93 ± 17 μM) than when tested as a stock 
solution in water (IC50 = 13 ± 3 μM). Replacement of one of the three Ser residues at the 
N-terminus of P7 (derivatives P7bd, Table 5) resulted in a significant loss in the inhibitory 
activity of the corresponding peptides (IC50 (P7bd) > 500 μM). This result suggests that 
the Ser-Ser-Ser motif at the N-terminus of the peptide chain plays an essential role in the 
protein-recognition process and thus in the inhibitory activity observed for P7. When 
replacing the Pro residue at the fourth position of the chain with an Ala residue, the 
inhibitory activity is improved with respect to P7 (P7e, IC50 = 43 ± 13 μM). This fact might 
indicate that the presence of a small, hydrophobic residue, is the most suitable for this 
position, but the specific conformational preferences imposed by Pro might disfavor the 
interaction between P7 and D. radiodurans DXS. In general, replacement of the 
hydrophobic core of the peptide, up to the C-terminus (P7fi) leads to at least a ten-fold 
loss in inhibitory activity. Even the presence of Ala instead of Val or Leu (P7f and P7h, 
respectively) causes substantial or complete loss of activity (P7f: IC50 > 300 μM; P7h: IC50 
= 252 ± 23 μM), showing how important inter- or intramolecular hydrophobic interactions 
seem to be for the inhibitory activity of P7. Modification of the first residue at the C-terminus 
shows that there is room for improvement of the inhibitory potency of P7: the presence of 
an Ala rather than an Arg residue (P7l), doubled the inhibitory potency (IC50 = 47 ± 13 μM), 
suggesting that different, small, hydrophobic residues might be suitable in this position 
when optimizing the inhibitory activity of P7. On the other hand, amidation of the C-
terminus (P7a) resulted in a complete loss of the inhibitory potency (IC50 > 300 μM). 
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Table 7. Ala scan of P7. 
 
Peptide ID Sequence Solvent[a] IC50 (μM) 
P7 (ref) SSSPVAWALAMR H2O 13 ± 3 
P7 (ref) SSSPVAWALAMR DMSO 93 ± 17 
P7a SSSPVAWALAMR-NH2 H2O >300 
P7b ASSPVAWALAMR DMSO >500 
P7c SASPVAWALAMR DMSO >500 
P7d SSAPVAWALAMR DMSO >500 
P7e SSSAVAWALAMR DMSO 43 ± 13 
P7f SSSPAAWALAMR H2O >300 
P7g SSSPVAAALAMR DMSO 422 ± 99 
P7h SSSPVAWAAAMR H2O 252 ± 23 
P7i SSSPVAWALAAR H2O 170 ± 23 
P7l SSSPVAWALAMA DMSO 47 ± 13 
[a] It refers to the solvent (H2O or DMSO) used to prepare the stock solutions. 
On the way to rationalize the importance of the Ser-Ser-Ser motif, we did preliminary 
modeling studies with the software Moloc, in which we performed an energy minimization 
of this trimer both within the TDP- and within the substrate-binding pockets of 
D. radiodurans DXS (Figure 3a and 3b, respectively). As one can observe, both pockets 
are likely to be occupied by the trimer, which is engaged in numerous hydrogen-bonding 
interactions with the protein. In particular, in the substrate-binding pocket, the trimer is able 
to interact with the residues, which are supposed to be involved in the catalytic process of 
DXS or in the substrate-recognition event (Figure 3b). 
(a)  (b) 
 
Figure 3. Modeled binding mode of the trimer Ser-Ser-Ser in: (a) the TDP-binding 
pocket and (b) the substrate-binding pocket of D. radiodurans DXS (PDB: 2O1X). Color 
code: protein (shown as cartoon): C: gray; O: red; N: blue; S: yellow. Ser-Ser-Ser 
skeleton: C: green. TDP (shown as lines): C: purple. Hydrogen bonds below 3.5 Å shown 
as dashed lines. 
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3.8 In vitro activity against Mycobacterium tuberculosis DXS and cell-based 
assays 
 
We tested our two most promising peptides, P7 and P13 also against M. tuberculosis 
DXS but they did not show any inhibitory potency in this case. As discussed already in 
Chapter 2 and as we will discuss further in the coming chapters, despite having a high 
degree of sequence and presumably also structural homology, surprisingly most often 
our inhibitors do not show the same behavior against the two orthologues of DXS. 
P7 was tested also in cell-based assays against multi-drug resistant (MDR) strains of 
M. tuberculosis, namely 1011200345 (resistant to isoniazide, rifampicine, pyrazinamide, 
ethambutol, streptomycin, ciprofloxacin and clarithromycin), 1010901458 (resistant to 
isoniazide, rifampicine, ethambutol and streptomycin) and 101100966 (resistant to 
isoniazide, rifampicine, ethambutol, streptomycin and pyrazinamide). In all cases, the 
Minimum Inhibitory Concentration (MIC) value turned out to be > 20 μM. The fact that no 
cell-based activity was observed, does not come as a surprise. In fact, standard peptide 
sequences composed of natural amino acids are, besides few exceptions, too polar to 
be able to cross cellular membranes and have to be carefully optimized for their 
physicochemical properties and pharmacokinetic profiles. Moreover, M. tuberculosis is 
known to have a particularly thick and hydrophobic cell wall,25 which renders the 
optimization of any peptidic inhibitor, a necessary step to develop any hit compound into 
an efficient antituberculotic agent. 
 
 
3.9 Conclusions and outlook 
 
In summary, we reported the identification of the first peptidic inhibitor of the enzyme 
DXS. In fact, all reported inhibitors of DXS are small, organic molecules. The use of 
phage display enabled us to rapidly and efficiently identify peptidic inhibitors with an 
activity in the low micromolar range (P7), comparable in potency to the most active 
small-molecule inhibitors discovered so far (Chapter 1, Figure 11). The Ala scan of P7 
demonstrated the essentiality of the N-terminal Ser-Ser-Ser motif in the amino acid 
sequence, together with other key parts of the sequence that we will exploit to enhance 
the inhibitory potency of P7 in future optimization cycles. Therefore, our work sets the 
stage for the development of potent, peptidic inhibitors of DXS as anti-infective agents. 
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Truncation studies to understand which amino acid residues are essential for the binding 
– and therefore for the inhibitory potency – of P7 to DXS, should be carried out. Certainly, 
the trimer consisting of Ser-Ser-Ser should be tested. 
One should also exploit the advantage of phage display, which can generate wide 
libraries of peptides without the need for their costly and time-consuming synthesis and 
allows to rapidly screen them as binders – and therefore potential inhibitors – of a certain 
target. For example, a further phage display cycle, could include the screening of a 
library containing only two randomized positions, namely the Pro and the Arg residue 
(SSSXVAWALAMX), which did not lead to any drop of the inhibitory potency when 
replaced by Ala. This could help to identify suitable amino acid residues for these two 




Bacterial strain. E. coli ER2738 (NEB E4104S) (Geno-type: F´proA+B+ lacIq Δ(lacZ)M15 
zzf::Tn10(TetR)/ fhuA2 glnV Δ(lac-proAB) thi-1 Δ(hsdS-mcrB)5) is a male E. coli in which 
the F ́can be selected for using tetracycline, it allows Blue/White screening and it is an 
amber mutant strain. It was used for cloning and expression of the phage library, for titering 
and for the inoculation of the sequencing plates. 
Phage Display I. The first phage-display selection protocol was carried out using the 
commercially available M13 library PhD12 (NEB E8111L) consisting of M13 phages 
expressing a 12aa peptide at the N-terminus of each coat protein pIII a small linker Gly-
Gly-Gly-Ser was inserted between the peptide and the coat protein to increase the 
conformational freedom of the exposed peptides and to minimize the contribution of the 
protein pIII to the overall binding. The schematic sequence of this library is N-term-X12-
GGGS-p3-C-term. Three rounds of selection were performed in PBS buffer (1 mL, sodium 
phosphate 50 mM, NaCl 150 mM, pH 7.5) incubating 10E10 phages with D. radiodurans 
DXS (1 mg) in a 2 mL protein-low-binding tube for 30 min on ice. For the first two rounds, 
DXS functionalized with NHS-Desthiobiotin and Dynabeads MyOne Streptavidin C1 
(Invitrogen 65001) were used to capture DXS from the solution. For the third round, to 
avoid selection of phages against streptavidin and given that D. radiodurans DXS contains 
an N-terminal His-tag, MagneHis Ni-Particles (Promega V8560) were used as capturing 
system. After the incubation step, 0.1 mL of beads were added to the solution, which was 
mixed in a thermo shaker at 4 °C for 15 min. The tube was placed in a magnetic rack to 
allow for the adhesion of the magnetic beads on one side of the tube. Phages expressing 
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DXS-binders were retained on the bead surface, the buffer containing unbound phages 
was gently discarded from the tube. To further remove weakly bound phages, the beads 
were washed with PBST (10 x 1 mL PBS with 0.05% Tween 20) whilst retaining them using 
a magnetic rack. The elution of strongly bound phages from the beads was achieved by 
suspending the beads in the elution buffer (1 mL, 1 mM Biotin in PBS for rounds 1 and 2 
and 500 mM imidazole in PBS for round 3). After separation of the beads, the solution 
containing the eluted phages was used to amplify the selected pool of phages by infecting 
a fresh culture of E.coli ER2738. Infection, production and purification of the phages were 
carried out following the manufacturer’s manual. Peptides P1 ̶ P4 were purchased from 
CASLO (Lyngby, Denmark) with purity > 97% according to HPLC. 
Library design and cloning. A custom-made library was designed in order to include the 
motif Ser-Ser at the N-terminus of the peptide library. Two oligomers, one coding for the 
library itself and one used for cloning purposes were designed: 
Library Oligo: 
CATGTTTCGGCCGA(MNN)9GGAGGAMNNAGAGTGAGAATAGAAAGGTACCCGGG  
Extension Primer: CATGCCCGGGTACCTTTCTATTCTC 
The “Library Primer” codes for the reverse strand of the library and it includes two flanking 
regions that contain the restriction site for KpnI/Acc651 and EagI needed for cloning into 
the M13KE vector. The random part of the peptide sequence is coded by NNK codons 
(reverse complement of MNN) where N is any of the bases while K represents G or T (thus, 
M represents C or A). An NNK codon can encode for all 20 amino acids but only for one 
stop-codon: TAG.  Combining the use of NNK codons with amber mutant strains like E. 
coli ER2738, ensures that the whole library will code for full-length peptides. The 
“Extension Primer” is partially complementary with the library-coding oligomer and it was 
used to generate the dsDNA needed for the cloning. The preparations of the library duplex 
and the cloning were performed as indicated in the manufacturer’s manual (NEB E8mL). 
Phage Display II. Two rounds of selection were performed using a custom-made phage 
library. The schematic sequence of the expressed library is: N-term-XSSX9-GGGS-p3-C-
term. TBS was used as incubation buffer, TBST (TBS with 0.05% Tween 20) as washing 
buffer, MagneHis Ni-Particles (Promega V8560) were employed for protein recovery and 
1 mM TDP in TBS as elution buffer. TDP was chosen as competitive eluent to specifically 
elute peptides interacting with the TDP-binding site of DXS. The same procedure as 
described for Phage Display I was used with the following modifications: DXS (1 mg) was 
incubated simultaneously with phages from the new library, phages from the original PhD-
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12 library were added to increase sequence complexity, and wild-type phages were 
supplemented to screen for non-specific binders. The different phage pools were mixed at 
a 1:1:1 ratio prior to incubation with the target.  
Sequencing. The last elution fractions from the phage display experiments were serially 
diluted (1:10) and used to infect a fresh culture of E. coli ER2738. The infected culture was 
plated on LB-agar supplemented with Tetracycline, IPTG and XGal. Blue colonies resulting 
from phage infection were picked and sent for Sanger sequencing (at GATC Biotech) using 
a custom designed M13-specific sequencing primer (GTACAAACTACAACGCCTGT). 
Peptides P5–P13 and P7a–P7l were purchased from ProteoGenix SAS (Schiltigheim, 
France) with purity > 95% according to HPLC. 
Gene expression and protein purification of D. radiodurans and M. tuberculosis 
DXS. Gene expression and protein purification of D. radiodurans and M. tuberculosis DXS 
were performed as reported in Chapter 2. 
Spectrophotometric assay for the determination of IC50 values against 
D. radiodurans and M. tuberculosis DXS. Direct measurements of the inhibitory 
activities with the spectrophotometric assay, were performed as reported in Chapter 2. The 
tolerance of DXS with respect to DMSO concentration was determined by measurement 
of the reaction velocity in the presence of different concentrations of DMSO. The activity 
of the enzyme was found to be stable in presence of up to 3% DMSO. For determining the 
inhibitory activity of the peptides after incubation, several solutions were prepared 
containing degassed Tris-HCl (pH = 7.6, 100 mM. 300 μL), D. radiodurans DXS (0.79 μM) 
and different concentrations of each peptide, with a dilution factor of 1:2 starting, when 
possible, from 1000 μM. The solutions were incubated at room temperature or at 4 °C for 
30 hours. Preliminary control experiments have shown that the activity of D. radiodurans 
DXS is unchanged at room temperature or at 4 °C after 30 hours. After the incubation time, 
each incubated solution (95 μL) was transferred to a 96-well plate, and a buffer containing 
Tris-HCl (pH = 7.6, 100 mM) and D-glyceraldehyde-3-phosphate (4.0 mM) was added (47.5 
μL). The reaction was started by addition of a buffer solution (47.5 μL) containing Tris-HCl 
(pH = 7.6, 100 mM), MnCl2 (16 mM), dithiothreitol (DTT, 20 mM), NADPH (2.0 mM), sodium 
pyruvate (2.0 mM), TDP (4.89 μM) and E. coli IspC (8.2 μM). A control experiment with the 
enzyme incubated in Tris-HCl buffer (and DMSO when testing peptides as stock solutions 
in DMSO) at the same temperature and for the same time, was carried out in parallel to 
monitor for potential loss in activity of the enzyme itself, which has never been observed. 
Determination of the exact concentration of P7 in solution by absorbance 
measurement. The concentration of P7 in aqueous solution was calculated applying the 
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following equation: [Peptide concentration] mg/mL = (A280 x DF x MW) / ε, where A280 is 
the absorbance of the peptide solution at 280 nm in a 1 cm cell, DF is the dilution factor, 
MW is the molecular weight of the peptide and ε is the molar extinction coefficient of Trp 
at 280 nm (5690 M−1cm−1). 
Gene expression, purification of E. coli IspC and biochemical evaluation of 
inhibitory activity against E. coli IspC by spectrophotometric assay. Gene expression 
and purification of E. coli IspC and biochemical evaluation of inhibitory activity of P7 
against E. coli IspC was performed as reported previsouly.26 
Cell-based assays. A total of three MDR M. tuberculosis isolates, and one control strain 
(H37Rv) were selected and subcultured on a Middlebrook 7H10 tube until use. 
Susceptibility testing using the absolute concentration method were carried out by 
preparing 25-well plates with solid 7H10 medium containing different concentrations (20, 
10, 5, 2.5, 1.25 μM) of P7. The plates were subsequently inoculated by adding 10 μL 
Mycobacterium suspension to each well. Then the plates were incubated at 35.5 °C in a 
CO2 incubator. After appropriate incubation, the MICs were assessed. The reading of the 
plates was carried out when the bacterial growth on the two control wells without P7 was 
sufficient, i.e., when colonies were clearly visible. 
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Rationalization of observed activities of 
thiamine and thiamine diphosphate 
derivatives as inhibitors of two 
orthologues of DXS 
 
In this chapter, we will discuss the rationalization of the differences in inhibitory activity of 
D. radiodurans and M. tuberculosis DXS of a selection of thiamine and thiamine 
diphosphate analogues. By advanced docking studies, we were able to develop and 
validate a homology model of M. tuberculosis DXS, which can be used for rational design 
of inhibitors for M. tuberculosis DXS in the absence of crystallographic information. 
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 Chapter 4 
4.1 Thiamine and thiamine diphosphate analogues 
Thiamine (1) and thiamine diphosphate (TDP, 2) derivatives have been widely studied in 
the past as inhibitors of TDP-dependent enzymes and riboswitches but none of them has 
been exploited to date as an inhibitor of DXS.1 One of the most potent inhibitors of several 
TDP-dependent enzymes is 3-deazathiamine diphosphate (3), where the replacement of 
the charged thiazolium ring of TDP with a neutral thiophene ring results in total loss of the 
catalytic activity, whereas the affinity and the speed of the binding event are enhanced 
with respect to those of the natural cofactor. For example, the binding of 3 to the E1 subunit 
of α-ketoglutarate dehydrogenase from E. coli was shown to be 500 times stronger than 
that of TDP, with a Ki value of approximately 5 nM, while the binding of 3 to Zymomonas 
mobilis pyruvate decarboxylase (PDC) was found to be ~ 25,000 times tighter than that of 
TDP, with a dissociation constant in the low picomolar region or less, resulting in an 
essentially irreversible inhibition, although it was proven that no covalent adduct was 
formed. In both cases, the binding occurred at a faster rate than the natural coenzyme (7-
fold and 74-fold for PDC and α-ketoglutarate dehydrogenase respectively).2  
Derivatives of 3 at the C-2 position of the thiophene ring (4, 5), proved to be even better 
inhibitors than 3 itself of the E1 components of pyruvate dehydrogenase with Ki values of 
0.44 nM (4) and 0.17 nM (5) for the E1b subunit of PDH, whereas 4 showed Ki = 0.1 nM 
and 5 no detectable inhibition for the E1p subunit of PDH.1 Moreover, co-crystal structures 
of 4 have also been reported, which helped to further understand the TDP-catalyzed 
reaction of several TDP-dependent enzymes and the corresponding conformational 
changes that the protein would adopt upon formation of the enamine intermediate. In 
particular, crystal structures have been obtained of 4 complexed with phenylpyruvate 
decarboxylase3 and the branched-chain keto acid decarboxylase from Lactococcus lactis.4 
Diphosphate-free derivatives have been extensively studied to circumvent cell-penetration 
issues due to the presence of the very polar diphosphate moiety. On the one hand, few 
TDP-derivatives bearing both charged and neutral diphosphate mimics have been 
reported (e.g., compound 6 and 7, Figure 1), which showed very good inhibitory activity 
(6, Ki = 0.95 μM against Zymomonas mobilis PDC; 7, IC50 = 5.33 PM against E. coli E1 
subunit of PDH and high antifungal activity against Rhizoctonia solani and Botrytis cinerea 
at a dosage of 100 μg/mL).5,6 On the other hand, TDP-derivatives lacking the diphosphate 
mimic have been extensively studied given that they should be diphosphorylated in the 
cytosol by the enzyme thiamine pyrophosphokinase (TPPK).  Based on a careful analysis 
of the murine TPPK crystal structure,7 a few derivatives were rationally designed and 
tested against transketolase (TK), so as to retain TPPK activity. 
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Figure 1. Structures of thiamine (1), thiaminediphosphate (2) and a selection of TDP- and 
thiamine-derivatives (310) as inhibitors of various TDP-dependent enzymes. 
 
Deazathiamine (8) displays a Kd of 18 μM for TK and compounds 9 and 10 showed Kd = 
2.2 μM and Kd = 1.1μM, respectively. Although retaining TPPK activity, their activity in the 
cell-based assay decreased with respect to the charged thiamine mimics and this is 
probably due to the fact that these scaffolds are not recognized by thiamine transporters.8  
The fact that no TDP-derivatives had been reported in the literature as inhibitors of the 
enzyme DXS, encouraged us to synthesize a series of them and study their inhibitory 
activity against D. radiodurans and M. tuberculosis DXS. Given the lack of structural 
information regarding M. tuberculosis DXS, we initiated a structure-based effort by first 
constructing a homology model, followed by docking studies in the attempt to rationalize 
the activity differences of the TDP derivatives against two orthologues of DXS, namely 
D. radiodurans and M. tuberculosis DXS. The M. tuberculosis DXS model-building was 
carried out by Dr. Kontoyianni at the Southern Illinois University, US, and will not be 
discussed in detail in this thesis. The crystal structure of D. radiodurans DXS in complex 
with TDP (Protein Data Bank code: 2O1X)9 was used as a template for building the model 
and a sequence alignment of 2O1X with the primary sequence of M. tuberculosis DXS 
was generated by using ClustalW.10 Further refinement of the model and its assessment 
based on multiple criteria (e.g., presence of hydrophobic residues on the protein’s surface 
or polar residues buried in the core which are penalized with lower scores , analysis of 
Ramachandran plots) led to the final homology model, which we used for rationalizing the 
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differences in inhibitory potencies of the thiamine and TDP analogues discussed in Section 
4.2. 
 
4.2 Synthesis and biochemical evaluation of thiamine and TDP derivatives 
First, we decided to investigate two very closely related derivatives of TDP, 3-
deazathiamine diphosphate (3) and racemic 2-(1-hydroxyethyl) thiamine diphosphate (4). 
The two compounds were synthesized by the group of Prof. Leeper at the University of 
Cambridge. 3 was synthesized according to a literature procedure,11 whereas 4 was 
synthesized starting from deazathiamine (8, synthesized according to a literature 
procedure).11  
Whereas 3 displays nanomolar IC50 values both against D. radiodurans DXS and 
M. tuberculosis DXS (3: IC50 = 0.034 ± 0.006 μM, D. radiodurans DXS; IC50 = 0.74 ± 
0.13 μM, M. tuberculosis DXS), biochemical evaluation of 4 resulted in a single-digit 
micromolar IC50 value against M. tuberculosis DXS (IC50 = 1.4 ± 0.1 μM) but in a 
disappointing IC50 of 434 ± 50.6 μM against D. radiodurans DXS (Table 1). We also 
synthesized and tested a series of thiamine analogues lacking any diphosphate moiety. 
Not surprisingly, biochemical evaluation of 8, not bearing any diphosphate moiety, resulted 
in a decrease in inhibitory potency against D. radiodurans DXS (IC50 = 430 ± 68 μM), While 
no activity at all was observed against M. tuberculosis DXS. Compound 11 (synthesized 
according to a literature procedure)12 where the hydroxyethylene linker of 8 is substituted 
by a hydroxymethylene linker, shows a slightly higher IC50 value than 8 against 
D. radiodurans DXS (IC50 = 526 ± 52 μM) and no activity against M. tuberculosis DXS. In 
our previous work, where we validated the binding mode of 8 to D. radiodurans DXS in 
solution (Chapter 2),13 we showed that the hydroxyl group of 8 is engaged in a strong 
hydrogen-bonding interaction with the side chain of His82. From our molecular-modeling 
studies, performed with the software MOLOC,14 the hydrogen-bonding interaction with 
His82 is lost when shortening the linker and the newly formed hydrogen-bonding 
interaction with Ser186, causes a certain degree of intramolecular strain, which 
presumably explains the drop in inhibitory activity (Figure 2). Nevertheless, 11 is an 
interesting scaffold to be decorated with bulkier diphosphate-mimics, for which the 
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Table 1. Biochemical evaluation of a selection of thiamine and thiamine diphosphate 
analogues against two DXS orthologues. 
 
Compound IC50 (μM) 
  
 D. radiodurans DXS M. tuberculosis DXS 
 
3[a] 0.034 ± 0.006 0.74 ± 0.13 
      4[a, b] 434 ± 51 1.4 ± 0.1 
                                        8 430 ± 68 >2000 
 
 













       
 
255 ± 23 
 
>2000 
       
 













[a] Tested as a 1:1 mixture with NH4OTs. [b] Tested as a stock solution in water. 
 
Compounds 12 and 13 were synthesized according to literature procedures12 and tested 
to investigate the importance of the methyl substituent on the aminopyrimidine ring and of 
the hydroxyethylene linker, respectively. In both cases, the biochemical activity drops 
down substantially compared to that observed for 8. It might be worthwhile to explore ethyl, 
propyl or isopropyl substituents on the aminopyrimidine ring to determine whether more 
hydrophobic contacts can be created, that can help enhancing the inhibitory potency of 
this scaffold.  
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As we will discuss in detail in Section 4.3, there is a remarkable polarity difference in the 
pocket hosting the thiazolium ring of TDP between the two orthologues.  
 
 
Figure 2. Experimentally validated binding mode of 8 and modeled binding mode of 11 
within D. radiodurans DXS (PDB code: 2O1X). Color code: D. radiodurans DXS backbone, 
C: gray, N: blue, O: red, S: yellow. 8 backbone, C: purple. 11 backbone, C: green. The 
color code is maintained throughout the chapter, unless otherwise stated. 
 
To explore the possibility of gaining in affinity by increasing the hydrophobic contacts of 
the ligand with the enzyme, we synthesized compounds 14 and 15, following the synthetic 
route shown in Scheme 1.12  
 
Scheme 1. Synthesis of the TDP-analogues 14, 15 and 23. 
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The synthesis involves first the formylation of commercially available bromides 16 or 17 to 
yield aldehydes 18 and 19 in 74% and 70% yield, respectively. By treatment with 3-
anilinopropionitrile, we obtained 20 and 21 in 45% and 24% yield, respectively, which were 
ring-closed to afford the target molecules 14 and 15, bearing an aminopyrimidine ring 
(Scheme 1). 
Whereas we found 15 to be inactive against M. tuberculosis DXS, its inhibitory potency 
with respect to D. radiodurans DXS (IC50 = 109 ± 16 μM, Table 1) increased remarkably 
compared to 8, confirming that an increase in hydrophobic contacts in this subpocket can 
lead to a more potent inhibitor. Shortening the ethylene linker of 15 (compound 14, Table 
1) resulted in a decrease in biochemical activity (IC50 = 255 ± 23 μM) presumably due to 
the formation of a weaker hydrogen-bonding interaction with His304 (modeled pose not 
shown). Like compound 11, 14 could be a good scaffold to explore different and bulkier 
diphosphate mimics. 
Thiamine derivatives bearing a triazole ring have been extensively studied in the literature, 
given the possibility to synthesize them via convenient “click reactions”.15 We found, 
however, compound 22 (synthesized according to a literature procedure)5 to be inactive 
against both DXS orthologues, thus not constituting a good template to study, for example, 
diphosphate mimics, as we will discuss more in detail in Section 4.6. 
The advantage of the synthetic protocol proposed in Scheme 1 for the synthesis of 14 and 
15 is that many derivatives at the 2 position of the aminopyrimidine ring can be synthesized 
only by varying the last step of the procedure. For example, compound 23 was synthesized 
in an analogous way by reacting 21 with guanidinium chloride (Scheme 1). 23 did not result 
in any inhibitory potency above 1000 μM for both DXS orthologues, reinforcing our 
hypothesis that hydrophobic contacts might be responsible for the recognition process in 
this subpocket of DXS. 
 
4.3 Comparison of the TDP- and substrate-binding pockets in D. radiodurans DXS 
and M. tuberculosis DXS 
 
There is a high degree of sequence similarity between D. radiodurans DXS and 
M. tuberculosis DXS, which is particularly high in the TDP-binding pocket (85% similarity, 
70% identity). 
A detailed comparison of the amino acids lining the TDP- and substrate-binding pockets 
(Table 2), reveals the high degree of similarity. Especially in the subpocket hosting the 
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Table 2. Comparison of the amino acids in the TDP-binding pocket of D. radiodurans 
DXS (PDB code: 2O1X) and M. tuberculosis DXS (homology model) 
 
D. radiodurans DXS 
(2O1X) [a] 
























Ser156 (N-H)[b] Ala146 
Asn183 Asn173 












[a] Amino acid residues, which are conserved, are shown in bold, 
whereas non-conserved amino acid residues are shown in italics. 
[b] Non-conserved amino acid residues, which are involved in 
binding TDP using the protein backbone. 
[c] Non-conserved amino acid residues, with a high degree of 
similarity in terms of polarity. 
 
In the diphosphate-binding pocket, where a lot of the interactions rely on hydrogen bonds 
with the protein backbone, a strict conservation might not be needed to preserve the 
strength of the binding. It is particularly interesting that the small subpocket hosting the 
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thiazolium ring of TDP shows the lowest degree of similarity. Residues Val80, Ile187 and 
Ile371 in D. radiodurans DXS are engaged in hydrophobic interactions with the thiazolium 
ring. In M. tuberculosis DXS, the hydrophobic contacts are fewer due to the replacement 
of Val80 and Ile187 by Thr69 and Tyr177, respectively. Moreover, the side chain of Tyr177 
points out of the pocket so as to form a favorable, intramolecular edge-to-face SS-stacking 
interaction with His296 and, as a result, it lies too far from the thiazolium ring to interact 
with it (Figure 3). 
 
Figure 3. Superimposition of D. radiodurans DXS (PDB code: 2O1X) and M. tuberculosis 
DXS (homology model). Amino acids lining the thiazolium- and diphosphate-binding 
pocket, which are different in the two orthologues, are shown. Thiamine diphosphate 
(TDP) is also shown. Color code: TDP, C: yellow; D. radiodurans DXS backbone, C: green. 
M. tuberculosis DXS, C: pink. 
 
4.4 Assessment of docking accuracy and rationalization of the differences in activity 
between the two DXS orthologues 
First, the docking accuracy of Glide, the software that was used for the docking studies, 
was assessed by Dr. Kontoyianni.16,17 To do so, 8 and 24 (Figure 4) – for which we 
validated the binding mode within D. radiodurans DXS by STI-NMR, as discussed in 
Chapter 2 – were first docked into D. radiodurans DXS. The top-ranked docked poses that 
were obtained from Glide superimposed with the validated pose. 
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Figure 4. The binding mode of 24 was validated by STI-NMR, as discussed in Chapter2. 
Glide was then used to dock a selection of the thiamine and TDP-analogues described in 
Table 1 (compounds 3, 4, 8, 11, 14 and 15) into D. radiodurans DXS and the homology 
model of M. tuberculosis DXS so as to rationalize the differences in activities between the 
two orthologues. By a detailed analysis and comparison of the top-ranked poses, the 
observed activity differences could be rationalized. 
 
4.5 Phosphate and diphosphate bioisosteres 
Phosphate (P) and diphosphate (DP) groups play very important roles in cellular function.18 
The design of potential drugs, which have the ability to act as competitive-inhibitors of P- 
or DP-containing substrates or cofactors is recognized as a particularly challenging goal. 
In fact, the incorporation of a P or DP group into a drug is unattractive, due to the probable 
inability of the resulting molecule to cross the cell membrane. Furthermore, these groups 
have low cellular stability and are prone to hydrolysis by phosphatases. Over the past 
years, the molecular recognition of P and DP moieties by proteins has been extensively 
studied. 19 The design of suitable P or DP bioisosteres has attracted a lot of attention. 
However, this design is far from being trivial and requires to pay particular attention to 
many factors such as pKa values and polarity of the bioisosteric moiety. A few examples 
of groups, which have been used as P bioisosteres are shown in Figure 5.20 DP 
bioisosteres are less well studied than P bioisosteres. 
 
Figure 5. Examples of phosphate bioisosteres. 
 
4.6 Sugars as diphosphate mimics 
As discussed in Chapter 2 of this thesis, the DP moiety of TDP accounts for a good part 
of the binding energy of the cofactor to DXS and consequently, for a good part of the 
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inhibitory potency of TDPcderivatives such as 3. Therefore, we decided to employ a 
thiamine analogue as a template to exploit suitable diphosphate mimics. Given that phenyl 
derivatives 14 and 15 resulted in better IC50 values against D. radiodurans DXS than 
thiazoles 8 and 11 (Table 1), we decided to use 14 and 15. 
Given the complex network of hydrogen-bonding interactions, in which the DP moiety of 
TDP is engaged, we thought about the use of sugar moieties as DP mimics. Sugars have 
the great advantage that they can be easily “tuned” to fill the desired pocket in the optimal 
way by, for instance, choosing pentoses or hexoses, by further selective derivatization of 
certain hydroxyl groups, by inserting halogens which can be engaged in halogen bonds 
and might help to reduce the polarity of the resulting inhibitor. Our initial idea was 
confirmed by the preliminary results we obtained while working on a subproject with the 
software KRIPO (not discussed within this thesis).21  KRIPO allows for structure-based 
pharmacophore searches in the PDB and gives, as an output, moieties, which have been 
co-crystallized in pockets similar to the one we are interested in, in terms of 
pharmacophore features. Interestingly, we noticed that most of the outputs we obtained in 
the DP pocket, turned out to be sugars. 
Therefore, we decided to perform preliminary modeling studies to identify a suitable sugar 
moiety which could fill the DP pocket of D. radiodurans DXS. First of all, we observed that 
it was necessary to use compound 14 rather than 15, to avoid clashes with the protein. 
Moreover, we modeled several pentoses and hexoses, with both α and β anomeric centers 
and we observed that, in most cases, pentoses with the anomeric center in the β 
configuration, resulted in better modeled poses. Compound 25, bearing a β-D-ribose, 
emerged as the best from our modeling studies (Figure 6). The interactions involving the 
left-hand side of 25 with DXS remained unchanged with respect to 14, while many 
hydrogen-bonding interactions could be formed on the right-hand side of 25, thanks to the 
sugar moiety. In fact, the hydroxyl groups of ribose are engaged in favorable hydrogen 
bonding interactions with the side chains of His82 (d(OH..N(His82) = 2.9 Å), Ser54 
(d(OH..OH(Ser54) = 2.8 Å), Asp154 (d(OH..O=C(Asp154) = 2.7 Å and with the NH 
backbone of Asp154 (d(OH..NH(Asp154) = 3.1 Å) (Figure 6). 
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Figure 6. 25 and its modeled pose within D. radiodurans DXS. Color code: 25, backbone, 
C: yellow; thiamine diphosphate, backbone, C: pink. 
 
4.6.1 Synthesis of the sugar derivatives 
The synthesis of 25 was first attempted as shown in Scheme 2. Peracetylated β-D-
ribofuranose (26) was first selectively deprotected at the anomeric center following 
literature procedures, either by using NaOMe in THF or (CH3COO)NH4 in DMF.22,23 27 was 
then conveniently converted into the corresponding trichloroacetimidate 2822 and reacted 
with 14 in a BF3.Et2O-mediated glycosylation. Given that no product formation was 
observed after 8 hours and the reaction mixture was still a suspension (14 not being 
soluble in CH2Cl2), we added an excess of BF3.Et2O, but still no product was formed after 
16 hours. Meanwhile, we also attempted the synthesis of 29 by direct BF3-mediated 
glycosylation of 14 with 26, only optimizing the conditions such as to work with an excess 
of 26 and BF3.Et2O, in case the presence of the nitrogen atoms of 14 could cause 
coordination of the catalyst. We first attempted the reaction using dioxane as a solvent (in 
which 14 is soluble), but no product was formed. Upon switching solvent to CH2Cl2, the 
initial suspension became a solution after a few hours, yielding 29 and a byproduct, 
presumably corresponding to an acetylated form of 14 (according to LC-MS and 1H-NMR). 
Given that the two products were not separable at this stage, we performed the 
deacetylation of the crude product and we obtained 25 as a pure compound in 50% yield 
over two steps, while recovering the unreacted 14 back. 
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Scheme 2. Synthesis of the sugar derivative 25. 
We therefore decided to synthesize two other sugar derivatives, by using two sugars we 
had available in the laboratory, namely D-xylose and D-mannose. Compounds 30 and 31 
(Figure 7) were obtained by the same protocol as the one described in Scheme 2, via the 
corresponding acetylated derivatives, although in much lower yields (see experimental 
part). The fact that the reaction mixtures remained suspensions might be one of the 
reasons why we could not isolate the products in higher yields. 
 
Figure 7. Sugar derivatives 30 and 31 (synthesis not shown). (a) 30 was isolated and tested 
as a mixture of the α and β anomer (1 : 0.2 according to 1H-NMR spectroscopy). 
 
4.6.2 Biochemical evaluation of the sugar derivatives 
The sugars that we synthesized as described in Section 4.6.1 were tested for their 
inhibitory potency against both DXS orthologues, together with other sugars derivatives 
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that were synthesized by the group of Prof. Leeper, at the University of Cambridge (3237, 
Table 3, synthesis not shown). None of the compound we synthesized (25, 30, 31) resulted 
in an IC50 value below 1000 μM against D. radiodurans DXS, while all of them were 
completely inactive against M. tuberculosis DXS (Table 3). This result is particularly 
disappointing for 25 which, according to our modeled pose, fits the TDP-binding pocket of 
DXS very well. No or only very weak activity was observed for compounds 3237 either 
(Table 3); these compounds bear a central triazolyl ring rather than a phenyl ring. As 
shown in Table 1, the parent compound 22 lacking the sugar moiety did not give any 
biochemical activity against both DXS orthologues.  
Table 3. Biochemical evaluation of compounds 25, 3037. 
 25 30(a) 31 
    
IC50 (μM)       
D. rad DXS 
1250 ± 140 1375 ± 165 1030 ± 98 
IC50 (μM)       
M. tub DXS 
>2000 >2000 >2000 




 32 33 34 
    
IC50 (μM)       
D. rad DXS 
804 ± 106 >2000 1680 ± 47 
IC50 (μM)       
M. tub DXS 
>2000 >2000 >2000 
    
 
   
 35 36    37 
     
    
IC50 (μM)       
D. rad DXS 
>2000 >2000  >2000 
IC50 (μM)       
M. tub DXS 
>2000 >2000 >2000 
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This fact, together with the fact that compounds 3439 bear only hexoses presumably 
causing steric clashes with the protein, according to our modeling studies  might be the 
reasons why we did not observe any significant biochemical activity. 
 
4.7 Conclusions and outlook 
Thiamine and TDP analogues are very useful tools that can be used to gain a deeper 
insight into many aspects of TDP-dependent enzymes. Surprisingly, no thiamine or TDP 
analogues had been so far reported in the literature as inhibitors of DXS. In our project, 
we synthesized and tested a selection of them against both D. radiodurans and 
M. tuberculosis DXS. Although there is a high degree of identity and similarity among these 
two orthologues, particularly in the TDP-binding pocket, we observed striking differences 
in inhibitory potency for all derivatives we tested. 
We built and assessed a homology model of M. tuberculosis DXS and performed 
advanced docking studies, which helped us rationalizing the differences in biochemical 
activities observed for a selection of thiamine and TDP analogues. The use of the crystal 
structure of D. radiodurans DXS (PDB code: 2O1X) as a model enzyme for the rational 
development of DXS inhibitors as antituberculotic agents is very limited, and our homology 
model might serve as a very useful tool to overcome this issue. 
Being aware that the DP moiety of TDP accounts for a good part of the cofactor binding 
energy, we exploited the use of sugars as DP mimics. However, we could not improve the 
inhibitory potency of the corresponding reference compound with the free alcohol moiety 
and we observed in all cases a dramatic drop in inhibitory potency with respect to that of 
14. The fact that 25 is only a weak inhibitor of D. radiodurans DXS and is inactive against 
M. tuberculosis DXS is particularly disappointing, given that 25 was carefully designed so 
as to optimally fill the DP subpocket of the TDP-binding pocket. Nevertheless, 25 was the 
only compound we tested bearing a pentose sugar: it would certainly be worthwhile 
synthesizing more derivatives with other pentoses, given that we observed potential 
sterical clashes between the protein and the DP mimic, in most cases when modeling 
hexoses. Overall, our results highlight the fact that the identification of suitable DP mimics 
is particularly challenging. It would be probably worthwhile to take a step back and exploit 
more traditional P mimics first, such as phosphonates or sulfur-based P mimics and 
introduce chemical diversity incrementally. At a later stage, extension from the P to the DP 
mimics might lead to further improvements in inhibitory potency. This process would allow 
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us to obtain more information on the flexibility of the protein in this specific subpocket of 
DXS. In fact, one reason why none of our sugar derivatives showed strong inhibitory 
potency against DXS might be that structure-based design does not take into account any 
potential protein flexibility. It might be worthwhile to consider the use of molecular dynamic 
simulations to rationalize our and future biochemical results. For example, the side chain 
of Lys289, supposed to help balance the extra negative charge on the terminal phosphate, 
is engaged in two hydrogen-bonding interactions with the protein in the co-crystal structure 
of D. radiodurans DXS with TDP, but when forced closer to the terminal phosphate, it 
engages in favorable electrostatic interactions with it. The Mg2+ cation should be also taken 
into account and it might be worthwhile performing modeling studies both in absence and 
in presence of the cation. It should be kept in mind that efficient binding of phosphates 
(and therefore of phosphates analogues) to proteins without any metal cation is confirmed 
by the fact that out of 3003 structures containing bound organophosphate, 2456 bind to 
phosphates without the assistance of a metal ion.19 
 
4.10 Experimental 
For general experimental detail, see Chapter 2, Section 2.8 
Compounds 3,11 8,11 1115,12 22,5 27,22,23 28,22 D-mannopyranose, 1,2,3,4,6-
pentaacetate24 and D-xylose tetraacetate25,i were synthesized according to literature 
procedures. 
General procedure for the glycosylation reaction (GP1) 
A dry flask was charged with the tetra- or pentaacetylated sugar (3 eq.) and CH2Cl2 (2.5 mL 
for 0.65 mmol of 14) and the mixture was cooled to 0 °C. 14 (1 eq.) and BF3.Et2O (5 eq.) 
were added, and the suspension was left to warm up to room temperature and stirred for 
616 h. The reaction mixture is then quenched by addition of sat. aq. NaHCO3 and let stir 
for 10 min. The organic layers were extracted with CH2Cl2, washed with sat. aq. NaCl 
solution, dried over Na2SO4, filtered and concentrated in vacuo.  
General procedure for the deacetylation reaction (GP2) 
The crude mixture obtained in the previous step was dissolved in dry MeOH (1 mL for 
100 mg. A freshly prepared solution of NaOMe in MeOH (2 M, 0.2 mmol) was added, and 
the mixture was left to stir at room temperature for 4060 minutes. The reaction was 
quenched with acidic ion exchange resin (Amberlite® 120 H+-form) and stirred for an 
additional 10 minutes, then filtered through a paper filter. The filter was washed with 
MeOH, and the filtrate was concentrated in vacuo and purified by column chromatography. 
                                                          
i Synthesized and used as a 1:0.2 mixture of α- and β-anomer 
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2-(3-((2,4-Diaminopyrimidin-5-yl)methyl)phenyl)ethan-1-ol (23) 
To a solution of 21 (150 mg, 0.539 mmol) in anhydrous EtOH 
(4.0 mL), guanidine hydrochloride (co-evaporated previously 
with toluene) (52 mg, 0.54 mmol) and NaOEt (2.0 M in 
anhydrous EtOH, 1.1 mL) were added. The reaction mixture 
was stirred at reflux for 20 h, cooled down and concentrated in 
vacuo. Purification by CC (SiO2; CH2Cl2/MeOH, 90:10), followed by washing with CH2Cl2 
and a few drops of MeOH, afforded 23 as yellow solid (50 mg, 38%). 1H NMR (400 MHz, 
CD3OD): δ=7.28 (t, J = 7.6, 1H), 7.22 (s, 1H), 7.177.13 (m, 2H), 7.08 (d, J = 7.6, 1H), 
3.75 (t, J = 6.9, 2H), 3.70 (s, 2H), 2.81 (t, J = 6.9, 2H). 13C NMR (101 MHz, CD3OD): 
δ=166.2, 156.6, 141.5, 141.2, 138.0, 130.7, 129.9, 128.8, 127.6, 110.8, 64.1, 40.1, 33.7. 




(a) GP1 starting from commercially available 
peracetylated β-D-ribofuranose (26, 625 mg, 2.00 mmol), 
14 (150 mg, 0.654 mmol) and BF3.Et2O (0.40 mL, 
3.3 mmol) in CH2Cl2 (2.5 mL). The reaction mixture was 
left to stir at room temperature for 6 h. To remove the 
excess of 26, the residue was taken up in CH2Cl2 and 
filtered. The filter was washed with CH2Cl2/MeOH (95:5), the filtrate concentrated in vacuo 
and used in the next step without further purification.  
(b) GP2 starting from the crude product obtained in the previous step (100 mg) and NaOMe 
(2 M in MeOH, 0.1 mL) in MeOH (1.0 mL). The mixture was left to stir at room temperature 
for 40 min. Purification by CC (SiO2; CH2Cl2/MeOH, 92:8 to 87:13) afforded 25 as a pale 
yellow solid (117 mg, 50% over two steps). 1H NMR (400 MHz, CD3OD): δ=7.74 (s, 1H), 
7.30 (t, J = 7.6, 1H), 7.24 (s, 1H), 7.21 (s, 1H), 7.15 (d, J = 7.6, 1H), 4.93 (s, 1H), 4.74 (d, 
J = 11.8, 1H), 4.47 (d, J = 11.8, 1H), 4.08 (dd, J = 7.0, 4.7, 1H), 3.97 (td, J = 6.7, 3.4, 1H), 
3.92 (d, J = 4.7, 1H), 3.79 (s, 2H), 3.74 (dd, J = 11.8, 3.4, 1H), 3.55 (dd, J = 11.8, 6.5, 1H), 
2.40 (s, 3H). 13C NMR (101 MHz, CD3OD): δ = 165.9, 164.1, 153.0, 139.9, 139.0, 130.0, 
129.6, 129.3, 127.7, 108.0 (2C), 85.1, 76.5, 72.9, 70.2, 65.1, 34.3, 24.4. HR-MS (ESI) 
calcd. For C18H24N3O5 [M+H]+: 362.1711, found: 362.1708. IR (cm1): 3324, 322, 2925, 





a) GP1 starting from D-xylose tetraacetate (α/β, 1:0.2, 
832 mg, 2.61 mmol) 14 (199 mg, 0.870 mmol) and 
BF3.Et2O (0.54 mL, 4.4 mmol) in CH2Cl2 (3.5 mL). The 
reaction mixture (suspension) was left to stir at room 
temperature for 16 h. Additional BF3.Et2O (0.16 mL, 
1.3 mmol) was added and the suspension was left to stir 
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for an additional 3 h. To remove the excess of D-xylose tetraacetate, the residue was taken 
up in CH2Cl2 and filtered. The filter was washed with CH2Cl2/MeOH (92:8), the filtrate 
concentrated in vacuo, and the resulting oil used in the next step without further 
purification.  
(b) GP2 starting from the crude product obtained in the previous step (100 mg) and NaOMe 
(2 M in MeOH, 0.1 mL) in MeOH (1.0 mL). The mixture was left to stir at room temperature 
for 60 min. Purification by CC (SiO2; CH2Cl2/MeOH, 92:8 to 87:13) afforded 30 as a 1:0.2 
mixture of the α- and β-anomer (36 mg, 12% over two steps). 1H NMR (400 MHz, CD3OD): 
δ=7.74 (s, 1H α-30, 1H β-30), 7.317.25 (m, 3H α-30; 2H β-30), 7.167.14 (m, 1H α-30; 
2H β-30), 4.82 (dd, J = 11.9, 1.4, 1H, α-30), 4.77 (d, J = 12.0, 1H, β-30), 4.61 (dd, J = 
11.9, 1.4, 1H, α-30), 4.51 (d, J = 12.0, 1H, β-30), 4.27 (dd, J = 7.4, 1.4, 1H, α-30), 4.09 
(dt, J = 5.1, 1.7, 1H, β-30), 4.06 (s, 1H, β-30), 3.86 (ddd, J = 11.4, 5.3, 1.4, 1H, α-30), 3.82 
(dd, J = 4.7, 1.4, 1H, β-30), 3.78 (s, 2H α-30; 2H β-30), 3.783.73 (m, 1H, β-30), 3.523.46 
(m, 1H, α-30), 3.35 (d, J = 1.4, 1H, α-30), 3.273.14 (m, 2H, α-30; 2H, β-30), 2.39 (s, 3H 
α-30; 3H β-30). HR-MS (ESI) calcd. For C18H24N3O5 [M+H]+: 362.1711, found: 362.1715.  
(2R,3R,4S,5R,6R)-2-((3-((4-Amino-2-methylpyrimidin-5-yl)methyl)benzyl)oxy)-6-
(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (31) 
a) GP1 starting from D-mannopyranose 1,2,3,4,6-
pentaacetate (1.66 g, 4.24 mmol), 14 (323 mg, 
1.41 mmol) and BF3.Et2O (0.87 mL, 7.1 mmol) in CH2Cl2 
(5.5 mL). The reaction mixture (suspension) was left to 
stir at room temperature for 16 h. Additional BF3.Et2O 
(0.44 mL, 3.5 mmol) was added and the suspension was 
left to stir for an additional 6 h. To remove the excess of 
D-mannopyranose 1,2,3,4,6-pentaacetate, the residue was taken up in CH2Cl2 and filtered. 
The filter was washed with CH2Cl2/MeOH (92:8), the filtrate concentrated in vacuo, and 
the resulting oil used in the next step without further purification.  
(b) GP2 starting from the crude product obtained in the previous step (100 mg) and NaOMe 
(2 M in MeOH, 0.1 mL) in MeOH (1.0 mL). The mixture was left to stir at room temperature 
for 1h. Purification by CC (SiO2; CH2Cl2/MeOH, 92:8 to 87:13) afforded 31 as a white solid 
(23 mg, 4% over two steps). 1H NMR (400 MHz, CD3OD): δ=7.73 (s, 1H), 7.30 (t, J = 7.1, 
1H), 7.26 (s, 1H), 7.24 (s, 1H), 7.15 (d, J = 7.1, 1H), 4.81 (s, 1H), 4.72 (d, J = 11.9, 1H), 
4.50 (d, J = 11.9, 1H), 3.81 (d, J = 1.7, 2H), 3.79 (s, 2H), 3.733.69 (m, 2H), 3.653.57 (m, 
2H), 2.40 (s, 3H). 13C NMR (101 MHz, CD3OD): δ = 166.5, 163.8, 154.7, 139.8, 139.4, 
130.0, 129.6, 129.3, 127.7, 115.4, 100.9, 75.1, 72.8, 72.3, 69.9, 68.8, 63.1, 34.4, 24.8. 
HR-MS (ESI) calcd. For C19H26N3O6 [M+H]+: 392.1816, found: 392.1818. IR (cm1): 3332, 
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Chapter 5 
TPPQuery-based design of potential 
inhibitors of DXS and their synthesis via 
multicomponent reactions 
 
In this chapter, we will describe the development and use of a web-based software called 
TPPQuery, which allows for pharmacophore-based searching of anchor-oriented virtual 
libraries and helps in identifying potential thiamine diphosphate (TDP)-competitive 
inhibitors that can be readily synthesized via multicomponent reactions. We will discuss 
the putative binding modes of a selection of scaffolds, their synthesis via the Zhu, Van 
Leusen and Groebke reactions and their biochemical activities against D. radiodurans and 
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5.1 Multicomponent reactions in medicinal chemistry 
Multicomponent reactions (MCRs) are defined as one-pot reactions involving at least three 
components, leading to the formation of one single product.1 MCRs are a convergent 
synthetic strategy and have several advantages over linear synthesis, including step 
efficiency and atom economy. Because of these advantages they are particularly suited to 
meet the needs of the pharmaceutical industry, which strives for cheap and efficient 
methods to prepare drugs at the industrial scale. MCRs are certainly also invaluable for 
early stage drug discovery since they enable rapid access to diverse scaffolds and 
subsequently derivatives for structure-activity relationships (SARs). Moreover, the fact that 
MCR products are often assembled starting from simple, cheap and commercially 
available starting materials renders them ideal synthetic protocols for the development of 
drugs for developing countries, where the cost-of-goods is a critical factor.2 
The possibility to explore a big fraction of the chemical space is another feature which is 
particularly appealing for medicinal chemists, given the increasing need for new chemical 
entities as potential drug candidates.3 Thanks to their high tolerance for a wide range of 
unprotected functional groups, the primary MCR product – bearing chemically reactive 
functionalities – can be often further transformed, for example by ring closing reactions 
(e.g., the second step in Scheme 1).4 By adopting this strategy, the initial scaffolds can be 
further diversified. This great advantage has been exploited also in combinatorial 
chemistry for the synthesis of libraries of new drug candidates, particularly employing 
isocyanide-based MCRs (IMCRs), where isocyanides offer the possibility to access more 
diversity and structural variation than other starting materials.5 
A lot of progress has been made in the field of MCRs since Strecker first prepared α-
aminonitriles through condensation of aldehydes with ammonia and hydrogen cyanide in 
1850, constituting the first report of a MCR in history.6 Several enantioselective and 
diastereoselective versions are now available for numerous MCRs.7 
Several commercial drugs have been prepared by MCRs, such as the anti-schistosomiasis 
drug praziquantel ((±)-1). Dӧmling and co-workers reported a two-step synthesis of 
racemic 1 involving an Ugi reaction of compounds 25 followed by a Pictet–Spengler 
cyclization of 6, giving 1 in an overall 75% yield (Scheme 1).4 This synthetic route is much 
more efficient than the industrial route, which involves a five-step synthesis.8,9 All 
components of this route are inexpensive or can be prepared in a cost-efficient way, which 
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is particularly important given that schistosomiasis (also known as bilharzia) is a neglected 
tropical disease that affects mainly the population of sub-Saharan Africa. 
 
Scheme 1. Synthesis of praziquantel (1) reported by Dӧmling et al.4 
 
5.2 AnchorQuery and TPPQuery 
To combine the advantages of pharmacophore-based virtual screening (VS) with the 
possibility to synthesize the obtained hits by convenient MCR protocols, Camacho and co-
workers developed AnchorQuery, a user-friendly, open-access technology allowing for 
rapid identification of scaffolds with potential biological activity.10 
The technology was first developed to support the discovery of molecules targeting 
protein–protein interactions (PPIs). In fact, due to the high complexity of these systems 
(e.g., they involve very large contact surfaces and they are typically flat), it is very 
challenging to rationally design de novo inhibitors of PPIs and high-throughput screening 
(HTS) approaches are also not suitable, being often based on rigid frameworks which are 
not suitable for the diverse chemotypes present in PPIs.11 Although structure-based VS of 
tailor-made chemical libraries helps to increase the hit rates to 20% or more, the 
optimization of the hits targeting PPIs still constitutes the bottleneck of this approach (and, 
in general, of all virtual screening approaches), given that it can require several synthetic 
steps. Using a combinatorial chemistry approach, AnchorQuery is able to screen in a few 
seconds thousands of virtual compounds, all of them readily accessible by MCRs, thus 
combining the advantages of ligand-based virtual screening (the similarity with the natural 
binder of the target is, in fact, taken into account during the screening), docking (every hit 
is docked automatically into the pocket) and pharmacophore-based searches (screening 
the docked hits for the defined pharmacophore features). The technology is based on the 
concept of anchor residues, which are deeply buried hot spots of the PPIs involved in the 
molecular-recognition process.12 Based on this concept, biased libraries including millions 
of compounds, which contain specific mimics of amino acid residues (e.g., Trp-biased 
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libraries contain an indole scaffold, which can mimic the tryptophan residue of the protein) 
have been created and implemented in the software. A pharmacophore-based search of 
these anchor-oriented virtual libraries (possessing explicit conformations) using 
AnchorQuery provides a series of hits, which can be easily synthesized by MCRs and 
tested for their biochemical activity. Camacho and co-workers have shown how this 
technology can be successfully applied, obtaining a broad set of novel potent inhibitors of 
the MDM2–p53 PPI.10 
Recently, the groups of Camacho and Dӧmling, have developed the web-based software 
TPPQuery (http://tppquery.csb.pitt.edu/). By analogy to AnchorQuery, TPPQuery is based 
on a pharmacophore-based search technology and it can generate thousands of mimics 
of thiamine and thiamine diphosphate (TDP, 7), which can be synthesized by MCRs. A lot 
of human and bacterial TDP-dependent enzymes exist, which all catalyze the cleavage 
and formation of bonds adjacent to the carbon of a carbonyl group. Some examples 
include transketolase (TK), α-keto acid decarboxylases (e.g., pyruvate decarboxylase) and 
dehydrogenases (e.g., the E1p subunit of the pyruvate dehydrogenase multienzyme 
complex). Given that they play key roles in many metabolic pathways, they are therefore 
interesting targets for pharmaceutical and agrochemical industries. 13 For instance, TK 
plays an essential role in the pentose phosphate pathway and it has been shown that 
inhibition of its activity can be exploited for the development of anticancer drugs.14 This 
fact, together with the availability of several hundred crystal structures of enzymes in 
complex with TDP deposited in the RCSB Protein Data Bank,15 have encouraged the 
groups of Camacho and Dӧmling to develop TPPQuery. 
As discussed in the introduction of this thesis, TDP-binding pockets are highly conserved, 
also among humans and bacteria. This fact leads to selectivity issues, when targeting 
bacterial TDP-dependent enzymes. Nevertheless, these pockets offer a balanced 
ensemble of pharmacophore points to address (highly hydrophobic regions, hydrogen-
bond donor and -acceptor residues and charged areas of the pocket), which can ensure 
sufficient binding energy for inhibition, while selectivity can be gained from growing the 
TDP mimic toward other pockets lying in close proximity, such as the substrate-binding 
pocket. Due to the particularly high degree of sequence (and structural) identity in the 
aminopyrimidine sub-pocket of the TDP-binding pocket (as discussed in Chapter 4 of this 
thesis) and the fact that the aminopyrimidine ring of TDP is engaged in a nice set of 
balanced hydrophobic and hydrophilic interactions, the anchor was defined as shown in 
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Scheme 2, where few examples of commercially available or easily accessible starting 
materials corresponding to the anchor moiety are also depicted. 
 
Scheme 2. Definition of the anchor for TPPQuery and few examples of commercially 
available or easy-to-synthesize anchors. 
 
The aminopyrimidine scaffold of 7 has been defined as an anchor in the TPPQuery, 
meaning that the software will keep this part of the molecule constant in terms of 
pharmacophore features. Therefore, all the results from the query will bear an aromatic 
moiety capable of interacting ideally with the residue Phe 398 of D. radiodurans DXS via 
π-π interactions and will target residues Glu373, Ala125 and Gly123 via hydrogen bonds 
(see Figure 1, Chapter 2). 
Prior to using the software, we had to equip TPPQuery with a library of building blocks 
correlated to the anchor part of 7, keeping in mind all possible MCRs in which the anchor 
could take part and consequently look for anchors with the corresponding functional 
groups. A detailed search allowed us to select a large number of commercially available 
building blocks. Scaffolds that one can synthesize in maximum a two-step synthesis were 
also included in the database. 
 
5.3 Workflow in TPPQuery 
Having uploaded the crystal structure of our target protein (PDB code: 2O1X)16 and 7, we 
edited the pharmacophore features. Beside the pharmacophore features of the anchor, 
which are already fixed, one can choose whether to request or enable several other 
features, which are listed in the graphical user interface and will be highlighted on the 
scaffold of TDP once the user has selected them. Upon submission of the query, the 
software ranks the results according to several criteria, such as the MCR by which that 
molecule can be synthesized and the pharmacophore matches. A last necessary step 
includes the energy minimization of the hits obtained in a proper software (e.g., MOLOC) 
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to evaluate intermolecular clashes with the protein. In fact, TPPQuery docks every single 
building block leading to the final MCR scaffold, but does not take care of docking the final 
hit.  
 
5.4 TPPQuery with Deinococcus radiodurans DXS 
We have performed several queries using the co-crystal structure of 7 in complex with 
D. radiodurans DXS, both selecting few pharmacophore features so as to get a feel for 
suitable smaller moieties (fragments) able to occupy a certain subpocket as well as using 
many pharmacophore features so as to force the software to create a TDP-mimic targeting 
all subpockets of the TDP-binding pocket (the aminopyrimidine-binding pocket, where the 
anchor lies, the thiazolium pocket and the diphosphate pocket). Interestingly, several hits 
contained substituted aromatic rings in the thiazolium-binding pocket, bearing vectors 
pointing toward the substrate-binding pocket. All the results obtained have been grouped 
according to the corresponding MCR by which they could be synthesized. From this 
detailed analysis, it was immediately obvious that three MCRs lead to suitable TDP-
mimics: the Zhu, the Van Leusen and the Groebke reactions. Having selected the most 
interesting hits from each group, we performed their energy minimization using the 
software MOLOC17 and analyzed the contribution of each moiety of the TDP-mimic 
scaffold in terms of polar and apolar interactions, as well as their conformation. In this way, 
we were able to rationally design/optimize several hits for each class of MCR, taking the 
output obtained from TPPQuery as a starting point. In the following sections, we will 
discuss the modeled binding modes for each class of molecules together with their 
synthesis and biochemical evaluation against D. radiodurans and M. tuberculosis DXS. 
 
5.5 Scaffold 1: Zhu reaction 
The Zhu reaction consists of the condensation of a carbonyl compound with an amine to 
afford an imine, which then reacts with an α-amido isonitrile.18,19 Subsequent 
intramolecular cyclization leads to the formation of substituted 5-amino oxazoles (Scheme 
3). The fact that oxazoles are present in a number of bioactive marine natural products20 
and that they are used as conformationally restricted peptidomimetics,21 renders this 
reaction particularly interesting. 
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Scheme 3.  A Zhu multicomponent reaction. 
The reaction is usually performed in toluene or MeOH and is promoted by using weak 
Brønsted acids like NH4Cl, pyridine.HCl or Et3.HCl. The fact that the starting materials can 
be used in approximately equimolar amounts, significantly simplifies the work-up. Although 
one chiral center is generated in the condensation process, very little attention has been 
paid to the stereoselectivity of this Ugi-type condensation. 22, 23 Despite its great potential, 
the Zhu reaction still suffers from many limitations and specific optimization of the reaction 
conditions is in most of the cases crucial for optimal performance. On the one hand, either 
aldehydes or ketones can be used as the carbonyl component, although aldehydes are 
usually preferred. On the other hand, primary amines usually give lower yields than 
secondary amines due to the higher reactivity of the iminium ion. Most of the problems and 
limitations arise from the isocyanide building block, which will be briefly discussed in the 
following section. 
 
5.5.1 Problems and limitations associated with the isocyanide building block in the 
Zhu reaction 
First of all, the nucleophilicities of the isonitrile (isocyanide) carbon and of the α-methylene 
carbon atoms need to be carefully counterbalanced in order to direct the Zhu reaction 
toward the formation of the 5-amino oxazole. To this end, Zhu and co-workers introduced 
the use of α-isocyanoacetamides instead of α-isocyanoacetates (Figure 1). The fact that 
the pKa of the α-CH of an amide is 24 units higher than that of an ester, together with the 
fact that the amide oxygen atom has stronger Lewis basic character – kinetically favoring 
the ring-formation process – proved to be sufficient driving forces toward the desired 
product. In fact, under the conditions optimized by Zhu, no formation of 2-imidazolines – 
typically obtained as the main product when using isocyano esters – is usually observed.24  
Nevertheless, more recently, Zhu and co-workers reported the formation of oxazoles also 
by using an isocyano ester with a strongly electron-withdrawing group at the α position.25 
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Figure 1. Specific features of the isocyanide partner toward a selective synthesis of 5-
amino oxazoles according to the Zhu reaction. 
 
For the derivatization of the α-isocyanoacetamide nitrogen atom, morpholine is typically 
used. Few other examples include different dialkylamino substituents, 26,27 but no 
examples have been reported with mono-substituted amides and no explanation for this 
lack of data is available in the literature. One possible reason could be connected to the 
instability of the resulting 5-aminooxazole bearing a secondary amino functionality. As 
shown in Scheme 4a, secondary α-isocyanoacetamides could participate in the reaction 
when a quaternary carbon atom is present on the same substrate.28 
D-Unsubstituted isocyanoacetamides have rarely been investigated because of their 
inherent instability and the side reactions caused by the competing nucleophilic methylene 
carbon leading to more complexity, namely the double addition product depicted in Figure 
1. Few successful examples have been reported. Nevertheless, in these cases, the 
reaction conditions had to be thoroughly optimized in order to obtain the desired product.23 
Moreover, also in these successful cases, the formation of the product coming from a 
tautomerization-cyclization of the isocyanide could not be entirely suppressed and 
additional isocyanide had to be supplemented to obtain high yields. More recently, Zhu 
and co-workers reported the formation of 2-keto-5-aminooxazoles via a slightly different 
protocol, utilizing acyl chlorides instead of imines (or iminium ions) (Scheme 4b).29 
Remarkably, secondary α-isocyanoacetamides were found to be as reactive as tertiary 
ones, presumably because of the stabilizing effect of the electron-withdrawing acyl group 
at the 2 position of the ring. Notably, in many of the reported examples, the α-position of 
the isocyanide is unsubstituted.  
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Scheme 4. (a) Successful reaction of secondary α-isocyanoacetamides bearing a 
quaternary α-carbon atom; (b) Formation of 2-keto-5-aminooxazoles employing acyl 
chlorides. 
 
5.5.2 Selection of the Zhu scaffold 
Initially, we modeled and attempted the synthesis of Zhu scaffolds bearing secondary 
amides and unsubstituted isocyanoacetamides, which precluded product formation and 
led to recovery of the starting materials. These results will not be discussed in detail in this 
thesis. To overcome the synthetic issues discussed in Section 5.5.1, we modeled 
compound (SS)-8 (Figure 2a), with the newly formed chiral center in the S-configuration. 
As shown in Figure 2b, the aminopyrimidine ring of (SS)-8 is perfectly superimposed with 
that of 7 and the network of pharmacophore features is preserved. A vector pointing toward 
the putative substrate-binding pocket allows (SS)-8 to interact with few residues 
presumably involved in catalysis or in the substrate-recognition process. The hydroxyl 
group is engaged in a hydrogen bond with the side chain of His434 (d(His 434-N)…..HO = 
3.43 Å) and the phenyl ring has hydrophobic contacts with Tyr395. Given that this part of 
the protein is believed to be rather flexible and to close upon substrate-binding, other 
residues might eventually be involved in binding (SS)-8 (e.g., Arg480, Arg423, His51, 
His304). Nevertheless, these interactions are not predictable. The CH2CH-linker is also 
involved in few hydrophobic contacts with Phe398, Tyr395, and Ile187. The oxazole and 
morpholine rings of (SS)-8 overlap with the thiazolium ring and the ethylene linker of 7 and 
are involved in the same hydrophilic contacts as 7. In particular, the methyl substituent on 
the oxazole ring, is favorably interacting with His82 via a CH–π interaction and has 
hydrophobic contacts with His51 and His304. When replacing the morpholine scaffold by 
a piperidine moiety, one would have the proper vector to further grow (SS)-8 toward the 





 Chapter 5 






Figure 2. (a) Structure of the modeled Zhu scaffold. The configuration of the newly 
formed stereocenter, upon Van Leusen reaction, is not defined. (b) Modeled pose of 
(SS)-8 within Deinococcus radiodurans DXS (PDB: 2O1X). Color code: protein skeleton: 
C: gray; O: red; N: blue; S: yellow. (SS)-8 skeleton: C: yellow. Hydrogen bonds below 
3.5 Å are shown as dashed lines. The units for the distances indicated and the color 
code are maintained throughout, if not otherwise stated. All the figures of this chapter 
refer to compounds modeled within D. radiodurans DXS (PDB: 2O1X) unless otherwise 
stated and they were all generated using the software PyMOL.30 
 
According to the modeling studies, the other diasteroisomer of 8 having the newly formed 
stereocenter in the R-configuration, would not fit in the pocket. To obtain a first indication 
of the inhibitory activity of this scaffold, we decided to attempt the synthesis of 8 and test 
it as a racemate in the first place. 
 
5.5.3 Retrosynthesis of 8 
The starting materials for the synthesis of 8 are shown in Scheme 5. α-Isocyanoacetamide 
9 is a tertiary amide and bears a methyl group at the α-position so as to reduce the side 
reactions discussed in Chapter 5.5.1. To decrease the risk of side reactions caused by the 
nucleophilic character of the hydroxyl group of 10, we decided to protect it with a tert-
butyldimethylsilyl (TBDMS) group. Ideally, the same strategy would be used for the free 
amino group of 11, which we planned to protect with a tert-butyloxycarbonyl (BOC) group. 
Final deprotection of the Zhu product, would afford the potential inhibitor 8. 
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Scheme 5. Retrosynthetic scheme for the synthesis of 8. 
 
5.5.4 Synthesis of the starting materials for the Zhu reaction 
We carried out the synthesis of 9 starting from commercially available 12, which was first 
amidated with morpholine and subsequently α-methylated with MeI, using CsOH as a base 
to promote the reaction.31, 32 The relatively low yield of the second step (lit. 80%) can be 
ascribed to the formation of a side product in 30% yield, presumably the tautomerization-
cyclization product of 13, compound 14 (Scheme 6a). 
 
Scheme 6. Synthesis of 9 (Scheme 6a) and 10 (Scheme 6b), starting materials for the 
Zhu reaction. 
 
We carried out the protection of the hydroxyl group of 15 with a TBDMS-protecting group 
by a standard literature procedure and obtained 10 in 57% yield (Scheme 6b).33 
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For the synthesis of 11, we first performed a four-component MCR consisting of the 
sequential addition of N, N-dimethyl formamide and dimethyl sulfate (forming the adduct 
16 in situ), malonitrile (17), and acetamidine, which must be liberated from its HCl salt prior 
to addition to the reaction mixture (Scheme 7). Nitrile 18 was isolated as a white solid 
simply by filtering the reaction mixture.34 The low yield of 38% (lit. 71%) is due to the 
formation of an unknown side product. This fact might indicate that a very careful control 
of the temperature is necessary to obtain 18 in high yield. To convert 18 into aldehyde 19, 
we first attempted a hydrogenation using Pd/C and conc. H2SO4. On the one hand, the 
reaction resulted in only 50% conversion of the starting material after three hours. On the 
other hand, after 16 hours we observed full conversion but no product formation. 
Hydrogenation using a Raney-Nickel catalyst in formic acid resulted in the formation of 19 
in 64% yield (Scheme 7). All attempts to Boc-protect 19 to afford 20, summarized in 
Scheme 3, failed, leading to the (partial) formation of an unknown product. Therefore, we 
decided to attempt the protection of the amino group of 18 and convert the cyano group 
into the desired aldehyde at a later stage. We tried many reactions conditions (e.g., DMAP 
0.1 eq., Boc2O 1.2 eq., THF or DMAP 0.1 eq., Boc2O 1.0 eq., Et3N 1.1 eq., CH2Cl2) but in 
every case we observed both the mono- and the di-Boc-protected product, even when 
working with stoichiometric amounts of Boc2O. By using a large excess of Boc2O for 
prolonged time, we managed to obtain 21 in 84% yield.  
 
Scheme 7. Attempted synthesis of 20 and 22. 
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Unfortunately, when treating 21 with DIBAL-H to obtain the aldehyde 22, a complex crude 
mixture was observed, presumably containing partially deprotected starting material and 
product.. We therefore decided to synthesize a simplified version of the anchor part of 8, 
and we performed a mono-Boc protection of commercially available 23, obtaining 24 in 
75% yield (Scheme 8).35  
 
5.5.5 Screening of conditions for the Zhu reaction 
With all the starting materials in hand, we started to screen conditions for the Zhu reaction 
to obtain product 25. Table 1 constitutes a selection of the conditions we have tried. We 
started from screening the best conditions reported by Zhu and co-workers,19 consisting 
of performing the reaction in MeOH with NH4Cl as acid catalyst. No product formation was 
detected after 16 hours at room temperature, both using 1.5 eq. and 3.0 eq. NH4Cl. Only 
the imine formed by reaction of 24 and 10 could be recovered (Table 1, entry 1 and 2). 
Increasing the temperature, did not lead to product formation and promoted the formation 
of significant amounts of a product coming from the tautomerization-cyclization of 9 (Table 
1, entry 3). We decided to screen other catalysts mentioned in the work of Zhu, such as 
Et3N.HCl, camphor sulfonic acid and Yb(CF3SO3)3 but in any of these cases we observed 
product formation (Table 1, entries 46). The main limiting factor for this reaction seems 
to be the lack of reactivity of 9, which, moreover, readily tautomerizes and cyclizes when 
increasing the reaction time and temperature. 
 
Scheme 8. Scheme of the Zhu reaction. 
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Table 1. Screening of several conditions for the Zhu reaction. 





1 24 NH4Cl  
(1.5 eq.) 
16 h / r. t. Imine 
     
2 24 NH4Cl  
(3.0 eq.) 
16 h / r. t. Imine 
     
3 24 NH4Cl  
(3.0 eq.) 
48 h / 60 oC Imine, cyclization 
isocyanide 
     
4 24 Et3N.HCl 
(3.0 eq.) 
16 h / r. t. 
16 h / 60 oC 
Imine, cyclization 
isocyanide 
     
     
5 24 camphor 
sulfonic acid 
(0.1 or 3.0 eq.) 
8 h / r. t. Imine / Decomposition 
of most SMs 
     
6 24 Yb(CF3SO3)3 
(3.0 eq.) 
6 h / r. t. Decomposition of 
most SMs 
     
7 26 - 16 h / r. t. 
16 h / 60 oC 
Imine, cyclization 
isocyanide 
     
8 26 NH4Cl  
(3.0 eq.) 
10 h / r. t. 
10 h / 60 oC 
Imine, decomposition 
of isocyanide 
     
9 27 - 16 h / r. t. 
24 h / 60 oC 
Imine, cyclization 
isocyanide 
     
10 27 NH4Cl  
(3.0 eq.) 
24 h / 60 oC Imine, cyclization 
isocyanide 
 
To simplify building block 24 even further, we decided to use 26 and 27 as the aldehyde 
components, but also in these cases (Table 1, entries 710) no product formation was 
observed. 
The fact that only two examples of aromatic aldehydes have been reported in the literature 
for this reaction (benzaldehyde and 4-methoxy benzaldehyde) and no heteroaromatic 
aldehydes have ever been used,19 suggests that the scope of this MCR might be very 
limited. Therefore, we decided to abandon the synthesis of this scaffold. 
 
5.6 Scaffold 2: Van Leusen reaction 
The Van Leusen synthesis is a three-component reaction involving the cycloaddition of 
tosylmethyl isocyanides (TosMICs) to imines, which can be formed in situ from the 
corresponding amines and aldehydes (Scheme 9).36 The reaction leads to the formation 
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of trisubstituted imidazoles, which are important moieties present in numerous natural 
products and biologically active compounds37 and is usually carried out under mild 
conditions, allowing for an extensive functional group tolerance, especially when TosMICs 
bearing aromatic substituents at the α position are used. Typical experimental conditions 
involve for example the use of DMF as a solvent and K2CO3 as a mild base to promote the 
cycloaddition. Other typical solvents for this reaction are MeOH (also as a mixture with 
dimethoxyethane (DME)), EtOAc, THF, ACN, or DCM and a wide variety of bases (e.g., 
piperazine, morpholine, NaH, tBuOK) can be exploited to optimize the reaction conditions 
(solubility, ease of product isolation) and therefore the yields. 38,39 When TosMICS bearing 
an aliphatic substituent at the α position or α-unsubstituted TosMICs are used, a stronger 
base such as tBuOK is usually needed.36 
 
Scheme 9. The Van Leusen reaction. 
 
The scaffolds that we selected based on the results of our TPPQuery search, are depicted 
in Figure 3a (compounds 2830) while in Figure 3b we report the predicted binding mode 
of 28 after energy minimization in MOLOC. As one can see, the anchor part of 28 is 
perfectly overlapping with the aminopyrimidine moiety of 7 and the network of interactions 
defined in the pharmacophore search is preserved (Scheme 2). The imidazole ring is 
slightly displaced with respect to the thiazolium ring of 7, but the hydrophobic contacts with 
Ile187, Ile371 and Val80 are preserved. The methyl substituent – coming from the 
aldehyde – allows for a more extended hydrophobic contact with the same residues. 
Moreover, one of the nitrogen atoms of the imidazole ring is engaged in a favorable 
hydrogen bond with the side chain of Ser186 (d(Ser186-HO)…N = 3.19 Å). So as to occupy 
the diphosphate-binding pocket of 7, we chose a dihydroxyl-substituted phenyl ring, which 
provides a good balance of polar and apolar contacts. In fact, on one hand, the two 
hydroxyl groups are engaged in two hydrogen bonds with the side chain of His304 
(d(His304-N)…HO = 3.19 Å) and the backbone of Met185 (d(Met185-C=O…HO = 3.02 Å). 
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Figure 3. (a) Van Leusen scaffolds identified using TPPQuery and further rationally 
optimized with MOLOC. (b) Modeled binding mode of 28. 
 
On the other hand, the phenyl ring is involved in an amide-π stacking interaction with the 
peptidic bond connecting Ser186 and Ile187 and in additional hydrophobic contacts with 
Ile187, His82, Gly155 and Ile371. 
To explore what we have defined as the “histidine-rich pocket” in Chapter 2, we modeled 
compounds 29 and 30. The ethyl and thiophenyl substituents in 29 and 30, respectively, 
are supposed to increase the hydrophobic contacts of these scaffolds with the protein. In 
particular, the sulfur atom of the thiophenyl substituent in 30 is proposed to be involved in 
a sulfur–π interaction with His82. 
                
5.6.1 Retrosynthesis of 2830 
The retrosynthetic scheme for the synthesis of compounds 2830 is shown in Scheme 10. 
All aldehydes we used (3133) are commercially available. To avoid possible side 
reactions, we decided to work with benzyl-protected hydroxyl groups on the TosMic 34, 
which can be removed in the very last step (deprotection of 3537) after performing the 
Van Leusen imidazole synthesis. We decided to attempt the Van Leusen reaction keeping 
the aminopyrimidine group of 38 unprotected. Based on the very weak nucleophilicity of 
this group, we were confident that it would not compete with the primary amino group 
during imine formation. 
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Scheme 10. Retrosynthetic scheme for the synthesis of 2830. 
 
5.6.2 Synthesis of the starting materials for the Van Leusen reaction 
We carried out the synthesis of 38 and 34 as shown in Scheme 11. We obtained 38 via a 
Raney-Nickel reduction of 18 (Scheme 11a), the latter prepared as discussed in Scheme 
7 of Section 5.5.4.34 
 
Scheme 11. Synthesis of 38 (Scheme 11a) and 34 (Scheme 11b) as starting materials of 
the Van Leusen reaction. 
 
We performed the synthesis of 34 via a three-step sequence adapted from a literature 
procedure.40 p-Toluenesulfinic acid (39), obtained from the corresponding sodium salt 
(40), was reacted with the commercially available aldehyde 41 to yield formamide 42, 
which was then subjected to dehydration with POCl3 to afford TosMIC 34 in 80% yield 
(over two steps). While most synthetic procedures report the synthesis of TosMICs at 
temperatures below 0 °C, in this case it was necessary to increase the temperature to 
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5.6.3 Screening of conditions for the Van Leusen reaction 
The Van Leusen imidazole synthesis (Scheme 12) was first performed under classical 
conditions, using DMF as a solvent and K2CO3 as a base (Table 2, entry 1). These 
conditions led to formation of the desired product 35 only in 20% yield, probably due to 
incomplete formation of the imine.  
 
Scheme 12. Scheme of the Van Leusen reaction. 
In fact, no traces of imine were observed in the crude reaction mixture, meaning that 34 – 
completely soluble in DMF – reacted completely with the imine. Addition of drying agents 
such as MgSO4 or 4-Å molecular sieves, did not improve the conversion toward the imine. 
On the other hand, when performing the same reaction in MeOH as the solvent (Table 2, 
entry 2), full conversion to the imine was observed, but after addition of 34 and K2CO3, no 
product formation was observed during the reaction time, probably due to the very low 
solubility of 34 in this solvent. To overcome this problem, we decided to pre-form the imine 
in MeOH, evaporate the solvent upon complete imine formation and then add DMF, 34, 
and K2CO3 in a second stage (Table 2, entry 3). Surprisingly, we did not observe any 
product formation after stirring the reaction mixture for 24 hours at room temperature 
followed by 24 hours at 60 °C. The same strategy was applied when trying to perform the 
reaction in the presence of 2.5 equivalents of a stronger base such as NaH (Table 2, entry 
4), but also in this case we did not observe any product formation. Performing the reaction 
in MeOH using organic bases such as morpholine or piperazine (Table 2, entry 5 and 6), 
also did not lead to any product formation. Performing the reaction with propionaldehyde 
(32) led to the formation of two inseparable products, presumably the expected product 36 
and compound 43i (Figure 4, 2: 1 ratio according to 1H-NMR), in which the pyrimidine-NH2 
also reacted with 32. When performing the reaction with 3-thiophenecarboxaldehyde (33) 
(Table 2, entry 8), complete imine formation was observed, and the product 37 was 
obtained in 37% yield.  
                                                          
i According to UPLC-TQD analysis of the mixture of the inseparable products 
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Table 2. Screening of conditions for the Van Leusen reaction of 38, 3133 and 34 
 





1 31 K2CO3 
(1.0 eq.) 
DMF 16 h/r.t. 35 (20%) 
      
2 31 K2CO3 
(1.0 eq.) 
MeOH 16 h/r.t. - 
      





24 h/r. t. + 
24 h/40 °C 
- 
      





24 h/r. t. + 
6 h/40 °C 
- 
      
5 31 Morpholine 
(1.0 eq.) 
MeOH 24 h/r. t. + 
6 h/40 °C 
- 
      
6 31 Piperazine 
(1.0 eq.) 
MeOH 24 h/r. t. + 
6 h/40 °C 
- 
      
7 32 K2CO3 
(2.0 eq.) 
DMF 24 h/r. t. 36+43 (2:1) 
(35% 
conversion) 
      
8 33 K2CO3 
(1.0 eq.) 
DMF 16 h/r. t. 37 (37%) 
      
9[2] 33 K2CO3 
(1.0 eq.) 
DMF 24 h/r.t. + 
6 h/40 °C 
37 (30%) 
[1] All reactions were carried out with 1.2 eq. of 38, 1.3 eq. of 3133 and 1.0 eq. of 
34. 




Figure 4. By-products observed when performing the Van Leusen reaction with aldehydes 
32 and 33. 
 
We also observed the formation of a side-product, which could correspond (by 1H-NMR 
analysis) to the product of the Knoevenagel condensation of 34 and unreacted 33 
(compound 44, Figure 4). Therefore, we performed the same reaction using an inverted 
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ratio of 33 and 38 but this did not lead to an improvement of the yield (Table 2, entry 9). 
Finally, hydrogenolysis of 3537 should afford the final compounds 2830 (Scheme 13). 
Whereas the reactions with 35 proceeded smoothly, yielding 28 quantitatively, several 
reaction conditions involving the use of Pd/C resulted to be unsuccessful for the 
debenzylation of 37 (Table 3, entries 36). It has been reported for similar substrates that 
standard debenzylation conditions with Pd/C might not work due to the presence of the 
sulfur atom.41 Therefore we attempted the synthesis of 30 by treatment of 37 with BF3.Et2O 
and EtSH in CH2Cl2. In these conditions, the reaction works but does not go to completion 
and purification of the product is not trivial due to its decomposition on silica gel. 
 
Scheme 13. Final debenzylation step. 
 
Table 3. Screening of conditions for the hydrogenolysis of 35 and 37 
Conditions A 






1 35 MeOH/H2O (9:1) 1 16 h/r.t. 28 (quant.) 
      
2 37 MeOH/H2O (9:1) 1 72 h/r.t. - 
      
3 37 MeOH 1 16 h/r.t. - 
      
4 37 MeOH 20 24 h/r.t. + 
24 h/55 °C 
- 
      
5 37 EtOAc 20 24 h/r.t. + 
24 h/55 °C 
- 
 
To confirm whether potential oxidation of the catechol system of 28 (especially when 
stored for a long time in a DMSO solution) to the corresponding benzoquinone system is 
indeed occurring, we acquired 13C-NMR spectra of 28 in d6-DMSO at different time 
intervals up until 18 days after sample preparation. We found 28 to be stable in its catechol 
form and we tested it for its biochemical activity against D. radiodurans and M. tuberculosis 
DXS. While we detected only weak inhibition against D. radiodurans DXS (IC50 = 1904 ± 
233 μM), 28 gave double-digit micromolar inhibitory potency against M. tuberculosis DXS 
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(IC50 = 29 ± 12 μM). This value has yet to be confirmed due to the presence of positive 
absorbance dynamics for the data point at the highest inhibitor concentration. 
To rationalize the weak inhibitory potency observed against D. radiodurans DXS, we 
compared the torsional angle of the biaryl system in our modeled pose (τ(Nimidazole–C–C–
Cphenyl) = 131°) with that of similar scaffolds in the CSD database. 42 We did this by using 
the software Conquest,43 but our search did not lead to conclusive results, given the small 
number of similar hits found. Nevertheless, for analogous structures bearing a substituent 
at the R1 position of the imidazole moiety, we observed a rotation of up to 50° with respect 
to the expected planarity of the unsubstituted biaryl scaffold. This fact might suggest that 
partial rotation of this kind of scaffold is not unfavorable and that the weak inhibitory 
potency of 28 against D. radiodurans DXS might be the consequence of other factors. It 
might be that a substituted six-membered aromatic ring is not the most suitable moiety to 
fill the diphosphate subpocket of DXS, although no strong clashes were observed in the 
modeled pose of 28 and D. radiodurans DXS. Nevertheless, to understand whether the 
low inhibitory potency arises from steric clashes between the protein and the six-
membered aromatic ring in the diphosphate-binding pocket, one could synthesize and test 
a close analogue of 28 bearing a heteroaromatic five-membered ring, ideally substituted 
with polar groups (e.g., -OH, -COOH) to render the system more polar. 
On the way to rationalizing the remarkably different biochemical activity of 28 against the 
two DXS orthologues, we docked 28 both into the crystal structure of D. radiodurans DXS 
and into the homology model of M. tuberculosis DXS that we built, as discussed in Chapter 
4. We performed the docking with the software LeadIT44 defining the receptor such that it 
includes the TDP-binding pocket of DXS and found that most of the docked poses are in 
this pocket in both cases. Nevertheless, the top-ranked pose of 28 docked into 
D. radiodurans DXS has a calculated 'Gbind according to HYDE45 of 30.1 kJ/mol, whereas 
the top-ranked pose of 28 docked into the homology model of M. tuberculosis DXS has a 
calculated 'Gbind of 18.9 kJ/mol. Moreover, while the top-ranked pose in D. radiodurans 
DXS resembles the modeled pose very closely and overlaps with TDP rather well, the top-
ranked pose in M. tuberculosis DXS has a completely different binding mode. This could 
also suggest that 28 binds in a yet undiscovered pocket within M. tuberculosis DXS, which 
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5.7 Scaffold 3: the Groebke reaction 
The Groebke reaction consists of the reaction of aromatic heterocyclic 2-aminoazines with 
aldehydes and isocyanides in the presence of a variety of Lewis or Brønsted acids, yielding 
fused 3-aminoimidazoles (Scheme 14).46 The formation of the bicycle occurs through an 
iminium intermediate, in a similar manner as the four-component Ugi reaction. In contrast 
to the classical Ugi reaction, the protonated Schiff base, containing both nucleophilic and 
electrophilic centers, undergoes a [4+1] cycloaddition with the isocyanide to yield the 
aromatic bicyclic system after rearomatization via a 1,3-hydrogen shift. Imidazopyridines, 
imidazopyrazines and imidazopyrimidines, have received a great deal of attention in drug 
discovery across a broad range of therapeutic areas.47, 48 
 
Scheme 14. The Groebke reaction. 
MeOH is usually the solvent of choice and the ideal concentration of the 2-aminoazine 
component is 0.30.5 M, while the aldehyde and the isocyanide components are usually 
employed in slight excess. In most cases, reactions are fast at room temperature and are 
not sensitive to oxygen or moisture, which renders them ideal for the efficient synthesis of 
libraries of compounds even in 96-well plates.49 
The two scaffolds we selected and further optimized, based on the TPPQuery output, are 
depicted in Figure 5a (compounds 45 and 46). The modeled binding mode of 45 is depicted 
in Figure 5b. The aminopyrimidine anchor part of 45 is slightly rotated with respect to the 
one of 7, but the π–π interaction with Phe398 and the other pharmacophore features are 
preserved. The overall Groebke scaffold is rather different with respect to the Zhu and the 
Van Leusen scaffolds, where the thiazolium ring of 7 was simply replaced by another 
heteroaromatic five-member ring. In this case, a benzimidazole ring points directly toward 
the substrate-binding pocket, and it is positioned in the “histidine-rich pocket”, where it is 
involved in many hydrophobic contacts with the side chains of Phe398, His434, Phe109, 
His51, His304 and Ile187, according to our modeling studies. The aldehyde partner 
provides an aromatic ring, which partially occupies the thiazolium-binding pocket, being 
involved in the same hydrophobic contacts as 7. Moreover, the para-position of the phenyl 
ring can function as a vector that points toward the diphosphate-binding pocket, where the 
sulfonamide moiety perfectly overlaps with the first phosphate group of 7 and is engaged 
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in two hydrogen bonds with the backbone of the protein, specifically with the backbone 
nitrogen atoms of Gly155 (d(Gly155)NH…O=S = 2.81 Å) and Ser156 (d(Ser156)NH…O=S 
= 3.05 Å). The methyl substituent on the sulfonamide is also involved in hydrophobic 







     (b) 
 
Figure 5. (a) Structures of the modeled Groebke scaffolds 45 and 46. (b) Modeled pose 
of 45. Color code: 45 skeleton: C: green. 
 
5.7.1 Retrosynthetic scheme of 45 and 46 
The synthesis of 45 (and 46) can be carried out starting from isocyanide 47, the 
commercially available amine 48 and aldehydes 49 and 50. Ideally, we would like to protect 
the free amino group of 47 to avoid any possible side reactions of this group (Scheme 15). 
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5.7.2 Synthesis of the starting materials for the Groebke reaction 
For the synthesis of 49, we first protected the commercially available alcohol 51 with a 
trimethylsilyl (TMS) group, obtaining 52 in 89% yield. To introduce the 
methanesulfonamide group, we attempted the treatment of 52 with KOH and 
methanesulfonamide, but we did not obtain the desired product 53. By treating 52 with 
Cs2CO3 as base and [Cu(OH)TMEDA]2Cl2 as a catalyst,50 we obtained 53 in 65% yield. 
[Cu(OH)TMEDA]2Cl2 is believed to promote a four-centered transition state, which favors 
benzylation of amides even with benzyl chlorides using very mild conditions. Performing a 
Swern oxidation of 53, led to the aldehyde 49 in 20% yield (Scheme 16a). 
Scheme 16. Synthesis of the aldehyde building blocks for the Groebke reaction. 
For the synthesis of aldehyde 50, we first protected the hydroxyl group of 54 as 
tetrahydropyranyl (THP) ether, obtaining 55 in 83% yield. 55 was then treated with n-BuLi 
and DMF but surprisingly, only starting material was recovered (Scheme 16b).51 Synthetic 
approaches aimed at obtaining a nitrile as an intermediate toward the aldehyde, were also 
not successful. Therefore, we decided to synthesize a slightly different aldehyde (56), 
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Scheme 17. Attempted synthesis of 47 and 61. 
We attempted the synthesis of 47 starting from 38, which was synthesized as described 
above. Monoformylation of 38 with ethyl formate, yielded 58 in 91% yield but the 
subsequent dehydration of 58 with POCl3 was not successful (Scheme 17). Therefore, we 
decided to carry out the protection of 58 and attempt the dehydration in a second stage. 
Treatment of 58 with Boc2O in several reaction conditions led to mixtures of products in 
which the formamide group was also protected. Treatment of 58 with phthalic anhydride 
for 3 days at 100 oC, led to the formation of a mixture of 59 and 60 in very low yield. 59 
could be isolated but treatment with POCl3 and Et3N did not lead to the desired isocyanide 
61, even after heating at 50 oC for 16 h (Scheme 17). 
On the one hand, the use of other dehydrating agents (e.g., (CO)2Cl2, SOCl2) might be 
more suitable to obtain 47 (or 61). Moreover, the Hoffmann synthesis of isocyanides under 
biphasic conditions could also be attempted (Scheme 18a). On the other hand, one could 
also attempt the synthesis of simplified versions of 47. In particular, the amino group – 
whose presence could cause problems and whose protection is apparently troublesome – 
could be introduced in the very last stage via an SN2 or a Buchwald cross-coupling reaction 
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Scheme 18. (a) An alternative synthetic plan for the synthesis of 47; (b) A synthetic plan 
to obtain a simplified version of the isocyanide component. 
 
5.8 Conclusions and outlook 
MCRs are very attractive considering that one can obtain complex scaffolds in a one-pot 
synthesis. Nevertheless, the use of MCRs is far from trivial and often requires a careful 
tuning of the reaction conditions. In particular, when the desired scaffold contains groups 
that interfere with the MCR (e.g., free amino or hydroxyl groups), many 
protection/deprotection steps are necessary, which renders the synthesis less efficient. As 
a precaution, one should ideally start with a simplified version of the building blocks to 
evaluate the reactivity of the components. 
Moreover, the fact that compound 28 – obtained via a Van Leusen reaction – showed only 
weak inhibitory potency against D. radiodurans DXS, might suggest that a broader 
chemical diversity is necessary to develop potent TDP-competitive inhibitors. In fact, 
although 28 constitutes a new chemical entity, its scaffold resembles that of the cofactor 7 
rather closely, despite bearing a completely different moiety in the diphosphate pocket. 
Given the close similarity of 28 and 7 in the aminopyrimidine- and thiazolium-binding 
pocket, one could also attempt to draw the conclusion that its low inhibitory potency can 
be ascribed to the substituted aromatic ring in the diphosphate-binding pocket. As 
discussed in Section 5.6.3, although no steric clashes are observed between the modeled 
pose of 28 and D. radiodurans DXS, the rigidity of the biaryl system might not be suitable 
to fill this pocket. To rule out that the weak inhibitory activity is caused by steric clashes of 
this part of the molecule, one could exploit the use of TosMICs bearing a heteroaromatic 
five-membered ring, such as a thiophene, ideally substituted with more polar groups to 
render the compound sufficiently hydrophilic. The inhibitory potency of 28 against 
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M. tuberculosis DXS has yet to be confirmed experimentally. This is particularly important, 
especially in light of the remarkably lower value for the calculated Gibbs free energy of 
binding that we obtained for the top-ranked pose of 28 docked into the homology model of 
M. tuberculosis DXS compared to the top-ranked pose of 28 docked into D. radiodurans 
DXS, as we discussed in Section 5.6.3. If the discrepancy between the experimental IC50 
value and the calculated binding energy of the top-ranked docked pose will be confirmed, 
this might suggest that 28 binds in a yet undiscovered pocket within M. tuberculosis DXS, 
which was not considered in the docking studies. Further studies – for instance, 
determining the mode of inhibition or validating the binding mode by the STI-NMR 
methodology discussed in Chapter 2 – should be carried out to rationalize our first results. 
In general, the fact that van Leusen reactions are known to work more efficiently with 
aromatic TosMICs than with aliphatic ones, indeed constitutes a limitation for further 
exploring this reaction in this context. 
The Groebke scaffold might be worth exploring more, given its different structure, which 
occupies the TDP-binding pocket in a different manner compared to the Zhu and the van 
Leusen scaffolds. 
Moreover, while performing our queries, we identified a few other interesting scaffolds, 
which might be worth exploring too, given their broader chemical diversities with respect 
to the scaffold of TDP. In particular, the hydantoine (Scheme 19a), the Doebner (Scheme 
19b) and the sulfonamide (Scheme 19c) scaffolds resulted in promising binding modes 
according to our modeling studies. 
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5.9 Experimental 
General Experimental Details 
For general experimental detail, see Chapter 2, Section 2.8 
Compounds 9,31 13, 32 10,33 18,34 38,34 39,40 55,51 56,52 were synthesized according to 
literature procedures and the spectral data are consistent with those reported in the 
literature. 
General procedure 1 (GP1) for a Van Leusen reaction. 
A dry flask was charged with the amine (1.2 eq.), the aldehyde (1.3 eq.) and anhydrous 
DMF (1 mL for 0.15 mmol of TosMic). The mixture was left to stir at room temperature for 
4 h, and then the TosMic (1.0 eq.) and K2CO3 (2.0 eq.) were added. After 24 hours, water 
and EtOAc were added and the mixture was left to stir for an additional 10 minutes. After 
transfer to a separatory funnel, the aqueous layers were extracted with EtOAc (3x), dried 
over Na2SO4, filtered and concentrated in vacuo. The residue was then purified by column 
chromatography. 
4-Amino-2-methylpyrimidine-5-carbaldehyde (19) 
To a solution of 18 (120 mg, 0.895 mmol) in formic acid (1.2 mL) at room 
temperature, Raney-Nickel was added (120 mg, 50% slurry in water). The 
reaction mixture was heated at 75 °C for 3 h. Another portion of Raney-
Nickel was added (120 mg, 50% suspension in water), and the reaction was 
stirred at 75 °C for 16 h. After that, the reaction mixture was filtered and washed with formic 
acid (3 x 0.5 mL) followed by water (3 x 3.0 mL). To the filtrate, CH2Cl2 (15 mL) was added 
and the resulting mixture was vigorously stirred and slowly basified using aq. NH4OH 
(25%). The organic layers were separated, and the aqueous layers washed with CH2Cl2 
(2 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo.  
Purification by CC (SiO2; EtOAc/toluene/Et3N, 2:1:0.3) afforded 19 as a white solid (79 mg, 
64%). 1H NMR (400 MHz, DMSO-d6): δ=9.82 (s, 1H), 8.64 (s, 1H), 8.15 (s, 1H), 7.90 (s, 
1H), 2.41 (s, 3H). 13C NMR (101 MHz, DMSO-d6): δ=192.4, 171.0, 164.1, 160.7, 109.8, 
26.0 ppm. HR-MS (ESI) calcd. for C6H8N3O [M+H]+: 138.0662, found: 138.0654. IR (cm1): 
3401, 3374, 3038, 1677, 1646, 1583, 1533, 1511, 1432, 1405, 1287, 1189, 1043, 1012, 
963, 792, 645, 585. Mp = 189193 °C. 
Tert-butyl (5-cyano-2-methylpyrimidin-4-yl) dicarbamate (21) 
To a suspension of 18 (150 mg, 1.12 mmol) and DMAP (14 mg, 
0.11 mmol) in anhydrous THF (8.0 mL) at room temperature, Boc2O 
(0.25 mL, 1.1 mmol) was added. The resulting yellow solution was left 
to stir at room temperature. After 16 h, another portion of Boc2O 
(0.46 mL, 2.0 mmol) was added and the solution was left to stir at room 
temperature for 56 h. The reaction mixture was then diluted with EtOAc 
(15 mL), and the organic phase washed with sat. aq. NaHCO3 solution (15 mL) and sat. 
aq. NaCl solution (15 mL), dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. Purification by CC (SiO2; EtOAc/pentane, 1:3) afforded 21 as a yellow oil (314 mg, 
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84%). 1H NMR (400 MHz, DMSO-d6): δ=9.34 (s, 1H), 2.74 (s, 3H), 1.43 (s, 18H). 13C NMR 
(101 MHz, DMSO-d6): δ=171.6, 162.8, 159.9, 148.9, 113.4, 103.2, 84.9, 27.2, 25.9 ppm. 
HR-MS (ESI) calcd. for C11H14N4O2 [M+H–Boc]+: 235.1117, found: 235.1191 (mono-Boc 
product). IR (cm1): 2982, 1807, 1770, 1737, 1579, 1533, 1440, 1396, 1370, 1243, 1148, 
1118, 1099, 848, 824, 777, 725, 633.   
Tert-butyl (3-formylpyridin-2-yl)carbamate (24) 
A solution of 23 (1.0 g, 8.2 mmol) and Boc2O (2.82 mL, 12.3 mmol) in 
anhydrous CH3CN (10 mL) was left to stir at 50 oC for 24 hours. After 
cooling down, the reaction mixture was diluted with EtOAc (10 mL), 
washed with sat. aq. NaCl solution (3 x 10 mL), dried over Na2SO4, 
filtered and concentrated in vacuo. Purification by CC (SiO2; 
EtOAc/pentane, 10:90 to 40:60) afforded 24 as a white solid (1360 mg, 
75%). 1H NMR (400 MHz, CDCl3): δ=10.14 (s, 1H), 9.89 (s, 1H), 8.64 (dd, J = 4.8, 1.9, 
1H), 7.97 (dd, J = 7.6, 2.0, 1H), 7.12 (dd, J = 7.6, 4.9, 1H), 1.53 (s, 9H). 13C NMR (101 
MHz, CDCl3): δ=193.2, 154.7, 152.7, 150.8, 144.1, 117.8, 116.8, 81.8, 28.4 (3C). HR-MS 
(ESI) calcd. for C11H15N2O3 [M+H]+: 223.1077, found: 223.1077. IR (cm1): 2980, 1723, 
1581, 1508, 1441, 1369, 1243, 1148, 770. Mp = 110113 °C. Anal. calcd. for C11H15N2O3: 
C 59.45, H 12.61, N 6.35; found: C 59.16, H 12.42, N 6.30. 
4-(1-((4-Amino-2-methylpyrimidin-5-yl)methyl)-5-methyl-1H-imidazol-4-yl)benzene-
1,2-diol (28) 
A mixture of 35 (10 mg, 0.020 mmol) and Pd/C (10% wt, 5 mg, 
20 mol%) in MeOH/H2O (0.9 mL:0.1 mL) was left to stir under 
atmospheric pressure of H2 at room temperature for 16 h. The 
reaction mixture was filtered through celite, the filter pad was 
washed with MeOH, and the filtrated was concentrated in 
vacuo and washed multiple times with pentane and Et2O in the ultrasound bath to get rid 
of aliphatic impurities. 28 was obtained as a pale yellow solid (6 mg, quant.). 1H NMR 
(400 MHz, CD3OD): δ=7.64 (s, 1H), 7.48 (s, 1H), 6.99 (d, J = 2.0, 1H), 6.86 (dd, J = 8.2, 
2.1, 1H), 6.80 (d, J = 8.2, 1H), 5.02 (s, 2H), 2.41, (s, 3H), 2.28 (s, 3H). (NH2 and OH not 
visible). 13C NMR (101 MHz, CD3OD): 166.6, 161.3, 152.4, 144.8, 144.2, 138.0, 135.7, 
126.3, 122.7, 118.8, 114.9, 114.4, 109.4, 41.9, 23.5, 8.1. HR-MS (ESI) calcd. for 
C16H18N5O2 [M+H]+: 312.1455, found: 312.1466. IR (cm1): 3334, 3163, 1640, 1600, 1564, 
1505, 1443, 1274, 1202, 1112, 786. Melting point > 200 °C (decomposition). 
(((4-(Isocyano(tosyl)methyl)-1,2-phenylene)bis(oxy))bis(methylene))dibenzene (34) 
(a) A dry flask was charged with 39 (240 mg, 1.54 mmol) and 
41 (326 mg, 1.02 mmol). Anhydrous CH3CN (0.70 mL) and 
anhydrous toluene (0.70 mL) were added, followed by 
formamide (0.10 mL, 2.55 mmol) and chlorotrimethyl silane 
(0.14 mL, 1.1 mmol). The mixture was stirred at 45 oC for 
4.5 h, MeOH (3 mL) was added, and the white precipitate was 
filtered over a Buchner filter, washed with MeOH (20 mL) and 
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dried with an oil vacuum pump for 10 h to afford 42 as a crude product, which was used in 
the next step without any further purification. 
(b) A dry flask was charged with 42 (300 mg, 0.598 mmol) and anhydrous THF (2.3 mL). 
POCl3 (0.12 mL, 1.23 mmol) was added at room temperature, and the solution was left to 
stir for 15 min. The reaction mixture was cooled down to 0 oC, Et3N (0.53 mL, 3.80 mmol) 
was added dropwise, and the reaction mixture was left to warm gradually to room 
temperature. After 2 h 30 min, the conversion was complete (according to TLC), and 
EtOAc (5 mL) and H2O (5 mL) were added. After stirring for 5 min, the reaction mixture 
was transferred to a separatory funnel, the aqueous layers were discarded, and the 
organic layers were washed with water (2 x 10 mL), sat. aq. NaHCO3 solution (10 mL) and 
sat. aq. NaCl solution (10 mL). The organic layers were concentrated in vacuo, keeping 
the temperature of the bath below 40 oC to avoid product decomposition (closely related 
isocyanides are known to be thermally unstable at temperatures above 80 oC). Purification 
by CC (SiO2; EtOAc/pentane, 10:90 to 60:40) afforded 34 as an orange solid (290 mg, 
80% over two steps). 1H NMR (400 MHz, CDCl3): δ=7.53 (s, 1H), 7.51 (s, 1H), 7.26 ̶ 7.43 
(m, 12H), 6.88 (d, J = 2.2, 1H), 6.85 (d, J = 8.4, 1H), 6.78 (dd, J = 8.4, 2.2, 1H), 5.46 (s, 
1H), 5.16 (s, 2H), 5.05 (d, J = 4.2, 2H), 2.42 (3H).  13C NMR (101 MHz, CHCl3): δ=165.8, 
150.8, 148.8, 146.4, 136.6, 136.5, 130.5 (2C), 130.1, 129.7, 128.6 (4C), 128.0, 128.0, 
127.5, 127.2 (4C), 122.0, 119.1, 114.4, 114.1, 76.3, 71.3, 71.0, 21.8. HR-MS (ESI) calcd. 
for C29H25NO4S [M+Na]+: 506.1397 found: 506.1389. IR (cm1): 2132, 1520, 1323, 1268, 
1142, 1036, 1025, 811, 733, 694, 671, 560, 529. Mp = 9497 °C. Anal. calcd. for 
C29H24NO4S: C 72.03, H 5.21, N 2.90; found: C 71.66, H 5.17, N 2.98. 
5-((4-(3,4-Bis(benzyloxy)phenyl)-5-methyl-1H-imidazol-1-yl)methyl)-2-
methylpyrimidin-4-amine (35) 
35 was prepared according to GP1, starting from 38 
(103 mg, 0.745 mmol), 31 (50 μL, 0.81 mmol), 34 (300 mg, 
0.620 mmol), K2CO3 (171 mg, 1.24 mmol) and anhydrous 
DMF (4.1 mL). Purification by CC (SiO2; CH2Cl2/MeOH, 
95:5 to 91:9) afforded 35 as a pale yellow solid (61 mg, 20% 
yield). 1H NMR (400 MHz, CDCl3): δ=7.92 (s, 1H), 7.51 (s, 
1H), 7.45 (s, 1H), 7.43 (s, 2H), 7.377.24 (m, 8H), 7.07 (d, J = 8.3, 1H), 6.95 (d, J = 8.3, 
1H), 5.18 (s, 2H), 5.17 (s, 2H), 5.01 (s, 2H), 4.83 (s, 2H), 2.52 (s, 3H), 2.18 (s, 3H). 13C 
NMR (101 MHz, CHCl3): δ=168.6, 161.0, 155.9, 149.2, 148.1, 138.7, 137.6, 137.5, 128.7 
(4C), 128.4, 128.0 (2C), 127.9 (2C), 127.6 (2C), 127.5 (2C), 120.4, 115.4, 114.4, 108.0, 
71.6, 71.4, 43.8, 25.9, 10.1. HR-MS (ESI) calcd. for C30H30N5O2 [M+H]+: 492.2394 found: 
492.2385. IR (cm1): 3322, 3169, 1648, 1596, 1562, 1510, 1454, 1254, 1136, 1014, 736, 
697. Mp = 168171 °C. Anal. calcd. for C30H29N5O2: C 73.30, H 5.95, N 14.25; found: C 
72.33, H 5.92, N 14.17. 
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37 was prepared according to GP1, starting from 38 (25 mg, 
0.18 mmol), 33 (20 μL, 0.20 mmol), 34 (73 mg, 0.15 mmol), 
K2CO3 (21 mg, 0.30 mmol) and anydrous DMF (1.0 mL). 
Purification by CC (SiO2; CH2Cl2/MeOH, 99:1 to 97:3 to 
93:7) afforded 37 as a white solid (31 mg, 37%). 1H NMR 
(400 MHz, CDCl3): δ=7.77 (s, 1H), 7.53 (s, 1H), 7.45 ̶ 7.24 
(m, 12H), 7.16 (d, J = 1.9, 1H), 7.04 (dd, J = 8.4, 1.9, 1H), 6.95 (dd, J = 4.9, 1.2, 1H), 6.82 
(d, J = 8.4, 1H), 5.11 (s, 2H), 4.95 (s, 2H), 4.87 (s, 2H), 4.72 (s, 2H), 2.48 (s, 3H). 13C NMR 
(101 MHz, CHCl3): δ = 168.3, 160.8, 156.1, 149.0, 148.1, 139.5, 137.5, 137.4, 136.6 (2C), 
130.1, 129.3, 128.6 (2C), 128.6 (2C), 127.9, 127.9, 127.6, 127.5 (2C), 127.4 (2C), 126.9, 
122.6, 119.6, 115.22, 113.0, 108.5, 71.5, 70.9, 43.7, 25.8. HR-MS (ESI) calcd. for 
C33H30N5O2S [M+H]+: 560.2115, found: 560.2104. IR (cm1):1651, 1569, 1524, 1495, 1343, 
1318, 1257, 1246, 1215, 1107, 1011, 985, 852, 795, 733, 695. Mp = 170173 °C. 
N-(4-Formylbenzyl)methanesulfonamide (49) 
In a three-necked round-bottomed flask cooled to −78 ºC, oxalyl chloride 
(0.77 mL, 9.2 mmol) was added dropwise to a solution of anhydrous CH2Cl2 (3.0 
mL). To the stirred solution, a mixture of anhydrous DMSO (1.8 mL) in 
anhydrous CH2Cl2 (2.0 mL) was added dropwise and some precipitate was 
formed. After 10 min, a solution of 53 (1.8 g, 8.4 mmol) in anhydrous CH2Cl2 
(8.0 mL) and anhydrous DMSO (1.0 mL) was added dropwise to the mixture. 
The reaction was stirred at −78 ºC for 20 min. Et3N (5.9 mL, 42 mmol) was 
added dropwise. After the addition was complete, the mixture was allowed to reach room 
temperature and washed with water (3 x 10 mL) and sat. aq. NaCl solution (2 x 10 mL), 
dried over MgSO4, filtered and concentrated in vacuo. Purification by CC (SiO2; Pet. 
Ether/EtOAc, 80/20 to 40/60) afforded 49 as a white solid (360 mg, 20%). 1H-NMR 
(500 MHz, CDCl3): δ=10.01 (s, 1H), 7.85 (d, J = 7.9, 2H), 7.44 (d, J = 7.4, 2H), 4.45 (s, 
2H), 2.91 (s, 3H). 13C-NMR (125 MHz, CDCl3): δ = 191.5, 142.1, 136.2, 130.1 (2C), 129.0 
(2C), 50.7, 40.1. HRMS (ESI) m/z calculated for C9H12NO3S+ [M+H]+: 214.05; found [M-
H]+: 214.04. Melting point = 95−97 ºC. 
((4-(Chloromethyl)benzyl)oxy)trimethylsilane (52) 
To a stirred solution of 51 (500 mg, 3.19 mmol) in CH2Cl2 (5.0 mL), was added 
Et3N (0.67 mL, 4.8 mmol). The reaction was cooled to 0 ºC, and 
chlorotrimethylsilane (0.41 mL, 3.2 mmol) was added. After 30 min of stirring at 
0 ºC, the mixture was extracted with CH2Cl2 (3 x 10 mL), washed with sat. aq. 
NaCl solution (2 x 5 mL), dried over MgSO4, filtered and concentrated in vacuo 
to yield 52 as a pale yellow oil. The crude was used in the next step without any 
further purification. 1H-NMR (500 MHz, CDCl3): δ=7.36 (d, J = 7.4, 2H), 7.32 (d, 
J = 7.3, 2H), 4.69 (s, 2H), 4.58 (s, 2H), 0.16 (s, 9H). 
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N-(4-(Hydroxymethyl)benzyl)methanesulfonamide (53) 
A mixture of methanesulfonamide (143 mg, 1.50 mmol), Cs2CO3 (978 mg, 3.00 
mmol) and [Cu(OH)TMEDA]2Cl2 (23 mg, 0.050 mmol) in acetonitrile (3.0 mL) 
was stirred at room temperature for 15 min. To the green suspension, a solution 
of 52 in acetonitrile (1.0 mL) was added dropwise, and the reaction was stirred 
at room temperature for 16 h. The mixture was filtered and HCl (1N) was added 
to reach pH = 1. The acidified mixture was extracted with EtOAc (3 x 10 mL), 
washed with sat. aq. NaCl solution (2 x 10 mL), dried over MgSO4, filtered and 
concentrated in vacuo to yield 53 as white crystals (140 mg, 58% over two steps). 1H-NMR 
(500 MHz, CDCl3): δ=7.33 (d, J = 7.3, 2H), 7.28 (d, J = 7.3, 2H), 4.69 (s, 2H), 4.34 (s, 2H), 
2.82 (s, 3H). 13C-NMR (125 MHz, CDCl3): δ=140.6, 134.8, 129.0, 128.8, 127.4, 127.3, 
65.0, 50.0, 40.0. HRMS (ESI) m/z calculated for C9H14NO3S+ [M+H]+: 216.06; found 
[M+Na]+: 238.22. Mp = 100−102 ºC. 
N-((4-Amino-2-methylpyrimidin-5-yl)methyl)formamide (58) 
38 (2.0 g, 15 mmol) was dissolved in ethyl formate (25 mL). The reaction 
was stirred at room temperature for 16 h. The solvent was evaporated in 
vacuo to yield 58 as a pale yellow solid (2.2 g, 91%).1H-NMR (500 MHz, 
CDCl3): δ=8.24 (s, 1H), 7.96 (s, 1H), 6.00 (br. s, 1H), 5.82 (br. s, 2H), 4.3 
(d, J = 4.3, 2H), 2.48 (s, 3H). 13C-NMR (125 MHz, CDCl3): δ=167.3, 162.5, 161.8, 155.8, 
110.8, 36.0, 25.5. HRMS (ESI) m/z calculated for C7H11N4O [M+H]+: 167.09; found [M+H]+: 
167.20. Mp = 213−215 °C. 
N-((4-(1,3-Dioxoisoindolin-2-yl)-2-methylpyrimidin-5-yl)methyl)formamide (59) 
To a stirred solution of 58 (200 mg, 1.20 mmol) in THF (2.0 mL) and 
toluene (2.0 mL), Et3N (0.42 mL, 3.0 mmol) and phthalic anhydride 
(622 mg, 4.20 mmol) were added. The reaction was stirred at 100 °C for 
3 days. The solvent was evaporated in vacuo to yield a red oil. 
Purification by CC (SiO2; Pet. Ether/EtOAc, 50:50 to 0:100) afforded 59 
as a white solid (30 mg, 6%).1H-NMR (500 MHz, CDCl3): δ=9.64 (d, J = 
9.6, 1H), 8.68 (s, 1H), 7.89 (d, J = 7.9, 2H), 7.77 (d, J = 7.7, 2H) 4.71 (s, 
2H), 2.61 (s, 3H). 13C-NMR (125 MHz, CDCl3): δ=168.4, 162.2 (2C), 160.5, 156.0, 134.7 
(4C), 131.6 (2C), 124.0, 34.6, 25.8. MS (ESI) m/z calculated for C15H13N4O3+ [M+H]+: 
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Ligand-based virtual screening as a powerful 
tool for the discovery of DXS inhibitors with 
potent antituberculotic activity 
 
In this chapter, we will present a ligand-based virtual screening (LBVS) campaign that we 
carried out using the structures of our modeled inhibitors (Chapter 2) as reference 
molecules. After performing several cycles of LBVS by screening part of the ZINC 
database, we identified low-micromolar inhibitors of both Deinococcus radiodurans and 
Mycobacterium tuberculosis DXS having diverse scaffolds and with potent activity in cell-
based assays against multi- and extensively-drug resistant strains of M. tuberculosis. One 
of them also showed promising activity against the Plasmodium falciparum 3D7 strain in a 
preliminary cell-based assay. Moreover, we showed that the most promising hits have a 
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 Chapter 6 
6.1 High throughput screening and virtual screening in drug discovery 
High-throughput-screening (HTS) approaches, enabling testing large libraries of 
compounds in an automated fashion, have become popular over the past two decades 
mostly in the pharmaceutical industry but increasingly also in academia.1 Since its 
introduction in the 1990s,2 fast advances in automation and miniaturization have rapidly 
made HTS feasible, rendering it ever faster and efficient: 96-well plates have been 
replaced by higher density microtiter plates with up to 1586 wells per plate, low-volume 
assays (most commonly ≤ 50 μL) and novel fluorescence-based detection systems have 
been developed and screening robots have been fully adapted to desktop environments.3 
The main criticism of HTS campaigns, is associated with the size and quality of the libraries 
that are being screened. Nevertheless, a lot of progress has been made in this field since 
the 1990s, when the compound collections were assembled without giving much 
consideration to their suitability for drug discovery. Nowadays, libraries, which are tested 
in HTS, only include highly pure, drug-like compounds, taking into account parameters 
such as molecular weight (Mw) and cLogP.4, 5 Another notorious problem associated with 
HTS hits are false positives, arising mainly from promiscuous binders and solubility issues. 
The fact that assays are typically performed at a single concentration point, might lead to 
both false positives and false negatives.6 Despite being the main source of hits entering 
the drug-discovery pipeline, HTS requires very expensive equipment, which is usually not 
affordable for academic research. In general, target validation and assay development 
continue to present major bottlenecks: the availability or stability of the protein over the 
time requested for the HTS analysis or the kind of assay can make a target incompatible 
with HTS. For example, if the assay is based on kinetic measurements, the screening 
would require an enormous amount of instrument time. 
Virtual screening (VS), where large databases of compounds are screened in silico against 
a certain target, constitutes a complementary approach to classical HTS.7 The two main 
strategies used nowadays are ligand-based virtual screening (LBVS)8 and structure-based 
virtual screening (SBVS).9 Although structures of target proteins, which can be used as 
VS templates, are becoming increasingly available, LBVS continues to be prevalent, owing 
to the fact that hit (or lead) information is still the predominant type of knowledge used in 
numerous projects. Nevertheless, the two strategies are perfectly complementary. When 
the crystal structure of the protein of interest has been reported, SBVS campaigns can be 
carried out: a library of compounds is docked into the binding site of the protein and each 
compound is scored according to how well it fits the pocket in terms of calculated binding 
energy. On the one hand, SBVS strictly relies on the resolution of the crystal structure of 
the protein and suffers from the same limitations related to its static nature, namely protein 
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flexibility in solution or definition of a certain pocket only upon ligand binding. One the other 
hand, the only prerequisite for a LBVS campaign is the knowledge of a ligand for the 
protein of interest. The structure of this reference molecule is compared with a database 
of compounds according to several criteria, as discussed in Section 6.2. The database can 
be composed of commercially available molecules or can be an in-house database of 
compounds, as well as a combinatorial library of compounds. Each molecule of the 
database is ranked according to its similarity to the reference molecule and the top-scoring 
compounds are selected and evaluated in vitro for their inhibitory potency. The main 
advantage of LBVS over SBVS, besides not requiring the structure of the protein to be 
solved, is that the calculation power required is remarkably lower. 
 
6.2 Ligand-based virtual screening  
LBVS relies on the use of descriptors of molecular structures and properties to compare 
various molecules.10 As shown schematically in Figure 1, the molecular descriptors can be 
classified as one- two- or three-dimensional (1D, 2D or 3D) ones. 
 
Figure 1. Meaning of the 1D, 2D and 3D molecular descriptors used in virtual screening. 
The most straightforward and efficient similarity-based calculations are based on 2D 
molecular descriptors using fingerprints. They consist in binary bit string representations 
of many aspects and properties of the template molecule, encoding for the presence or 
absence of given properties.11 The fingerprint of the template molecule is then compared 
to those of the molecules present in the database, and the similarity of two different 
molecules according to their fingerprints is determined using similarity coefficients such as 
the Tanimoto coefficient.12 Going a step beyond 2D structures, similarity between 
molecules can also be analyzed using 3D shape similarities or pharmacophore models.13  
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In this project, two methods developed in the group of Prof. Reymond, at the University of 
Bern, were applied for the virtual screening of (parts of) the ZINC database.14, 15 The first 
method, called Xfp,16 is based on the concept of atom pairs originally proposed by 
Carhart17 and co-workers and relies on atom pair fingerprints counting atom pairs at 
increasing topological distances in 2D structures, without any atom-property assignment. 
The hydrophobicity, the number of hydrogen-bond donors and acceptors, and the planarity 
of the molecule are parameters, which are taken into account during the count of atom 
pairs. The method was developed to overcome the computational demand associated with 
precise 3D-shape screening of large databases and it was shown to correlate very well 
with various representations of molecular shape extracted from 3D structures.  
The second method, called translational Ligand Overlap Score (tLOS), compares the 3D 
shape of two molecules using an algorithm to optimize the spatial overlap between atoms. 
The fitting function takes into account the hydrophobicity and the hydrogen-bond donors 
and acceptors of the molecules, which are being compared. tLOS is computationally more 
demanding than the previously described Xfp, thus being limited to databases with 
restricted size.18, 19 
In the context of this project, we will also apply clustering methods, allowing for the 
classification of compounds obtained from the screening in groups of molecules according 
to their similarity.20 Each cluster will include a set of molecules with a high degree of 
diversity (however defined, depending on the algorithm) between the different clusters. 
This method is very useful when one has the possibility to purchase only a limited number 
of compounds for testing, but still would like to explore the inhibitory potency of very 
different chemical scaffolds in the first stage of a project. 
 
6.3 First round of LBVS based on known inhibitors for DXS 
Fluoropyruvate (1),21 ketoclomazone (2),22 gibberellic acid (3)23 and compound 424 are 
known inhibitors of various DXS orthologues (Table 1). 2 binds to an unknown binding site 
of DXS, which differs from the binding site of the two substrates. The binding modes of 3 
and 4 are unknown, the latter being identified starting from the scaffold of a known inhibitor 
of transketolase (TK).25 The fact that 4 targets M. tuberculosis DXS and its close analogue 
had shown activity against human TK  both thiamine diphosphate-dependent enzymes  
could suggest that 4 targets the cofactor-binding pocket of the two enzymes. 1 is supposed 
to be a covalent, irreversible inhibitor of DXS, presumably acting in a similar manner to the 
one shown for the E1 component of the pyruvate dehydrogenase complex (PDH).26  
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We performed the docking of compounds 14 with the FlexX27 docking module of the 
LeadIT suite using the complete structure of D. radiodurans DXS (Protein Data Bank code: 
2O1X),28 trying to identify trends, which could suggest a preferential binding pocket for 
each scaffold. Careful analysis of the distribution and ranking of the docked poses – 
according to the scoring function HYDE29,30 in the LeadIT suite –, however, did not enable 
us to draw any conclusions. When testing 2 and 3 for their inhibitory potency against both 
D. radiodurans and M. tuberculosis DXS, we observed no activity at 2000 μM. Although 
there is a high degree of sequence homology between different orthologues of DXS, one 
often observes tremendous differences in inhibitory potency for the same compound 
against different orthologues (e.g., IC50 of 2 with respect to Arabidopsis thaliana and 
Chlamydomonas DXS, Table 1).  
Table 1. Known inhibitors of DXS with their reported inhibitory potency. We tested 2 and 






  D. rad. DXS M. tub. DXS 
 
 
IC50 = 80 μM 






IC50 = 100 μM 
(Chlamydomonas DXS) 
 
IC50 = 0.08 μM 







~40% inhibition  
at 100 μM 
(male and female 













[a] IC50 values were determined using a photometric assay using the program Dynafit. 
Full details of the biochemical assay conditions are provided in the Experimental part of 
Chapter 2. Every IC50 value reported in this chapter has been determined with this 
assay, if not stated otherwise.  
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Given that these compounds constituted the only known inhibitors of DXS at the onset of 
the project, we decided to initiate a LBVS campaign by using them as reference molecules. 
First, the 3D structures of 14 were generated using the software CORINA,31 and their 3D 
shape compared with those of the commercially available compounds from the Princeton 
database. The compounds present in this database were ranked according to their 
similarity towards each reference resulting in four different series. Compounds with 
undesired functional groups such as ester and hydrazine moieties, were immediately 
excluded. The ten top-scoring compounds of each series were selected (40 compounds 
in total). Moreover, the 1000 top-scoring compounds of each series were clustered 
independently using the k-mean clustering algorithm. 20 to 30 compounds were manually 
selected in each series by visual inspection of the clusters, and were combined with the 
previously selected compounds. The derivatives of 1 resulting from the screening did not 
give sufficiently good scores when compared to the other derivatives. As a result, we 
decided to focus on the other three scaffolds. The selected compounds were docked within 
D. radiodurans DXS and the top-ranked poses were selected so as to reduce the number 
of candidates. Finally, eleven compounds were purchased, dissolved in DMSO at the 
highest concentration possible (ideally 80 mM) and tested for their inhibitory activity against 
DXS using the spectrophotometric assay as described in Chapter 2. 
Unfortunately, none of them inhibited D. radiodurans nor M. tuberculosis DXS at the 
highest concentration tested (depending on the solubility of each compound in DMSO and 
in the assay buffer, concentrations vary from 12 to 2000 μM). One explanation for these 
disappointing results might be that the subset of compounds tested was too small. Indeed, 
since a hit rate of 13% might be reasonably expected for this kind of approach, 
biochemical testing of 100200 compounds might have led to the identification of some 
hits. Moreover, as discussed above, 2 and 3 used as references for our virtual screening 
campaign were active on some DXS orthologues (Table 1) but we found them to be 
inactive against both D. radiodurans and M. tuberculosis DXS.  
 
6.4 First round of LBVS based on three novel scaffolds 
In Chapter 2, we introduced deazathiamine (5) as a moderate, thiamine diphosphate 
(TDP)-competitive inhibitor of D. radiodurans DXS. Moreover, we showed how we 
designed de novo two fragments, 6 and 7, which inhibit D. radiodurans DXS in the low 
millimolar and upper micromolar range, respectively. We validated the binding mode of 5 
and 6 by NMR studies and we proposed that 7 inhibits DXS with a mixed mode of inhibition, 
suggesting a binding mode similar to that proposed in Figure 5 (Chapter 2). We decided 
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to use 57 as reference molecules for performing a LBVS campaign aimed at obtaining 
more chemical diversity while enhancing the in vitro inhibitory potencies. Although we 
found the reference scaffolds 57 to be inactive against M. tuberculosis DXS, we decided 
to assess the inhibitory capacity of the hits found by LBVS also against the pathogenic 
enzyme. 
Table 2. Inhibitory potency of compounds 57, used as reference molecules for our 
ligand-based virtual screening project, against D. radiodurans and M. tuberculosis DXS. 
 
   
IC50 (μM) 
(D. rad. DXS) 
430 ± 68 1810 ± 480 762 ± 199 
IC50 (μM) 
(M. tub. DXS) 
>2000 >2000 >2000 
 
First, the 3D shape of 57 generated with CORINA was screened against the Princeton 
database. Clustering of the 1000 compounds with the highest similarity to each reference 
molecule was performed to support the manual selection. We selected the 20 compounds 
with the highest similarity score and combined them with the analogues selected by 
clustering. Visual analysis of the selection was performed so as to explore as much 
chemical diversity as possible given that this constitutes the first round of screening. This 
selection helped us in reducing the number of hits to purchase: 21, 25 and 27 analogues 
of 5, 6 and 7, respectively, were finally purchased in 1 mg batches. Stock solutions in 
DMSO were prepared for each compound based on the 1 mg batch provided by the 
company and a preliminary biochemical assay was carried out at one concentration point 
(in triplicate) or three concentration points. Compounds, which resulted in some inhibitory 
activity, were then tested with a complete dilution series of eight concentration points and 
an IC50 value was determined. Among the first series of compounds we tested, we could 
identify nine hits. Given the uncertainty regarding the exact weight of the purchased 
batches, we repurchased the hits in higher amounts to determine accurate IC50 values and 
confirm their inhibitory potency (Table 3, 811). We used this protocol (preliminary 
biochemical evaluation using the 1 mg batch based on one or three concentration points 
and repurchasing of promising hits) throughout the whole project. Nevertheless, the values 
reported in Table 3 will have to be confirmed, given that the biochemical assay was carried 
out at concentrations, which are very close to the solubility limits of the compounds. 
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Studies are currently ongoing to solve this problem, in which the biochemical assays are 
being carried out at higher percentage of DMSO in the assay mixture, namely 10%.  
Table 3. Most potent hits from the first round of ligand-based virtual screening starting 
with 57 as reference molecules. 
Compound Reference IC50 (μM)[a] 
Drad DXS 









17 ± 4 
 
60 ± 5 
 






252 ± 72 
 
 









398 ± 30 
 









































[a] Preliminary results that have to be validated, given that the highest 
concentrations used are close to the solubility limit. 
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Preliminary results on an exemplary compound of the LBVS series, provided the same 
IC50 value when the compound was tested in the presence of 5% and 10% DMSO in the 
assay mixture, suggesting that the data set is reliable and presumably was acquired 
sufficiently far from the solubility limit. Further assays of this type with the best hits from 
our LBVS campaign should be carried out to corroborate this assumption. By performing 
measurements at long wavelength (e. g., 800 nm), one could also monitor whether 
precipitates or aggregates are being formed. Given the fact that increasing percentage of 
DMSO could have severe effects on the protein, a dilution series should be carried out to 
check the effect of multiple DMSO concentrations on the activity of DXS. A fluorescent dye 
could be used to check whether any aggregates are present in the assay mixture, which 
could affect the IC50 determination. 
Structure-activity relationships (SARs) of analogues resulting from the whole LBVS 
campaign, will be discussed in Section 6.7.  
We obtained very interesting hits from all the reference molecules, with moderate up to 
striking enhancements of the inhibitory potency against D. radiodurans DXS. Moreover, 
the best hits reported in Table 3, are also active against M. tuberculosis DXS, with the 
deazathiamine derivative 8 being the most active one, having an IC50 of 60 ± 5 μM. Given 
that the spectrophotometric assay that we use to determine IC50 values uses IspC as an 
auxiliary enzyme, we also assessed the inhibitory potency of our hits against Escherichia 
coli IspC. 8 was the only compound, which we found to be active against E. coli IspC, with 
an IC50 of 3 ± 0.4 μM. In this case, a direct assay with DXS should be carried out so as to 
confirm the inhibitory activity of 8 against DXS, in the absence of the auxiliary enzyme. To 
do so, an NMR-based assay in which the DXS-catalyzed conversion of 13C-sodium 
pyruvate to 13C-1-deoxy-D-xylulose 5-phosphate is monitored, could be used. 
Alternatively, a fluorometric end-point assay based on the reaction of 1-deoxy-D-xylulose 
5-phosphate with 3, 5-diaminobenzoic acid in an acidic medium has been proposed, based 
on the formation of a highly fluorescent quinaldine derivative under these conditions.32 
Compounds 811 were used as references for performing another round of VS. 
Compound (E)-12, relatively close to (E)-11, was also used as reference, given its 
moderate activity against M. tuberculosis DXS combined with the fact that it is still a 
fragment-like molecule, with a Mw of 230 Dalton. Compound 13 was included as a 
reference molecule because its preliminary biochemical evaluation against M. tuberculosis 
DXS based on the 1 mg batch resulted in a moderate inhibitory activity, which we did not 
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6.5 Second round of LBVS 
For the second round of LBVS, we used two different similarity-search methods. In addition 
to the algorithm comparing the 3D shape previously used, the similarity between the 
reference molecules and the compounds present in the database was measured with the 
Xfp method, described in Section 6.2, comparing atom pair 2D-fingerprints. Besides the 
Princeton database, we also explored the libraries of Vitas-M and Specs. We selected 126 
compounds by visual inspection of the 1000 top-scoring compounds. We tried to include 
as many direct analogues as possible, to get a first insight into the SARs of these scaffolds 
and to focus our efforts, we decided to perform the biochemical assay only against 
M. tuberculosis DXS, our target enzyme. We found many commercially available 
derivatives of 8 and 9 and, although not leading to an improvement in the IC50 values with 
respect to 8 and 9, interesting SARs emerged (Section 6.7), which could further guide 
semi-rational chemical modification. 
We only found a few derivatives of (E)-12, which did not display enhanced inhibitory 
potency, and no SARs could be obtained.  
The best hits found within the second screening, are shown in Table 4, where we report 
the confirmed IC50 values after reordering them in higher amount. 14 was identified from 
12, which we eventually found to be inactive at 120 μM against both orthologues of DXS. 
Interestingly, 14, the most promising compound identified during this round of VS with an 
IC50 of 37 ± 5 μM against M. tuberculosis DXS, was retrieved using the Xfp algorithm as 
an analogue of 12 but did not appear in the 1000 top-scoring molecules when the 3D 
shape of 12 was compared with the compound library. This fact illustrates the 
complementarities of different similarity-search methods.  
15 and 16 proved to be eight to ten times more active than the corresponding reference 
molecules (10 and 11, respectively), although being structurally very similar to them. As 
one can observe from the cLogP values reported in Table 4, hits 1416 are slightly too 
hydrophobic considering their Mw. This feature renders their in vitro biochemical evaluation 
challenging and should be optimized on the way to larger and more potent inhibitors, which 
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Table 4. Most potent hits from the second round of virtual screening starting with 10, 11 
and 13 as reference molecules. 








































[a] Preliminary results that have to be validated, given that the highest 
concentrations used are close to the solubility limit. 
[b] cLogP values were calculated using ChemAxon.33 
 
6.6   Third and fourth round of LBVS 
We used the molecules depicted in Table 4 as references to run a third round of VS, using 
3D-shape similarity and substructure similarity. We decided to restrict our selection to 
direct analogues of the reference molecules to gain additional insight into the SARs and 
not to purchase any additional new scaffold. It should be noted that the activities of the 
derivatives tested within this round of VS are based on the preliminary biochemical 
evaluation of the purchased 1 mg batch and should be interpreted carefully. As a result, 
any difference in activity less than a factor of two, has not been considered as significant. 
We purchased in total 34 compounds. Only four analogues of 15 were available 
(compounds 1720, Table 5), thus we purchased them and tested them against M. 
tuberculosis DXS. Unfortunately, no direct analogues of 16 were available neither at 
Princeton nor at Vitas-M or Specs. Therefore, to get clearer insights into the SARs for 15 
and 16 and at the same time enhance their hydrophilicity, derivatives of these scaffolds 
should be obtained. Few synthetic protocols will be proposed in Section 6.12.1. Numerous 
derivatives of 14 were commercially available, and we present here a selection, collected 
in the multiple rounds of screening. These include also derivatives of 14 that we identified 
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during a fourth round of LBVS focused specifically on 14, during which we purchased 35 
more derivatives. 







142 ± 16 
 
279 ± 20 
 
284 ± 16 
 
> 150 
     
Several derivatives include modifications of part A of 14. The presence of a fluorine atom 
at the para position of ring A (20) led to a small loss in inhibitory potency (IC50 = 89 ± 
14 μM). Unfortunately, a direct comparison of 20 with 21, bearing the fluorine atom at the 
ortho position, is not possible given that 21 resulted in an IC50 > 60 μM. The presence of a 
trifluoromethyl group at the meta position (22) led approximately to a three-fold loss in 
inhibitory potency (IC50 = 124 ± 6 μM). When trying to introduce more polar substituents 
on ring A, such as hydroxyl and carboxyl groups, which also help enhance the 
hydrophilicity of these scaffolds, the inhibitory potency clearly decreases (23, 24). The 
presence of a methyl, methoxy or acetyl group at the para position of ring A (25, 26 and 
27, respectively), also did not lead to any improvement in the inhibitory potency. The fact 
that 2527 give essentially the same inhibitory potency (111149 μM), shows that several 
types of substituents are largely tolerated at this position. However, no inhibitory potency 
is observed at 150 μM when a diethylamino group is present (28). Replacing ring A with a 
para-chloro substituted or unsubstituted pyridine rings (2931) caused at least four-fold 
loss in inhibitory potency with respect to 14. 
An interesting series of compounds resulted from the substitution of the methyl group of 
ring C with an amino group. 32 is three times more active than its methylated analogue 
22. Interestingly, changing the position of the trifluoromethyl group (33, 34), hardly affects 
the inhibitory potency. When replacing ring A with a pyridinyl ring (35), the activity drops, 
consistent with our observation for the previously discussed series of compounds. 
Nevertheless, as shown by the biochemical activity of 36 and 37, the presence of certain 
substituents on this ring can help to recover the inhibitory potency. On the one hand, 36 
resulted in a double-digit micromolar IC50 value, while its methylated analogue 30 did not 
show any inhibition at 250 μM. 
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Table 6. Derivatives of 14 at ring A and C. 
 
Comp. R1 X Y R2 R3 IC50 
M. tub DXS (μM) 
14 CH3 C- C- 2-CH3, 3-Cl - 37 ± 5[a] 
21 CH3 C- CH 2-F - >60 
20 CH3 CH CH 4-F - 89 ± 14 
22 CH3 CH C- 3-CF3 - 124 ± 6 
23 CH3 CH C- 3-OH, 4-COOH - 178 ± 26 
24 CH3 CH C- 3-COOH, 4-OH - >330 
25 CH3 CH CH 4-CH3 - 149 ± 33[b] 
26 CH3 CH CH 4-OCH3 - 133 ± 27[b] 
28 CH3 CH CH 4-N(CH2CH3)2 - >150 
27 CH3 CH CH 4-COCH3 - 111 ± 11 
29 CH3 N CH H - 142 ± 59 
30 CH3 N CH 4-Cl - >250 
31 CH3 CH N H - 360 ± 90[b] 
       
32 NH2 CH C- 3-CF3 - 36 ± 9[a] 
33 NH2 C- CH 2-CF3 - 56 ± 4 
34 NH2 CH CH 4-CF3 - 45 ± 9[a] 
35 NH2 CH N H - 380 ± 102 
36[c] NH2 N CH 4-Cl - 56 ± 4[a] 
37 NH2 N C- 6-CH3 - 98 ± 37[b] 
38 NH2 CH C- 3-OH, 4-COOH - 129 ± 43 
       
39 - - - - 4-OH 69 ± 22 
40 - - - - 3-OH, 4-COOH 144 ± 12 
41 - - - - 3-COOH, 4-OH >220 
42 - - - - 3-CH3, 4-CH3 >60 
       
[a] IC50 values confirmed with exact amount of material;  
[b] The value has been extrapolated from an incomplete dataset, where only with one point is below 
the second plateau.  
[c] This compound was tested also against E. coli IspC, resulting in an IC50 value of 79 ± 11 μM. 
 
As discussed above, 32, bearing the amino group, was also approximately three-fold more 
active than the corresponding methylated compound 22. One the other hand, 35 and 31, 
which differ only in the presence of the amino group on ring C, resulted in comparable IC50 
values. The same holds true for 38, closely related to 23. It is therefore rather difficult to 
draw any conclusion about how important the amino group on these scaffolds is for the 
inhibitory potency. 
If the amino-substituted thiazolium ring in C is replaced by a six-membered aromatic ring, 
ideally substituted with polar groups to decrease the lipophilicity (3942), the inhibitory 
 168 
 
 Chapter 6 
activity decreases. It might therefore be better to keep the amino-substituted thiazolium 
ring in C and exploit different substitutents on part A. However, compounds 43 and 44 
(Figure 2), might be worthwhile exploring further, given that they display double-digit 
micromolar IC50 values while, being more polar than most of the compounds screened, 
including their direct analogues (22, 32 (Table 6) and 45 (Table 7), analogues of 43). 
 
Figure 2. Structures of 43 and 44. 
An interesting series of compounds resulted from the replacement of the thiazole ring C 
with a pyridine ring, as shown in Table 7 (4550). However, the inhibitory potencies are 
overall worse than those observed for compounds 3238, except for 49 and 50, which 
have IC50 values of 25 ± 6 μM and 55 ± 5 μM, respectively. The presence of the pyridinyl 
nitrogen atom seems essential given that 51 did not result in any inhibitory activity at 60 
μM. 
Table 7. Derivatives of 14 with a pyridinyl ring in part C 
 
Comp. X R IC50 
M. tub DXS (μM) 
46 N 2-CF3 86 ± 5 
45 N 3-CF3 168 ± 18 
47 N 2-F 100 ± 27 
48 N 4-F 101 ± 35 
49 N 2, 5-CH3 25 ± 6 
50[c] N 3, 4-CH3 55 ± 5[a, b] 
51 C 3, 4-CH3 >60 
 
[a] IC50 values confirmed with exact amount of material;. 
[b] The value has been extrapolated from an incomplete 
dataset, where only with one point is below the second 
plateau.  
[c] This compound was tested also against E. coli IspC, 
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Another series of compounds we found during the LBVS of 14 has the general scaffold 
depicted in Figure 3. Although some derivatives gave double-digit micromolar IC50 values, 
we believe it is not worthwhile investigating this scaffold further, given that the inhibitory 
potency is in the same range as the one displayed by much smaller molecules as 
discussed before. 
 
Figure 3. General scaffold of the tetracyclic scaffolds coming from the LBVS of 14. 
 
6.7   Discussion of structure-activity relationships (SARs) 
In this Section, we will present the most active scaffolds we identified within our LBVS 
campaign and we will briefly discuss the SARs. Although we will report also the inhibitory 
potencies against the model enzyme D. radiodurans DXS (when available), we will focus 
on the results we obtained against M. tuberculosis DXS, our target enzyme. 
8, derived from 5 as reference molecule, is a double-digit micromolar inhibitor of 
M. tuberculosis DXS. As one can observe by comparing the IC50 value of 8 with those of 
52, 53 and 54, the presence of the ethylene hydroxyl group as R2 seems fundamental for 
the inhibitory potency (Table 8). As for R1, a correct interpretation of the SARs is not 
possible, given that we could only test 5559 at relatively high concentrations because of 
solubility issues (Table 8). Methyl substituents on the fused pyridine ring (structures not 
shown) did not lead to any improvement in the inhibitory potency. 8 turned out to be a 
potent inhibitor of E. coli IspC, with an IC50 in the single-digit micromolar range. As a result, 
it could be interesting to test it against pathogenic orthologues of IspC as well as to exploit 
it as a multi-target inhibitor of both DXS and IspC. In the context of our project, we decided 
not to follow up on this compound given that, despite displaying a double-digit micromolar 
IC50 value against M. tuberculosis DXS, it has a higher Mw compared to 14, 15 and (E)-16. 
Moreover, as we will discuss in Section 6.10, it did not show any activity in the cell-based 
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Table 8. SARs of compound 8. 
 
Comp. R1 R2  R2   
     D. rad 
DXS 
M. tub  
DXS 
8[b] cyclohexyl CH2CH2OH C- 2-CH3, 3-Cl 17 ± 4[a] 60 ± 5[a] 
52 cyclohexyl CH3 CH 2-F 12 ± 4 >80 
53 cyclohexyl CH2CH3 CH 4-F >30 >60 
54 cyclohexyl C- 3-CF3 >30 >60 
55 CH3 CH2CH2OH C- 3-OH, 4-COOH nd >60 
56 CH2CH2CH3 CH2CH2OH C- 3-COOH, 4-OH nd >60 
57 
 
CH2CH2OH CH 4-CH3 42 ± 10 >60 
58 
 
CH2CH2OH CH 4-OCH3 nd 136 ± 32 
59 
 
CH2CH2OH CH 4-N(CH2CH3)2 >40 >60 
[a] IC50 values confirmed with exact amount of material. 
[b] This compound was also tested against E. coli Ispc, resulting in an IC50 = 3 ± 0.4 μM 
 
All the derivatives of compound 9 (obtained from 5 as the reference compound for the 
LBVS) that we purchased, bearing different substituents on the phenyl ring (Figure 4; e.g., 
R1, R2, R3 = halogens, hydroxyl groups) resulted in complete loss of the inhibitory potency. 
One could still explore multiple substitution patterns on the fused aromatic ring. However, 
given the fact that the scaffold is particularly hydrophobic and planar, we do not believe 9 
is the ideal hit to be followed up. 
 
Figure 4. Compound 9, one hit identified during the LBVS campaign. 
10 is closely related to 15, discussed in Section 6.6. As one can see from Table 9, 
substitution on the benzyl ring is essential. In fact, the completely unsubstituted derivative 
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(60), is ten times less active than 10 against M. tuberculosis DXS. The only substitution 
pattern among the ones shown in Table 9 (compounds 6166), which retains the inhibitory 
potency to a certain extent, is the 2,6-dichlorinated compound 65. Although 15 is more 
promising than 10 in terms of its inhibitory potency (IC50 = 56 ± 12 μM, M. tuberculosis 
DXS, Table 4), the data reported in Table 9 might be useful for the optimization of 15. 








(E)-11 is closely related to (E)-16, featuring two phenyl substituents on the oxime carbon 
rather than one phenyl and one benzyl substituent. As for the derivatives of 10, derivatives 
of (E)-11 shown in Table 10 might be useful to improve the inhibitory activities of (E)-16, 
which resulted in a much better inhibitory potency (IC50 = 56 ± 11, M. tuberculosis DXS, 
Table 4) than (E)-11 (IC50 = 528 ± 43, M. tuberculosis DXS, Table 10). As expected, the 
absence of any substituent on both phenyl rings, causes loss of activity (67). Moving the 
fluorine atom from the para to the ortho position ((E)-68), retains the inhibitory potency, 
while substituting the para-fluorine atom with a methyl group causes loss of the inhibitory 
activity (69). The presence of a 2-amino-5-chloro pattern ((E)-70) replacing the dihydroxyl 
pattern, enhances the inhibitory potency almost two fold with respect to (E)-11, although a 
direct comparison among the two compounds is not possible, due to the different 
substitution pattern on R2. However, by comparing the inhibitory potencies of 67 and (E)-
70, one could conclude that the 2-amino-5-chloro pattern might be worthwhile exploring 
more. Interestingly, when replacing the oxime moiety with a hydrazone moiety on (E)-70 
(structure not shown), the biochemical activity is retained (IC50 = 287 ± 140 μM). 
 
 
Comp. R1 IC50 
  D. rad. DXS M. tub. DXS 
    
10 4-iPr 298 ± 30[a] 317 ± 29[a] 
60 H nd 2900 ± 600 
61 3-CH3 >1000 >500 
62 4-tBu 243 ± 89 >300 
63 4-Cl 1308 ± 138 >500 
64 4-F >1000 >1000 
65 2,6-Cl nd 465 ± 167 
66 2-F, 6-Cl nd 900 ± 300 
 
 [a] IC50 values confirmed with exact amount of material. 
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Table 10. SARs of compound (E)-11. 
 
Comp. X R1 R2 IC50 
    D. rad. DXS M. tub. DXS 
      
(E)-11[b] CH 4-F 2, 4-OH 1385 ± 150[a] 528 ± 43[a] 
67 CH H H nd >600 
(E)-68 CH 2-F 2, 4-OH 914 ± 167 520 ± 45 
69[b] CH 4-CH3 2, 4-OH >1000 >1000 
(E)-70 CH H 2-NH2, 5-Cl nd 282 ± 128 
 
[a] IC50 values confirmed with exact amount of material. [b] The geometry of 
the double bond is unknown. 
 
Other scaffolds resulting in interesting IC50 values against M. tuberculosis DXS are 
reported in Table 11, which one could also explore as hits. 
 







M. tub. DXS 
165 ± 21 473 ± 188 
 
6.8   Distribution of molecular weight and cLogP among all hits of our LBVS project 
According to Lipinski’s rule of five, drug-like molecules with the potentiality to have good 
absorption and permeation properties, therefore being likely orally active drugs, should 
contain no more than five H-bond donors and ten H-bond acceptors, should have a Mw 
below 500 Dalton and a cLogP value (where c stands for calculated and P is the partition 
coefficient between octanol and water) not greater than five.34 In analogy to the rule of five, 
a rule of three has been introduced for fragment-based projects. Typically, fragments 
should have Mw < 300 Dalton, cLogP < 3, and fewer than three H-bond acceptors and 
donors. 35   
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We performed a detailed analysis of the whole series of compounds screened in our LBVS 
in terms of their Mw and cLogP (calculated with Chemaxon).33 As shown in Figure 5, all 
compounds tested have Mw < 500, with a mean value of 307 Dalton. In fact, a considerable 
number of them still belongs to the fragment world (Mw < 300), which is not surprising 
considering that the initial reference molecules were also fragments. Our most promising 
hits mainly range from Mw of 290 to 380 Dalton, showing that there is still room for 









Figure 5.  Distrubution of molecular weights (Mw) among the compounds tested during 
the three rounds of LBVS. 
 
As shown in Figure 6a, compounds with Mw < 300 have a mean cLogP value of 2.57, but 
most of the hits tend to be too hydrophobic according to the rule of three. Figure 6b 
represents the same type of distribution for compounds with Mw > 300. We can observe 
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 (a) (b) 


















Figure 6. cLogP distribution of the compounds tested during the three rounds of VS. (a) 
Compounds with Mw < 300; (b) Compounds with Mw > 300. The cLogP values were 
calculated with Chemaxon. 
 
6.9 Biochemical evaluation of the most potent hits against a mammalian thiamine 
diphosphate-dependent enzyme: pyruvate dehydrogenase 
As we discussed in Chapter 1 of this thesis, DXS has weak homology with other TDP-
dependent enzymes. The homology (identity) is particularly high within the TDP-binding 
pocket. Even though the binding mode of our most potent hits has not yet been 
established, we wanted to evaluate their activity against a representative mammalian TDP-
dependent enzyme. Given its commercial availability, we chose porcine pyruvate 
dehydrogenase (PDH). The PDH complex plays a vital role in cellular metabolism, 
catalyzing the oxidative decarboxylation of pyruvate and the subsequent acetylation of 
coenzyme A to acetyl-coenzyme A, which can enter the citric acid (Krebs) cycle.36  The E1 
subunit of the PDH complex is a TDP-dependent enzyme.37 
We ran the PDH assay in the optimal conditions for this enzyme, which differs from those 
adopted for the DXS assay, as described in detail in the experimental part. Nevertheless, 
the relative concentrations of pyruvate and TDP in both assays, with respect to their 
corresponding Km values, was kept the same (6 x Km and 6.5 x Km for pyruvate and TDP, 
respectively) for better comparison of the activity of our inhibitors against both enzymes. 
By dissolving each compound in 100% DMSO and slowly adding water to each solution, 
we could reach higher concentrations of the inhibitors in the assay media than the highest 
ones achieved in the DXS assay. We could in fact test most of the compounds at 100 or 
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36, 32 and 50 did not inhibit porcine PDH at 100 μM. Although every measurement was 
previously blanked by measuring the absorbance of each solution of inhibitor in DMSO at 
every concentration, we did observe slightly different initial absorbances for different 
batches of the same inhibitor at the zero point of the measurement for 32, 36 and 50. This 
fact could arise from the inhibitors reacting with one or more components of the PDH 
storage buffer and does not affect our qualitative evaluation of the data, although the actual 
concentration of every inhibitor in solution might be lower than the one we report. 
These results are very promising and suggest that selective inhibition of the pathogenic 
DXS over mammalian TDP-dependent enzymes might be possible. 
 
6.10 Cell-based assays against multiple strains of M. tuberculosis 
Thanks to a collaboration with the Rijksinstituut voor Volksgezondheid en Milieu, in 
Bilthoven (The Netherlands), we could obtain information about the potency of our best 
hits – based on the results of the in vitro biochemical assay – also in cell-based assays 
against multiple strains of tuberculosis (TB), including drug-resistant (DR), multi-drug 
resistant (MDR) and extensively-drug resistant (XDR) strains, as defined in Table 12.  
Table 12. List of all the strains of Mycobacterium tuberculosis used in our cell-based 
assays with the corresponding commercially available drugs to which they are resistant. 
DR-, MDR- and XDR-TB indicate drug-resistant, multidrug-resistant and extensively-
drug resistant strains of tuberculosis. 
 
A H37Rv All-susceptible 
(control strain) 
- 
B 1010900234[a] All-susceptible - 
C 1011000848[a] DR-TB Isoniazide 
D 1011200081[a] DR-TB Isoniazide 
E 1011200189[a] MDR-TB Isoniazide, rifampicine, ethambutol, 
streptomycin, pyrazinamide 
F 1011200345[a] MDR-TB Isoniazide, rifampicine, ethambutol, 
streptomycin, pyrazinamide, ciprofloxacin, 
clarithromycin 
G 1010900268[a] XDR-TB Isoniazide, rifampicine, ethambutol, 
streptomycin, pyrazinamide, kanamycin, 
capreomycin 
H 1010901542[a] XDR-TB Isoniazide, rifampicine, ethambutol, 
streptomycin, kanamycin. 
    
[a] The numbers correspond to patient isolate strains of M. tuberculosis, as identified with 
the reverse line blot from the company Hain Lifescience. 
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As mentioned before in the contest of this thesis, the discrepancy between in vitro 
inhibitory potency of a potential antituberculotic drug and its cell-based activity can be 
striking due to the remarkably thick and hydrophobic cell wall of M. tuberculosis. Therefore, 
it is particularly important to obtain and compare in vitro and cell-based activities when it 
comes to the early stages of development of an antituberculotic drug. We first tested the 
best hits obtained from the first round of virtual screening, namely 8(E)-11 (Table 13). All 
compounds, except for 8, showed moderate inhibition of bacterial growth of four different 
strains of TB, having MIC values between 10 and 100 μg/mL. When comparing the cLogP 
values of 8(E)-11, we realized that 8 has the lowest cLogP value of this series (2.37): the 
particularly polar character of 8 might explain why it is the only compound not displaying 
cell-based activity. 
Table 13. Minimum inhibitory concentration (MIC) values of 8(E)-11, 5 and 
71 against multiple strains of M. tuberculosis 
 
 MIC (μg/mL) 
 Strain A Strain B Strain E Strain F 
     
8 >100 >100 >100 >100 
9 10100 10100 10100 10100 
10 10100 10100 10100 10100 
(E)-11 10100 10100 10100 10100 
     
5 >100 >100 >100 >100 
 
71 >100 >100 >100 >100 
 
Despite being only moderate inhibitors of D. radiodurans DXS in vitro (5: IC50 = 430 ± 68 
μM; 71: IC50 = 109 ± 16 μM) and not showing any activity against M. tuberculosis DXS, 
thiamine derivatives 5 and 71 were also tested to investigate their potential as pro-drugs. 
In fact, whereas polar, diphosphorylated compounds cannot  permeate the bacterial cell 
wall – even in humans, external forms of thiamin such as thiamin phosphates are 
hydrolyzed to thiamin prior to uptake –, their dephosphorylated analogues could enter the 
cells, where they would be “activated” by being (di)phosphorylated. 
To better understand the role of thiamine analogues as potential pro-drugs, we studied in 
detail how bacteria synthesize thiamine and thiamine diphosphate, the essential cofactor 
for many metabolic reactions. In fact, while many eukaryotes have to take up thiamine 
(vitamin B1) from nutrition, most bacteria can produce thiamine and its diphosphorylated 
form de novo. Moreover, salvage and transport pathways, complement the necessity of 
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thiamine for most bacteria (Scheme 1).38 On the one hand, the synthesis of TDP in 
bacteria, goes through the corresponding thiamine monophosphate, which is 
phosphorylated by thiamine phosphate kinase (ThiL). On the other hand, many enzymes 
involved in the bacterial salvage pathways are responsible for the mono- or 
diphosphorylation of thiamine or its intermediates, such as ThiD (pyrimidine salvage, not 
shown), ThiK and ThiN (thiamine salvage, Scheme 1). M. tuberculosis lacks these salvage 
pathways and only relies on the de novo thiamine synthesis.39 This could be the reason 
why no cellular activity was observed for 5 and 71, which cannot be mono- or 
diphosphorylated within mycobacterial cells and are too weak to inhibit mycobacterial 
growth. It must be underlined that, in general, the strategy of taking advantage of kinases 
within the cells to activate pro-drugs, might be quite challenging, mainly due to the critical 
step of the substrate-recognition process.40, 41 
Scheme 1. Last three steps of the thiamine diphosphate biosynthesis in bacteria and two 
steps of thiamine salvage pathway. Enzymes involved in thiamine diphosphate 
biosynthesis are shown in bold and underlined. Enzymes involved in the thiamine salvage 
pathway are shown in italics. 
 
We obtained the results of the cell-based assay described in Table 13 at the same time as 
the in vitro inhibitory potencies of compounds 14, 15, 32, (E)-16 and 36, which turned out 
to be much more active. Therefore, we decided to focus on the last series, and accurately 
establish their cell-based activities. 
Preliminary tests to check the cell-based activity of 14, 15, 32, 36, (E)-16 and BAT_225 
were performed, where all compounds were tested for their ability to inhibit the growth of 
multiple strains of M. tuberculosis at a concentration of 20 μM. While for 14, 15, 32, 36 and 
(E)-16 a MIC value < 20 μM was measured, 50 did not inhibit the growth of most of the 
strains. The compounds resulting in no growth of M. tuberculosis at 20 μM (14, 15, 32, 36 
and (E)-16) were subsequently tested against multiple strains at different concentrations, 
namely 10, 5, 2.5 and 1.25 μM in a Middlebrook 7H10 agar medium. The results are 
summarized in Table 14. Although the results for 14 have to be finalized, one can conclude 
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that 14 has the most potent cellular activity of this series. Its close analogue 32 also 
displays good cellular activity, while 36 is slightly less potent. The other two scaffolds, 15 
and (E)-16 are overall less potent. 
Table 14. Minimum inhibitory concentration (MIC) values for compounds 14, 15, 32, (E)-
16, 36 against multiple strains of M. tuberculosis, including multi- and extensively-drug 
resistant strains. 
 
 MIC (μM) 
Strain        B               A               C               E                F               G               H 
  
14 2.55[a] 1.252.5[a] nd 1.252.5[a] nd <1.25 1.252.5[a] 
15 10 10 10 5 5-10[a] 510[a] 510[a] 
32 5 5 5 2.55[a] 5 2.55[a] 2.55[a] 
(E)-16 10 10 10 10 10 10 510[a] 
36 510[a] >10 5 5 10 510[a] 510[a] 
        
[a] The lower value of the range corresponds to the concentration (μM) at which the inhibitor causes 
less growth than 1% of the control. The higher value of the range corresponds to the first well of the 
series, where no growth is observed. 
 
6.11 Cytotoxicity assays and preliminary cell-based assays against Plasmodium 
falciparum 3D7 
A selection of compounds from our LBVS campaign, namely 5, 68, 78, 88 and 14, as 
DMSO solutions, has also been tested for their potential antimalarial activities. 5, 10 and 
(E)-11 were incubated in a P. falciparum 3D7 culture at 1 mg/mL for 48 hours, with an 
initial parasitemia of 2%. 9 was incubated at 8.6 mg/mL. Additionally, a P. falciparum 
culture control with 1% v/v DMSO was analyzed. The parasitaemia was measured by flow 
cytometry and standardized to the control. As shown in Figure 7, 5 has almost no 
antimalarial effect compared to the control, while 14 reduces the parasitemia of about 20%.  
 
Figure 7. Evaluation of the antimalarial effect in P. falciparum 3D7 of 5, 9, 10, (E)-11 and 
14. As control, P. falciparum 3D7 with 1% v/v DMSO was used. 
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10 and (E)-11 caused complete lysis of erythrocytes, which is why no data could be 
collected. A similar result was observed for 9, which caused partial lysis of the red blood 
cells. 
 
6.12 Conclusions and follow up 
LBVS proved to be a successful strategy for the identification of hits that are able to inhibit 
M. tuberculosis DXS in the low micromolar range. LBVS is a particularly useful hit-
identification strategy when no or little structural information is available, which is the case 
for DXS. LBVS allowed us to explore a wide spectrum of chemical diversity, starting from 
the structures of three DXS inhibitors that we identified as described in Chapter 2. By 
purchasing closely related derivatives of the hit or lead compounds, we obtained a first 
series of SARs; a systematic evaluation of SARs will, however, require the chemical 
synthesis of more derivatives. A few, straightforward chemical routes for the synthesis of 
derivatives of the most interesting hits are proposed in Section 6.12.1. Many of the 
compounds we tested tend to be too hydrophobic (Figure 6), rendering their biochemical 
evaluation challenging, leading to often incomplete datasets. Moreover, having too 
hydrophobic scaffolds is not ideal for a potential drug. Therefore, especially for fragment-
like hits, the optimization stage should be aimed at enhancing both potency and polarity.  
We confirmed that selective inhibition of DXS over mammalian TDP-dependent enzymes 
is possible, by testing a few compounds against porcine PDH, a representative 
mammalian TDP-dependent enzyme. Our hits are active against multiple strains of 
M. tuberculosis, including MDR- and XDR-strains. In particular, 14 was identified as the 
most potent compound in the cell-based assays. Interestingly, 14 was also found to be the 
only compound among the LBVS hits we tested, having a weak antimalarial effect, 
reducing parasitemia by about 20% in a cell-based assay with P. falciparum 3D7. Building 
on this promising initial result, 15, (E)-16, 32 and 36 are going to be subjected to the same 
assay. 
The fact that the mycobacterial activity of 14 and the other compounds is due to inhibition 
of DXS should be also confirmed, by performing experiments to rescue the bacterial 
growth, for instance by supplementing the growth medium with 1-deoxy-D-xylulose (DX) – 
which is capable of penetrating the cell and undergoing intracellular phosphorylation to 
yield the product of the DXS-catalyzed reaction –42  or by overexpressing DXS. The fact 
that DXS is a branch point in bacterial metabolism, further complicates the validation of 
the intracellular target. Additional biosynthetic pathways including TDP and pyridoxal 
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phosphate biosynthesis should be affected by DXS inhibition, therefore rescue studies 
should also take these pathways into account (e.g., external supplementation of thiamine). 
Understanding the binding mode of the most potent representative scaffolds 14, 15 and 
(E)-16 by establishing their mode of inhibition or by using the STI-NMR methodology 
described in Chapter 2, is, without any doubt, the next step to rationally improve the in vitro 
inhibitory potencies of these scaffolds. Once the mode of inhibition has been established, 
one could perform docking studies focused on the specific subpocket where the molecule 
binds (substrate- or cofactor-binding pocket). These studies, together with a more 
complete set of SARs, would certainly guide a rational optimization of the best inhibitors. 
However, we would like to underline once more that the discrepancy between in vitro and 
cell-based data, especially for the development of antituberculotic drugs, can be dramatic. 
Therefore, it might be a good idea to perform the two assays in parallel, as much as is 
practically possible. 
 
6.12.1 General approaches for the synthesis of derivatives of the best hits 
As reported in the literature, 15 and many derivatives of this scaffold can be conveniently 
synthesized according to the retrosynthetic scheme shown in Scheme 2a.43 This route 
allows for exploring various substituents on the indole and phenyl rings, according to the 
commercial availability of the corresponding starting materials (or the possibility to 
conveniently synthesize them). The importance of the hydroxymethylene moiety on 15 
could also be explored by testing all corresponding aldehyde derivatives as well as by 
replacing it with other functional groups (e.g., -CH2CH2OH, CH2CH2CH2OH, H, CN, 
COCH3 etc..).43 
Oxime (E)-16 can be synthesized from the corresponding ketone, which can be obtained 
by a Friedel-Crafts reaction of resorcinol and para-chloro phenylacetic acid.44 Many 
derivatives of (E)-16 have been reported in the literature, but they all contain one phenyl 
ring (ring A) with two or three hydroxyl or methoxy groups.45 By using this methodology, 
one can exploit multiple substitution patterns on ring B (halogens, -OCH3, -NO2, Scheme 
1b),44 while the groups on ring A are limited to electron-donating groups. If the ring is 
sufficiently activated, some alkyl substituents might also be introduced. Derivatives with 
electron-withdrawing groups on A ring could be accessed by reacting a cyanide with a 
Grignard reagent (Scheme 2b).46 
We tested many derivatives of 14, which are all commercially available. However, to 
explore even more chemical diversity, one could follow the synthetic approach as shown 
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in Scheme 2c, where the second thiazolyl ring is formed in a ring-closing reaction in the 
last step. This synthetic approach allows access to a great variety of scaffolds, as already 
reported in the literature.47 
 
Scheme 2. Proposed retrosynthetic approaches for synthesizing more derivatives of 15, 
(E)-16 and 14. 
 
6.13 Experimental 
Characterization of compounds purchased in higher amount 
The compounds were purchased in 1 mg batches and directly dissolved in DMSO without 
further purification, so as to obtain 80 mM solutions, when possible. Their solubility in the 
assay buffer was tested prior to the inhibitory assay so as to reach 1000 μM as the highest 
concentration tested when possible. The most active compounds were re-ordered in 
higher amount (typically 25 mg) from Princeton Biomolecular Research, except otherwise 
mentioned, and analyzed by NMR and MS prior to IC50 determination. If the purity of the 
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sample as received from the supplier was below 95% (determined by Ultra-High 
Performance Liquid Chromatography (UHPLC) at 214 nm, they were further purified by 
reversed phase (RP)-HPLC, as described below. Low-resolution mass spectra were 
obtained by electron-spray ionization (ESI) in the positive mode on a Thermo Scientific 
LCQ Fleet. 1H-NMR spectra were obtained at 300 MHz with a Bruker AV300 spectrometer. 
Compound purity was determined by analytical RP-UHPLC. Analytical RP-UPLC was 
performed on a Dionex Ultimate 3000 RSLC System (DAD-3000 RS Photodiode Array 
Detector) and a Dionex Acclaim RSLC 120 column (C18, 3.0 x 50 mm, particle size 2.2 μm, 
120 Å pore size) at a flow rate of 1.2 mL min1. Compounds were detected by UV-
absorption at 214 nm. Data recording and processing was done with Dionex Chromeleon 
Management System Version 6.8. Preparative RP-HPLC was performed with Waters Prep 
LC4000 Chromatography System using a Reprospher 100 (C18-DE, 100 mm x 30 mm, 
particle size 5 μm, 100 Å pore size) column from Dr. Maisch GmbH and a Waters 489 
Tunable Absorbance Detector operating at 214 nm.  
Eluents for analytical RP-UHPLC were as follows: A: miliQ-deionized water with 0.05% 
TFA and D: HPLC-grade acetonitrile/miliQ-deionized water (9:1) with 0.05% TFA. The 
gradients for the analytical RP-UHPLC were: Method A: 100% A to 100% D in 2.2 minutes, 
Method D: 90%A/10%D to 100%D in 2.2 minutes and Method E: 80% A to 20% D to 
100%D in 2.2 minutes.  
Eluents for preparative RP-HPLC were as follows: A: miliQ-deionized water with 0.05% 
TFA, C: HPLC-grade acetonitrile/miliQ-deionized water (6:4) with 0.1% TFA and D: HPLC-










1H-NMR (300 MHz, DMSO-d6): δ=8.77 (dd, J = 1.6, 6.7, 
1H), 8.07 (br s, 1H), 7.89 (ddd, J = 1.6, 6.7, 8.7, 1H), 7.64 
(s, 1H), 7.34 (d, J = 8.7, 1H), 7.13 (td, J = 1.3, 6.7, 1H), 
4.93 (br t, J = 12.1, 1H), 4.77 (t, J = 5.5, 1H), 3.68–3.50 
(m, 4H), 2.45–2.22 (m, 2H), 1.93–1.75 (m, 2H), 1.75 – 
1.54 (m, 3H), 1.44–1.06 (m, 3H). LC-MS (ESI+): m/z 
431.12 ([M+H] +). Purity of the sample by RP-UHPLC 
could not be measured because it was insoluble in the 
eluents required for the measurement. 
4-(2,4-Dichlorophenyl)-4,10-dihydro-1H-[1,3,5]triazino[1,2-a]benzimidazole-2-
amine (9, supplier ID: OSSK_676817) 
 
 
1H-NMR (300 MHz, DMSO-d6): δ=8.04 (br s, 1H), 7.73 (d, 
J = 2.0, 1H), 7.45 (dd, J = 2.0, 7.8, 1H), 7.26 (d, J = 7.3, 
1H), 7.08 (m, 2H), 6.96 (t, J = 7.3, 1H), 6.80 (t, J = 7.3, 
1H), 6.62 (d, J = 7.8, 1H), 6.40 (br s, 2H). LC-MS (ESI+): 
m/z 332.14 ([M+H, Cl35]+), 334.07 ([M+H, Cl37]+). Purity of 
the purchased sample by RP-UHPLC (method A, tR = 1.8 
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1H-NMR (300 MHz, DMSO-d6): δ=7.61–7.53 (m, 1H), 
7.49–7.41 (m, 1H), 7.22–7.11 (m, 4H), 7.03 (d, J = 8.2, 
2H), 5.46 (s, 2H), 4.85 (t, J = 5.5, 1H), 3.85 (q, J = 6.8, 
2H), 3.00 (t, J = 6.8, 2H), 2.82 (d, J = 6.9, 1H), 1.15 (d, J 
= 6.9, 6H). LC-MS (ESI+): m/z 295.12 ([M+H]+). Purity of 
the purchased sample by RP-UHPLC (method A, tR = 1.8 
min) = 99%. 
4-[(4-Fluorophenyl)(hydroxyimino)methyl]benzene-1,3-diol  





This compound was purified by RP-HPLC (Gradient 85% 
A 15% D to 100% D in 40 minutes) prior to testing it. 1H-
NMR (300 MHz, DMSO-d6): δ=11.37 (s, 1H), 11.26 (s, 
1H), 9.77 (s, 1H), 7.39–7.25 (m, 4H), 6.53 (d, J = 8.6, 1H), 
6.31 (d, J = 2.4, 1H), 6.21 (dd, J = 2.4, 8.6, 1H). LC-MS 
(ESI+): m/z 248.02 ([M+H]+). Purity of the sample after RP-
HPLC purification, assessed by RP-UHPLC (method A, tR 
= 2.0 min) = 98%. 
 
2-Amino-6,7-dihydro-6-(1-(4-isopropylphenyl)ethyl)pyrrolo[3,4-d]pyrimidin-5-one 
(13, supplier ID: OSSL_332078) 
 
1H-NMR (300 MHz, DMSO-d6): δ=8.51 (s, 1H), 7.38 (br s, 
2H), 7.29–7.16 (m, 4H), 5.41 (q, J = 7.2, 1H), 4.37 (d, J = 
18.4, 1H), 3.91 (d, J = 18.4, 1H), 2.85 (hept, J = 6.9, 1H), 
1.57 (d, J = 7.2, 3H), 1.17 (d, J = 6.9, 6H). LC-MS (ESI+): 
m/z 297.11 ([M+H]+). Purity of the purchased sample by 
RP-UHPLC (method D, tR = 1.9 min) = 98%. 
  
N-(3-Chloro-2-methylphenyl)-4-(2,4-dimethylthiazol-5-yl)thiazol-2-amine 




1H-NMR (300 MHz, DMSO-d6): δ=9.63 (s, 1H), 7.92–7.80 
(m, 1H), 7.28–7.16 (m, 2H), 6.93 (s, 1H), 2.57 (s, 3H), 2.48 
(s, 3H), 2.32 (s, 3H). LC-MS (ESI+): m/z 336.12 ([M+H, 
Cl35]+), 338.01 ([M+H, Cl37]+). Purity of the purchased 
sample by RP-UHPLC (method A, tR = 2.2 min) = 99%. 
 
(1-(3,4-Dichlorobenzyl)-1H-indol-3-yl)methanol  






15 was purchased from Specs. 1H-NMR (300 MHz, 
DMSO-d6): δ=7.61 (d, J = 7.8, 1H), 7.57 (d, J = 8.3, 1H), 
7.50 (d, J = 2.0, 1H), 7.46–7.39 (m, 2H), 7.15 (dd, J = 2.0, 
8.3, 1H), 7.12–7.07 (m, 1H), 7.06–6.99 (m, 1H), 5.39 (s, 
2H), 4.82 (t, J = 5.3, 1H), 4.64 (d, J = 5.3, 2H). MS (ESI+): 
m/z 288.03 ([M-OH, Cl35]+), 290.03 ([M-OH, Cl37]+). Purity 
of the sample by RP-UHPLC could not be measured 
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4-[(4-Chlorobenzyl)(hydroxyimino)methyl]benzene-1,3-diol  
(16, supplier ID: ID STK858385) 
 (E)-16 was purchased from Vitas-M. 1H-NMR (300 MHz, 
DMSO-d6): δ=11.65 (s, 1H), 11.50 (s, 1H), 9.72 (s, 1H), 
7.34 (d, J = 8.7, 2H), 7.30–7.22 (m, 3H), 6.28–6.22 (m, 
2H), 4.16 (s, 2H). LC-MS (ESI+): m/z 278.12 ([M+H, 
Cl35]+), 280.11 ([M+H, Cl37]+). Purity of the purchased 
sample by RP-UHPLC (method E, tR = 1.9 min) > 99%. 
 
4-(2-Amino-4-methylthiazol-5-yl)-N-(4-(trifluoromethyl)phenyl)thiazol-2-amine  
(27, supplier ID: OSSK_523240) 
 
1H-NMR (300 MHz, DMSO-d6): δ=10.65 (s, 1H), 7.82 (d, 
J = 8.46, 2H), 7.65 (d, J = 8.46, 2H), 7.01 (s, 2H), 6.72 (s, 
1H), 2.33 (s, 3H). LC-MS (ESI+): m/z 357.14 ([M+H]+). 
Purity of the purchased sample by RP-UHPLC (method E, 
tR = 1.6 min) = 97%. 
4-(2-Amino-4-methylthiazol-5-yl)-N-(3-(trifluoromethyl)phenyl)thiazol-2-amine  
(32, supplier ID: STK729380) 
 
 
32 was purchased from Vitas-M. 1H-NMR (300 MHz, 
DMSO-d6): δ=10.61 (s, 1H), 8.41 (s, 1H), 7.64 (d, J = 7.9, 
1H), 7.53 (t, J = 7.9, 1H), 7.28 (d, J = 7.9, 1H), 7.12 (br s, 
2H), 6.69 (s, 1H), 2.35 (s, 3H). LC-MS (ESI+): m/z 357.14 
([M+H]+). Purity of the purchased sample by RP-UHPLC 
(method E, tR = 1.6 min) = 95%. 
N-(4-(2-Amino-4-methylthiazol-5-yl)thiazol-2-yl)-5-chloropyridin-2-amine  




36 was purchased from Vitas-M. 1H-NMR (300 MHz, 
DMSO-d6): δ=11.50 (s, 1H), 8.34 (d, J = 2.29, 1H), 7.81 
(dd, J = 2.62, 8.89, 1H), 7.11 (d, J = 8.48, 1H), 7.01 (br s, 
2H), 6.80 (s, 1H), 2.31 (s, 3H). LC-MS (ESI+): m/z 324.14 
([M+H]+). Purity of the purchased sample by RP-UHPLC 
(method A, tR = 1.9 min) = 97%. 
 
Cell-based assays with Mycobacterium tuberculosis strains. A series of drug-
susceptible, DR, MDR and XDR M. tuberculosis isolates, and one control strain (H37Rv) 
were selected and subcultured on a Middlebrook 7H10 agar medium until use. 
Susceptibility testing using the absolute concentration method was carried out by 
preparing 25-well plates with solid 7H10 medium containing different concentrations (20, 
10, 5, 2.5, 1.25 μM) of each inhibitor. The plates were subsequently inoculated by adding 
10 μL Mycobacterium suspension to each well. Then the plates were incubated at 35.5 °C 
in a CO2 incubator. After appropriate incubation, the MICs were assessed. The reading of 
the plates was carried out when the bacterial growth on the two control wells without 
inhibitor was sufficient, i.e., when colonies were clearly visible. 
Preliminary cell-based assays against Plasmodium falciparum 3D7. These assays 
were conducted according to literature procedures. 
Spectrophotometric assay for determining the biochemical activity against pyruvate 
dehydrogenase complex 
Pyruvate dehydrogenase from porcine heart was purchased from Sigma Aldrich as a 
buffered aqueous 50% glycerol solution containing approximately 9 mg/mL bovine serum 
albumin, 30% sucrose, 1.5 mM EDTA, 1.5 mM ethylene glycol tetraacetic acid (EGTA), 
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1.5 mM 2-mercaptoethanol, 0.3 TRITON® X-100, 0.003% sodium azide, and 15 mM 
potassium phosphate, pH 6.8. Each inhibitor was diluted in 100% DMSO, and bidistilled 
water was slowly added. The solutions were vortexed, and then the rest of the assay 
components was added in the following order: (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH = 8 (100 mM), bovine serum albumin (1 
mg/mL), cysteine (2 mM), TDP (0.325 μM), coenzyme-A (150 μM), (tris(2-
carboxyethyl)phosphine (TCEP, 300 μM), pyruvate (150 μM) and MgCl2 (1 mM). The final 
% of DMSO in the assay media was 10%. The assay was carried out as previously 
described.48 The UV/Vis spectrophotometer (Beckman Coulter DU800) was first blanked 
with each solution, and then NAD+ was added to a final concentration of 500 μM. The 
solutions were then preincubated for 5 minutes at 30 °C. Porcine PDH (final concentration 
of 0.01 U/mL) was then added to initiate the reactions which were monitored 
spectrophotometrically by measuring the appearance of NADH at 340 nm over time at 30 
°C. Initial rates of product formation (graphed as [NADH] versus time) were determined 
using Microsoft Excel. 
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Important pathogens such as Mycobacterium tuberculosis and Plasmodium falciparum, 
the causative agents of tuberculosis and malaria, respectively, utilize the 2-C-methyl-D-
erythritol 4-phosphate (MEP) pathway for the biosynthesis of isopentenyl diphosphate 
(IDP) and dimethylallyl diphosphate (DMADP), the universal precursors of isoprenoids. 
The fact that humans exclusively utilize the alternative mevalonate pathway for the 
synthesis of IDP and DMADP, together with the fact that the MEP pathway is essential in 
numerous organisms, make the enzymes of the MEP pathway attractive drug targets for 
the development of anti-infective agents. In particular, due to the emergence of several 
multi- and extensively-drug-resistant strains of M. tuberculosis and P. falciparum, there is 
a growing need for the development of new anti-infective agents with new mechanisms of 
action. Moreover, given that also plants use the MEP pathway for the synthesis of the 
isoprenoid precursors, the enzymes of this pathway are attractive targets for the 
development of herbicides as well. 
In Chapter 1 of this thesis, we give an overview of the most potent inhibitors reported for 
each enzyme of the MEP pathway and we discuss in detail the biological target of the 
research in this thesis, 1-deoxy-D-xylulose 5-phosphate synthase (DXS). DXS catalyzes 
the first and rate-limiting step of the MEP pathway using thiamine diphosphate (TDP) as 
cofactor. The involvement of DXS both in microbial thiamine (vitamin-B1) biosynthesis as 
well as in vitamin-B6 biosynthesis renders it a particularly interesting target, with the benefit 
of interfering with three crucial biosynthetic pathways at once. The two crystal structures 
of DXS in complex with TDP deposited in the Protein Data Bank are not of the pathogenic 
organisms, making the development of inhibitors for this enzyme a challenge. As a result, 
very few inhibitors of DXS have been reported in the literature. 
In this thesis, we present multiple hit-identification strategies aimed at the development of 
inhibitors of DXS, supported by computational studies and the use of biophysical 
techniques. In Chapter 2, we describe the first application of an innovative NMR 
methodology in a fragment-based design project. We first designed de novo a series of 
fragments aimed at occupying the TDP-binding pocket of DXS, with the potential of being 
grown towards the substrate- and diphosphate-binding pockets. We used a three-step 
NMR methodology, which allowed us to validate the binding mode of the fragment hits in 
solution and successfully guide the next cycle of fragment optimization given that a reliable 
protocol for protein crystallography was not available. 
In Chapter 3, we adopt a simple but powerful hit-identification methodology, namely phage 
display, for the development of the first peptidic inhibitors of DXS, displaying low 
micromolar activity against D. radiodurans DXS. We also describe the identification of key 
motifs responsible for the inhibitory activity as well as parts of the α-amino acid sequence, 
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which can be further modified to enhance the inhibitory potency of the peptide. This project 
sets the stage for exploiting peptides as potential anti-infective agents, which is particularly 
interesting given that over the past decade, the use of peptides as drug candidates is being 
increasingly encouraged and pursued, with some peptides having reached the market. 
In Chapter 4, we investigate thiamine analogues as inhibitors of D. radiodurans and 
M. tuberculosis DXS and rationalize the observed differences in inhibitory activity between 
the two orthologues. By advanced docking studies, we were able to develop and validate 
a homology model of M. tuberculosis DXS, which can be used for the rational design of 
inhibitors for M. tuberculosis DXS in the absence of crystallographic information. 
Moreover, we explored sugars as mimics of the diphosphate moiety of TDP. 
In Chapter 5, we describe the development and use of the web-based software TPPQuery, 
which enables a pharmacophore search of anchor-oriented virtual libraries and helps in 
identifying potential TDP-competitive inhibitors that can be synthesized via multi-
component reactions. We discuss the putative binding modes of a selection of scaffolds 
and their synthesis via the Zhu, Van Leusen and Groebke reactions. 
In Chapter 6, we demonstrate the power of ligand-based virtual screening (LBVS) as a hit-
identification methodology, especially in the case when very little structural information is 
available for the target. Starting from the scaffolds of some fragments that we designed 
and tested as reported in Chapter 2, we performed several cycles of LBVS to screen (part 
of) the ZINC database. This allowed us to identify low-micromolar inhibitors of both 
D. radiodurans and M. tuberculosis DXS, with potent activity in cell-based assays against 
MDR and XDR strains of M. tuberculosis. Our most potent inhibitors also display a high 
degree of selectivity over a representative mammalian TDP-dependent enzyme, pyruvate 
dehydrogenase kinase, and one of them has a weak antimalarial effect, reducing 
parasitemia by about 20% in a cell-based assay with the P. falciparum 3D7 strain. 
For a challenging and underexplored drug target such as DXS, the strategy of exploiting 
multiple hit-identification and optimization strategies in parallel, proved to be particularly 
effective. In fact, most of the approaches we employed turned out to be successfully 
complementary. The fragments that we designed de novo as presented in Chapter 2, are 
weak inhibitors of D. radiodurans DXS but served as reference molecules for the LBVS 
campaign. The absence of (co-) crystallographic information is considered a major hurdle 
for a medicinal-chemistry project. However, we demonstrated that this limit can be 
successfully overcome by employing, for instance, advanced NMR spectroscopy or by 
using screening methods for which this information is not necessary, such as phage 
display. The use of structure-based (SB) approaches (e.g., de novo design, SB-
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pharmacophore searches) alone is risky, especially when the only structure available is 
that of a model enzyme. Nevertheless, for example, the use of software like TPPQuery 
allowed us to explore the TDP-pocket with unprecedented and highly diverse scaffolds. 
However, a combination of SB- and LB-approaches maximizes the chances for success 

































Belangrijke pathogenen zoals Mycobacterium tuberculosis en Plasmodium falciparum, de 
ziekteverwekkers van respectievelijk tuberculose en malaria, maken gebruik van de 2-C-
methyl-D-erythritol 4-fosfaat (MEP) route voor de biosynthese van isopentenyl difosfaat 
(IDP) en dimethylallyl difosfaat (DMADP), universele bouwstenen van isoprenoïden. 
Aangezien mensen uitsluitend de alternatieve mevalonaat route benutten voor de 
synthese van IDP en DMADP, in combinatie met het feit dat de MEP route onmisbaar is 
voor veel organismen, maakt dat de enzymen van de MEP route aantrekkelijke doelwitten 
zijn voor de ontwikkeling van ontstekingsremmende medicijnen. De ontwikkeling van 
verschillende multi- en superresistente stammen van M. tuberculosis en P. falciparum in 
het bijzonder, maakt dat er een groeiende noodzaak is voor het ontwikkelen van nieuwe 
ontstekingsremmers met een nieuw werkingsmechanisme. Bovendien, aangezien planten 
ook gebruik maken van de MEP route om de bouwstenen van isoprenoïden te 
synthetiseren, zijn de enzymen van deze route ook interessante doelwitten voor de 
ontwikkeling van onkruidverdelgers. 
In hoofdstuk 1 van dit proefschrift geven we een overzicht van de meest actieve remmers 
die gepubliceerd zijn voor elk enzym van de MEP route en bediscussieren we het 
biologische doelwit van dit proefschrift, 1-deoxy-D-xylulose 5-fosfaat synthase (DXS), in 
detail. DXS katalyseert de eerste en snelheidsbepalende stap van de MEP route, waarbij 
thiamine difosfaat (TDP) als cofactor wordt gebruikt. Het feit dat DXS zowel bij de 
biosynthese van het microbiële thiamine (vitamine B1), als bij de vitamine-B6 biosynthese 
betrokken is, maakt het een bijzonder interessant doelwit, aangezien op deze manier drie 
cruciale biosynthetische routes tegelijkertijd verhinderd kunnen worden. De twee 
kristalstructuren van DXS in een complex met TDP die beschikbaar zijn in de Protein Data 
Bank, zijn niet afkomstig van pathogene organismen, wat de ontwikkeling van remmers 
voor dit enzym een uitdaging maakt. Dit heeft tot resultaat dat er maar weinig voorbeelden 
van remmers voor DXS in de literatuur gepubliceerd zijn. In dit proefschrift presenteren we 
meerdere hit-identificatie strategieën gericht op de ontwikkeling van remmers voor DXS, 
hierbij gebruik makend van computationele studies en biofysische methoden. In hoofdstuk 
2 beschrijven we de eerste toepassing van een innovatieve NMR methodologie op een 
fragmentgebaseerd ontwerp project. Allereerst hebben we de novo een serie fragmenten 
ontworpen, met als doel om in de TDP-bindingsholte van DXS te binden en de 
mogelijkheid om deze fragmenten in de richting van de substraat- en difosfaatholte te laten 
groeien. Hiervoor hebben we een driestaps NMR methodologie gebruikt, die ons in staat 
heeft gesteld om de bindingsmodus van de fragmenten in oplossing te valideren en de 
nieuwe fragment-optimisatiecyclus in te leiden, aangezien er geen betrouwbaar protocol 
voor eiwit kristallisatie beschikbaar was.  
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In hoofdstuk 3 passen we een simpele maar effectieve hit-identificatie methodologie, 
namelijk faagdisplay, toe om de eerste peptidische remmers voor DXS te ontwikkelen met 
laagmicromolaire activiteit tegen D. radiodurans DXS. We beschrijven tevens de 
identificatie van kernmotieven die verantwoordelijk zijn voor de activiteit van de remmers, 
en delen van de α-aminozuurvolgorde die verder aangepast kunnen worden om de 
activiteit van het peptide te verbeteren. Dit project opent de deur voor het toepassen van 
peptiden als potentiële ontstekingsremmers, wat vooral interessant is aangezien 
gedurende het afgelopen decennium het gebruik van peptiden als potentiële medicijnen 
steeds meer aangemoedigd en nagestreefd werd, met als resultaat dat een aantal van 
hen op de markt gebracht is.  
In hoofdstuk 4, onderzoeken we thiamine analoga als remmers voor D. radiodurans en 
M. tuberculosis DXS en rationaliseren we de opgemerkte verschillen in activiteit tussen de 
twee orthologen. Met behulp van geavanceerde docking experimenten hebben we een 
homologiemodel van M. tuberculosis DXS ontwikkeld en gevalideerd, dat gebruikt kan 
worden voor rationeel ontwerp van remmers van M. tuberculosis DXS in de afwezigheid 
van kristallografische informatie. Daarnaast hebben we onderzocht of suikers gebruikt 
kunnen worden ter vervanging van de difosfaat groep van TDP.  
In hoofdstuk 5, beschrijven we de ontwikkeling en het gebruik van een internetgebaseerde 
software genaamd TPPQuery, dat het mogelijk maakt om een farmacofoor zoektocht van 
anker-georiënteerde virtuele bibliotheken uit te voeren en tevens helpt om potentiële TDP-
competitieve remmers, die via multi-component reacties gesynthetiseerd kunnen worden, 
te identificeren. We bediscussiëren de vermeende bindingsmodi van een selectie van 
kernstructuren en hun synthese via de Zhu, Van Leusen en Groebke reacties. 
In hoofdstuk 6 demonstreren we de kracht van ligandgebaseerde virtuele screening 
(LBVS) als hit-identificatie methodologie, met name wanneer er zeer weinig structurele 
informatie beschikbaar is voor het doelwit. Uitgaand van de basisstructuren van enige 
fragmenten die we ontworpen en getest hebben in hoofdstuk 2, hebben we meerdere cycli 
van LVBS uitgevoerd om (een gedeelte van) de ZINC database te screenen. Hiermee 
hebben we remmers met laagmicromolaire activiteit tegen zowel D. radiodurans en M. 
tuberculosis DXS ontdekt, die goede activiteit vertonen tegen multi- en superresistente 
stammen van M. tuberculosis in celgebaseerde assays. Onze meest actieve remmers zijn 
tevens in hoge mate selectief voor DXS ten opzichte van pyruvaatdehydrogenase kinase, 
een TDP-afhankelijk zoogdier-enzym, en één van hen vertoont een zwakke activiteit tegen 
malariaparasieten, waarbij de parasitemie met ongeveer 20% werd gereduceerd in een 
celgebaseerd assay met P.falciparum 3D7. 
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Voor een uitdagend en weinig onderzocht doelwit zoals DXS, bleek de strategie om 
meerdere hit-identificatie en optimalisatie strategieën in parallel uit te voeren, zeer 
effectief. De meeste strategieën die we toegepast hebben, bleken elkaar zelfs goed aan 
te vullen. Bijvoorbeeld, de fragmenten die we de novo ontworpen hebben zoals 
gepresenteerd in hoofdstuk 2, zijn zwakke remmers van D.radiodurans DXS, maar dienen 
als referentie voor de LBVS campagne. De afwezigheid van (co)-kristallografische 
informatie wordt gezien als groot struikelblok voor een medicinale chemie project. Echter, 
we hebben laten zien dat deze barrière overwonnen kan worden, door bijvoorbeeld 
geavanceerde NMR technieken toe te passen, of door screening methoden te gebruiken 
waarvoor deze informatie niet noodzakelijk is, zoals faagdisplay. Het gebruik van 
structuurgebaseerde (SB) aanpakken (bijv. de novo ontwerp, SB-farmacofoor 
zoektochten) alleen is risicovol, vooral wanneer de enige beschikbare kristalstructuur die 
van een model enzym is. Desalniettemin, het gebruik van software zoals TPPQuery, heeft 
ons in staat gesteld om de TDP-holte te onderzoeken met ongehoorde en zeer diverse 
basisstructuren. Echter, de combinatie van SB- en LB-aanpakken maximaliseert de kans 
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Mamma, so che non è stato facile per te vedermi andare via, ma ti ringrazio per il tuo 
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